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1 Introduction 
1.1 Antitumor platinum complexes 
In 1844 Michele Peyrone synthesized cisplatin (cis-platinum(II)-diammine-dichloride, 
cDDP) without being aware of its tumor-inhibiting effect (Fig. 1-1). Not until the mid-
1960s Barnett Rosenberg discovered the inhibition of cell division in the presence of 
this platinum complex. Due to its outstanding effectiveness in treating numerous 
tumors, cisplatin became the prototype for a new class of antineoplastic substances. 
Meanwhile it has become one of the most frequently used cytotoxic drugs in tumor 
therapy. However, its use is limited due to the side effects and the development of 
resistance, which has led to the search for new platinum complexes with anticancer 
properties1. 
 
 
Fig. 1-1 Structure of cisplatin (cis-platinum(II)-diammine-dichloride). 
Most of the antitumor platinum complexes developed up to now are uncharged 
cis-configurated square-planar platinum(II) complexes that can be described by the 
general formula cis-[PtA2X2], with A2 as either two monodentate or one bidentate 
stable amine ligand(s) and X2 as two monodentate or one bidentate anionic leaving 
ligand(s). Octahedral platinum(IV) complexes, which are now under development, 
can be described by the general formula cis-[PtA2X2Y2] with Y2 as monodentate 
anionic leaving ligands. The advantage of platinum(IV) complexes is the possibility of 
oral administration due to their increased stability and solubility in the gastrointestinal 
tract1,2. 
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In the following chapters the processes taking place after the administration of 
cisplatin are described. 
1.1.1 Mode of action 
Bioactivation. After intravenous administration a high amount of cisplatin is bound to 
plasma proteins and thereby inactivated. Because of the high extracellular chloride 
concentration (≈ 100 mM), free cisplatin exhibits relatively low reactivity in the 
plasma. After entering the cell containing low chloride concentrations (≈ 4 mM) 
reactive monoaqua and diaqua complexes are formed by exchange of the chloride 
ligands. After activation, cisplatin is able to interact with a variety of macromolecules 
present in the cell3. 
Formation of platinum-DNA adducts. The cytotoxic effect is generally accepted to 
be mainly a consequence of the formation of platinum-DNA adducts. The primary 
target is the N7 position of the purine bases adenine and guanosine due to the high 
nucleophilicity of the imidazole ring. Cisplatin forms bifunctional 1,2- or 1,3-
intrastrand crosslinks (60 – 65 % intrastrand GG, 25 – 30 % intrastrand AG, 5 – 10 % 
intrastrand GNG adducts), interstrand crosslinks (1 – 3 % interstrand GG adducts) 
and monofunctional adducts (Fig. 1-2)4,5. 
 
 
Fig. 1-2 Formation of platinum-DNA adducts. G, guanosine; A, adenosine; N, 
nucleoside. 
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1.1.2 Cellular response 
Inhibition of DNA synthesis. As a result of the structural change of the DNA helix 
binding of DNA polymerases is hampered inhibiting replication and transcription5. 
DNA repair mechanisms. Platinum-DNA adducts are mainly repaired by nucleotide 
excision repair (NER) (Fig. 1-3)5,6. Due to small substrate specificity of this repair 
system, it is unlikely that platinum-DNA adducts of structurally different platinum 
complexes are differentiated4,7,8. A complete removal of the DNA damage is not 
possible in this way because of the limited capacity of the NER. Furthermore, 
adducts can be bypassed by some DNA polymerases. This translesion DNA 
synthesis – the so-called replicative bypass (post replicative repair) – allows the cells 
to progress through the S-phase (DNA replication) of the cell cycle. The mismatch 
repair (MMR) system is an important prerequisite for the cytotoxic activity of cisplatin. 
Base-pair mismatches are recognized and repaired by MMR proteins. The DNA 
strand previously synthesized is cut out and the DNA is again synthesized beyond 
the damaged sites entering in a vicious cycle. In the long term, these futile repair 
attempts lead to an induction of apoptosis. Thus, deficiency of MMR is associated 
with cisplatin resistance (see 1.1.3)6. 
Binding of HMG-proteins and transcription factors. The disturbance of the DNA 
structure results in binding of different proteins5. Among them high mobility group box 
proteins– such as HMGB1 – protect platinum-DNA adducts against repair proteins by 
stably binding to the platinum-DNA adducts. Many HMG box proteins are 
transcription factors and partly exhibit a higher affinity for the platinated DNA than for 
their natural substrate. The transcription factors are intercepted by the platinum-DNA 
adducts, therefore the transcription is inhibited. This phenomenon is called 
“transcription factor hijacking”5. 
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Fig. 1-3 DNA repair mechanisms. NER targets damaged or inappropriate bases 
within DNA. XPA and RPA are repair factors involved in the formation of a 
damage recognition subunit (1). This subunit triggers the recruitment of 
endonucleases (XPG and ERCC1-XPF) responsible for a dual incision at 
both 3´ and 5´ sites to the leasion (2). The damage-containing oligomers of 
22 to 32 nucleotides in length are excised (3). Finally, DNA resynthesis and 
ligation of the new strand to the parental DNA takes place (4). If a complete 
repair is possible, the cell will survive. Otherwise, the cell undergoes 
apoptosis (5). During replicative bypass DNA repair enzymes carry on DNA 
synthesis despite the presence of platinum-DNA adducts on the parental 
strand (6 + 7). Consequently, no gaps or discontinuities into the newly 
synthesized strand occur and the cell survives. However, base-pairing errors 
are produced in the course of replicative bypass. Mismatch repair proteins, 
called Mut proteins (hMLH1, hMLH2, hPMS2, hMSH2, hMSH3, hMSH6), are 
able to recognize these mismatched DNA base pairs (8) and initiate the 
assembly of proteins which excise the affected area (9). Because MMR is 
directed to the newly synthesized strand, the platinum-DNA adduct remains 
at the parental strand. Therefore, replicative bypass may start again (6). The 
continued action of these futile excision and resynthesis cyles results in the 
formation of gaps or strand breaks, which lead to cell death (10). Another 
mechanism that induces apoptosis is the activation of downstream signalling 
pathways by the binding of the MMR proteins to the platinum-DNA adduct 
(11). 
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Induction of apoptosis and necrosis. The DNA damage caused by cisplatin 
triggers apoptosis and necrosis (Fig. 1-4). Among others, the following ways of 
apoptosis are being discussed5: 
• The p53-dependent mitochondrial apoptosis with subsequent activation of 
caspase 9 and caspase 3. 
• The Fas/Fas ligand (FasL)- and caspase-8-mediated apoptotic cascade. 
• Activation of c-Abl tyrosine kinase and subsequent activation of p73 (p53 genes 
family). 
• Mitogen-activated protein kinase (MAPK) pathways. 
Necrosis occurs following excessive DNA damage, which induces hyperactivation of 
poly(ADP-ribose) polymerase (PARP). PARP causes ATP/NAD+ depletion leading to 
necrotic cell death5. 
 
 
Fig. 1-4 Cell death pathways activated in response to cisplatin (reproduced from 
Wang and Lippard5). TCR, transcription-coupled repair. 
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1.1.3 Mechanisms of resistance 
Resistance can be intrinsic or acquired by chronic drug exposure. Resistance to 
cisplatin is multifactorial, different resistance mechanisms may develop in parallel. 
Four major resistance mechanisms can be distinguished3,5,6. 
Reduced accumulation. After exposure to platinum complexes, a decreased influx, 
an increased efflux, or a combination of both phenomena was observed. Previously, 
it has been assumed that platinum complexes enter the cell primarily by passive 
diffusion (Fig. 1-5). During the last decade a link between copper transporters (CTR1, 
ATP7A, ATP7B) and platinum influx and efflux has been discovered in numerous 
studies. Recent results furthermore indicate an involvement of organic cation 
transporters (OCT1-3). Platinum resistance may develop by upregulation of efflux or 
downregulation of influx transporters. 
 
 
Fig. 1-5 Mechanisms of cisplatin influx, efflux and detoxification. ATP7A, adenosine 
triphosphate alpha-polypeptide; ATP7B, adenosine triphosphate beta-
polypeptide; CTR1, copper transporter 1; MRP2, multidrug resistance 
protein 2; OCT1-3, organic cation transporters 1-3. 
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Increased inactivation. Platinum complexes react to a great extent with intracellular 
molecules that contain thiol groups, e.g., glutathione (GSH) or metallothionein (MT). 
Only a relatively small fraction of intracellular cisplatin binds to genomic DNA. It has 
been estimated that only 1 % of the platinum that enters the cell binds to nuclear 
DNA9. According to prior studies more than 60% is bound to GSH10. However, recent 
results suggest that the fraction of platinum(II) bound to GSH is of maximum 20 %11. 
The platinum-GSH conjugate is biologically inactive and can be removed from the 
cell by the transporter MRP2 (Fig. 1-5)12. In addition, the formation of interstrand 
crosslinks can be prevented by interaction between thiol-containing molecules and 
monofunctional adducts. Therefore, an increased intracellular GSH production can 
contribute to the development of resistance5,6,13. 
Increased adduct tolerance and failure of apoptotic pathways. An increase of 
replicative bypass leads to an increased adduct tolerance as well as to a high 
mutation rate, whereby changes, which result in subsequent development of 
resistance, are favored. Defects in the MMR system prevent the beginning of futile 
repair cycles, hence contributing to resistance5. The complex cascades of apoptosis 
offer a further starting point for the development of resistance. Many factors can be 
changed, examples are the loss of p53 function, reduced activity of caspases, or a 
deregulated MAPK pathway5. 
Increased repair. A general resistance mechanism is increased repair by the NER 
system. The capacity of this kind of resistance mechanism seems, however, to be 
limited5. 
 
 
 
 
 
 
 
8  Introduction 
1.1.4 Clinical relevance 
Meanwhile platinum compounds are used in 50 % of all tumor therapies14. A 
selection of the EU-approved indications of cisplatin, carboplatin and oxaliplatin is 
presented in Tab. 1-115-17. The addition of all approved indications leads to not less 
than 26 different indications of cisplatin, three of carboplatin and five different 
indications of oxaliplatin18-20. 
Tab. 1-1 Selection of approved indications of cisplatin, carboplatin and oxaliplatin with 
a focus on those indications approved via the decentralised and mutual-
recognition procedure in EU countries. 
Platinum  
compound Indication 
Advanced or metastatic tumor of testis (palliative and curative 
therapy) 
Advanced or metastatic ovarian tumor 
Advanced or metastatic small cell lung carcinoma and non-small 
cell lung carcinoma 
Cisplatin 
Advanced or metastatic head and neck cancer (palliative therapy) 
Advanced epithelial ovarian cancer (first- and second-line) 
Carboplatin 
Small cell lung carcinoma 
Stage III colon cancer in patients who have undergone complete 
resection of the primary tumor (in combination with 5-fluorouracil 
(5-FU) and folinic acid; adjuvant therapy) Oxaliplatin 
Metastatic colorectal cancer (in combination with 5-FU and folinate) 
 
The greatest success of antitumor platinum complexes was achieved by cisplatin in 
the treatment of testicular cancer. The response rate increased from a historical 
control of 25 % to approximately 90 % in patients with good prognosis21. Another 
milestone in cancer chemotherapy was the approval of oxaliplatin. Oxaliplatin is 
effective in the treatment of metastatic colon/colorectal carcinoma, which exhibit 
intrinsic resistance to cisplatin and carboplatin22,23. 
However, the treatment is limited by a high rate of severe adverse effects. Although 
the incidence of severe adverse effects could be limited, e.g. by hydration for 
prevention of nephrotoxicity and using serotonine receptor antagonists (5-HT3), 
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dexamethasone and/or NK1 receptor antagonists for antiemetic prophylaxis, they still 
remain a problem in the treatment with platinum compounds24,25. Relevant and dose-
limiting adverse effects of cisplatin are nephrotoxicity, ototoxicity, emesis, and 
neurotoxicity18,22,25,26. The only dose-limiting adverse effect of carboplatin is 
myelosuppression. Among the severe adverse effects are imbalance of electrolytes, 
peripheral neuropathy and less-common visual disturbance22,26,27. The crucial and 
dose-limiting toxicity of oxaliplatin is peripheral sensory neuropathy28. 
Myelosuppression is low. Neither ototoxicity nor nephrotoxicity has been 
observed20,22,26. 
A further significant limitation toward the successful treatment of malignant cancers 
with platinum complexes is the emergence of drug resistance. It is hardly possible to 
quantify the degree of resistance, because a relapse of a patient might not only be 
due to resistance of tumor cells, but also due to rapid progression of the disease, 
characteristics of the drug (e.g., pharmacokinetics) and specific features of the 
patients (e.g., genetic polymorphisms)29,30. In case of advanced ovarian cancer a 
tumor is classified as platinum-resistant, if the treatment free interval is less than six 
months31. Almost all patients with advanced ovarian cancer at diagnosis relapse 
despite surgery and first-line therapy. With each relapse the response rate 
decreases31. The median progression-free survival is only 18 months and nearly all 
patients die of the disease30,31. In colorectal cancer the median progression-free 
survival increased from 12 to 22 months with the introduction of oxaliplatin and 
irinotecan32. Despite this amelioration, according to the Statistisches Bundesamt 
Deutschland a malignant neoplasm of the colon was still the ninth most frequent 
cause of death in Germany in 2008 with 17,920 deaths in total (2.1 %)33. 
To further improve platinum-based chemotherapy the underlying mechanisms of the 
development of toxicity and resistance have to be investigated in detail. Based on 
that knowledge supportive therapy might be improved and it might become possible 
to predict which patients will respond to platinum-based therapy. Because it is nearly 
impossible to conduct this kind of investigations in patients, many in vitro and some 
in vivo (e.g., knockout mice) models have been developed to elucidate the basic 
molecular principles of toxicity and resistance. Considerable process has been made 
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within the last years. Until today, the relevance of these findings could be only partly 
confirmed in patients29,30.  
An influence of different transporters on degree of toxicity was already demonstrated 
in in vivo models. For example, there is some evidence that the damage of outer hair 
cells of the cochlea resulting in ototoxicity is mediated by OCT234. Concomitant 
administration of imatinib, which inhibits the influx of cisplatin in human embryonic 
kidney cells via OCT2, and cisplatin decreased cellular accumulation of platinum and 
subsequent nephrotoxicity in rats35. Furthermore, the transporter CTR1 is involved in 
neurotoxicity. The degree of cell body atrophy of CTR1-positive and -negative rat 
dorsal root ganglia after administration of platinum drugs was compared leading to 
the result that CTR1-positive rat dorsal root ganglia were vulnerable to toxicity of 
platinum compounds, especially to oxaliplatin36. 
In spite of intensive efforts of the scientists, the clinical relevance of the mechanisms 
described at the cellular level regarding the influx mediated by transporters and the 
contribution of transporters to resistance still needs to be defined. To date, only 
limited data are available. For instance, the role of the copper efflux protein ATP7B 
was demonstrated in vivo. Patients whose carcinomas expressed high levels of 
ATP7B had a significantly poorer prognosis than patients with tumors that expressed 
low levels of ATP7B37-39. Also, ovarian tumor patients with increased levels of ATP7A 
had a lower survival rate than those without increased levels of ATP7A40. However, 
the findings on the cellular level, could not always be confirmed in patients. Thus, for 
example, the expression of OCT2 in ovarian cancer did not correlate with treatment 
outcome, although an influence of OCT2 on the influx of cisplatin was demonstrated 
at the cellular level41.  
In conclusion, there is a great need for large prospective clinical trials to confirm the 
findings on the cellular level in vivo. A further investigation of in vivo toxicity and 
resistance mechanisms should be valuable in reducing the toxicity of platinum-based 
chemotherapy and in allowing the prediction of clinical response to chemotherapy. 
Additionally, new treatments should be identified with a lower profile of toxicity and 
with improved outcome in platinum-resistant tumors.  
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1.2 Pharmacokinetics and pharmacodynamics of oxaliplatin 
To date, the platinum complexes cisplatin, carboplatin and oxaliplatin have gained 
worldwide approval (Fig. 1-6). The third-generation drug oxaliplatin shows an 
improved therapeutic profile compared to cisplatin and carboplatin. First, oxaliplatin 
produces cytotoxicity in platinum-resistant cell lines7,8. Furthermore, oxaliplatin has a 
better safety profile than cisplatin and carboplatin, because it lacks nephrotoxicity 
observed with cisplatin, produces less myelosuppression than carboplatin and 
patients experience only mild nausea/vomiting during treatment23,42,43. The superiority 
of oxaliplatin is based on changes in the molecular mechanisms. To elucidate the 
reasons for the superiority of oxaliplatin, the molecular mechanisms of oxaliplatin are 
described in the present chapter, with particular reference to influx as the main topic 
of this thesis. 
 
 
Fig. 1-6 Structure of A carboplatin and B oxaliplatin. 
1.2.1 Extracellular biotransformation 
After a 2 h infusion of oxaliplatin, 15 % of the administered platinum is present in the 
blood. The remaining 85 % has undergone distribution from the plasma into tissues 
or has been subjected to urinary elimination. 40 % of the platinum in blood is 
irreversibly bound to erythrocytes, about 30 % is bound to plasma proteins and the 
rest remains unbound44,45. The unbound fraction is supposed to contain the intact 
oxaliplatin and its biotransformation products. 
Biotransformation of oxaliplatin occurs rapidly and is nonenzymatic44. Several low 
molecular weight biotransformation products from reactions with water, chloride, 
glutathione, methionine and cysteine as well as unidentified products have been 
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observed in vitro and in vivo46-53. However, appearance and importance of these 
products are still a matter of discussion. In a pharmacokinetic study of oxaliplatin in 
Wistar rats following a bolus injection (20 µmol/kg), the plasma AUC was 30-fold less 
and cmax was 50-fold lower for Pt(DACH)Cl2 than for oxaliplatin50. The maximum 
plasma concentrations for Pt(DACH)(H20)Cl and Pt(DACH)(H2O)2 are at least 1,000-
fold lower than that for oxaliplatin. The low plasma concentrations of these 
biotransformation products might be explained by the low probability of Pt(DACH)Cl2 
to be hydrolyzed into aquated species to a significant extent in presence of the high 
plasma concentration of chloride ions (≈ 100 mM)50. However, this explanation only 
holds, if the formation of the chloro complex is a mandatory step prior to the 
formation of the aquated species, but this is not of necessity45,49. Recently, Ip et al. 
investigated the concentrations of oxaliplatin and Pt(DACH)Cl2 in plasma of 
colorectal cancer patients during (2 h of infusion, 130 mg/m2) and after infusion (up to 
2 h)48. During infusion 58 % (1 h) and 63 % (2 h) of total platinum in plasma 
accounted for oxaliplatin. At the end of infusion intact oxaliplatin decreased rapidly 
(t1/2 = 0.25 h). Pt(DACH)Cl2 was not detected in the plasma. The authors proposed 
that the appearance of the chloro complex in the earlier studies was an artefact of 
sample preparation or storage procedures48. 
Against the background of oxaliplatin influx, these investigations are of high 
relevance, because until now it was suggested that oxaliplatin enters the cell as a 
dichloro complex. The absence of the dichloro complex in vivo excludes a 
contribution of this complex to influx. The high fraction of intact oxaliplatin in the 
plasma could make one conclude that the cell takes up intact oxaliplatin. However, 
given the dynamic nature of the biotransformation and the compartmentalization of 
drug, it is still possible that a number of different species enter the cell by different 
routes with varying kinetics.  
1.2.2 Influx 
Gately and Howell postulated the influx of platinum complexes to be mediated by 
passive diffusion and by facilitated diffusion through a gated channel54. Later this 
model was broadened to include not only gated channels but facilitated and active 
transport mechanisms involving a number of transport proteins3. The contribution of 
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the copper transporter CTR1 and the organic cation transporters OCT1-3 to 
oxaliplatin influx is widely discussed3,55. 
1.2.2.1 Passive diffusion 
Characteristics. It is generally thought that many molecules are transported across 
biological membranes via passive diffusion. Passive diffusion occurs down a 
concentration gradient from high to low concentration. The concentration gradient 
disappears as diffusion proceeds. Therefore, the rate of diffusion is proportional to 
the difference in solute concentration on the inner and outer side of the membrane 
(Fick’s first law). Furthermore, the rate of diffusion mainly depends on size, 
lipophilicity and charge of the molecule. In general, passive diffusion of small, 
lipophilic and uncharged molecules is fast56.  
Role in influx of oxaliplatin. Platinum complexes are suggested to enter cells via 
passive diffusion3. This was not only demonstrated for cisplatin, but also for 
oxaliplatin. Mishima et al. showed that influx of oxaliplatin in five cell line pairs was 
neither saturated by time nor by concentration57. 
1.2.2.2 Copper transporter 1 (CTR1) 
Characteristics. The copper transporter 1 (CTR1) belongs to the solute carrier 
family SLC3158. CTR1 is a high affinity copper transporter, which mediates cellular 
influx of copper. It is suggested to be Cu(I)-specific, i.e. either prior to or concomitant 
with the influx, Cu(II) is reduced to Cu(I) by one or more metalloreductases59. Once 
inside the cell, copper is distributed to cellular proteins and compartments for the 
incorporation into copper-dependent proteins60. CTR1 consists of three 
transmembrane domains (190 amino acids), a methionine-rich N-terminus 
(M7XMXXM, M40MMMXM), a cysteine-histidine cluster in the C terminus and an 
MX3M motif in the second transmembrane domain (M150XXXM) (Fig. 1-7)61,62. The 
transporter is present in the membrane as a homotrimer that is likely to act as a pore 
between the subunit interfaces63,64. The pore involves a series of methionine rings 
(M150 and M154) each containing three methionines and a ring of three cysteines 
(C189)64. The pore diameter is ≈ 8 Å at its narrow end towards the extracellular exit 
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and ≈ 22 Å towards the intracellular end64. The passage of copper seems to be 
associated with conformational changes in CTR164. However, the details of the 
transport of copper across the membrane are still unknown61,65. The MX3M motif is 
essential for function of copper influx. Regarding the contribution of the N-terminal 
methionine-rich domain the results are contradictory. While Puig et al. demonstrated 
that this domain is only necessary under copper-depleting conditions, Liang et al. 
found that it is also essential for function of copper influx62,66. The extracellular 
methionine-rich domain is not involved in the process of oligomerization, because its 
deletion did not affect the ability of oligomerization, however, resulted in cytoplasmic 
localization of the transporter62. 
 
 
Fig. 1-7 A model for human copper transporter 1 (hCTR1) in the phospholipid bilayer. 
A hCTR1 monomer consists of 190 amino acids. The N terminus projects 
outside and the C terminus inside the cell. The extracellular domain has two 
methionine-rich domains ( ). Three hCTR1 monomers oligomerize to form 
a pore. The trimeric pore provides a series of stacked rings of methionines 
(M) and cysteines (C) that might participate in transchelation reactions 
(modified from Howell et al.65). 
Role in oxaliplatin influx. The copper transporter 1 (CTR1) appears to contribute to 
influx of oxaliplatin, as could be demonstrated by an impaired accumulation of 
oxaliplatin in CTR1-deficient cells55,67,68. Because the influx was dependent on CTR1 
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only at low oxaliplatin concentrations, oxaliplatin has been concluded to be a 
substrate for some other mechanism of cellular entry67. A further evidence for the 
contribution of CTR1 to oxaliplatin influx was provided using CTR1-positive and 
-negative neurons of rat dorsal root ganglia69. CTR1-positive neurons became 
atrophied after treatment with oxaliplatin, whereas CTR1-negative neurons showed 
less treatment-induced cell body atrophy69. Unfortunately, information about the 
mechanisms of influx of the drug via CTR1 is still limited. Most of the investigations 
have been carried out with respect to cisplatin. Nevertheless some general 
considerations are as follows: 
• The size of the pore (≈ 8 Å) may pose an obstacle for the passage of oxaliplatin 
(≈ 4 x 4 x 10 Å)65,70. However, the protein may be quite flexible. 
• Oxaliplatin as a soft Lewis acid forms weak bonds with one or more 
methionine(s). Therefore, it is conceivable, that oxaliplatin undergoes 
transchelation reaction from one methionine to the next. The molecular distance 
between the methionine rings formed by M154 and M150 is short enough to allow 
this reaction65. 
Influence on cytotoxicity of oxaliplatin. The crucial question, if the impaired or 
increased accumulation of oxaliplatin influences cytotoxicity, was also investigated. 
Regarding CTR1, a deletion of both alleles did not affect the growth inhibitory effect 
of oxaliplatin67. However, the concentrations used in the influx studies were not 
comparable with the concentrations used in the cytotoxicity studies67.  
Influence on resistance to oxaliplatin. The contribution of the transporter to 
resistance has been less investigated and the results are contradictory. Up- and 
downregulation of hCTR1 or even no changes in the expression of hCTR1 in different 
platinum-resistant cell lines were observed71-74. An explanation of these 
discrepancies might be, that CTR1 is not functional in some resistant cell lines, 
although it is expressed at a normal level65. This might be possible due to the failure 
of resistant cells to glycosylate CTR1 at T27. Consequently, the protein renders 
susceptible to proteases that excise the N-terminal domain and inactivate the 
transport function of CTR1 while leaving the rest of the protein in the membrane75. 
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1.2.2.3 Organic cation transporters (OCT1-3) 
Characteristics. The organic cation transporters belong to the SLC22 family 
encompassing not only the cation and carnitine transporters (OCTN1, OCTN2, 
OCT6) and the proton/cation antiporters (MATE1, MATE2-K, MATE2-B), but also the 
polyspecific cation transporters OCT1-3 (SLC22A1-3)76,77. OCT1 and OCT3 exhibit a 
broad tissue distribution including intestine, liver, kidney, lung, skin, epithelial and 
tumor cells. In contrast to OCT1 and OCT3, the tissue expression pattern of OCT2 is 
more restricted. It is strongly expressed in the kidney, however, also found in a 
variety of other organs76,77. The organic cation transporters contain 12 
transmembrane domains with one hydrophilic loop connecting the first and the 
second transmembrane domaine assigned to the extracellular side. Another 
hydrophilic loop is localized intracellular connecting the sixth and seventh 
transmembrane domaine (Fig. 1-8)76. 
 
 
Fig. 1-8 Predicted structure of hOCT1-3. N and C terminus are located intracellularly 
(in). The large extracellular loop between the first and the second 
transmembrane domain contains three N-glycosylation sites. 
Not only organic cations and weak bases that are positively charged at physiological 
pH, but also non-charged molecules are transported in an electrogenic manner. The 
transport across the plasma membrane is independent of sodium and proton 
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gradients and occurs in both directions. Transported substrates exhibit mutual 
inhibition, which may be total or partial. OCTs translocate a variety of molecules and 
numerous molecules are able to inhibit this transport. The question, which kind of 
properties a molecule has to possess to act either as a substrate or as an inhibitor, is 
difficult to answer, because the affinity of transported substrates and non-transported 
inhibitors overlap broadly77. In recent studies identifying molecular determinants of 
substrate/inhibitor binding to OCTs, pharmacophores for OCTs have been reported78-
85. Hydrophobicity and basicity are important determinants of substrate specificity for 
OCTs84. Three pharmacophores have been reported for OCT1. The first one consists 
of three hydrophobic sites and a positive ionizable site79. The alternative 
pharmacophores consist of a positive ion interaction site, a hydrophobic interaction 
site, and one or two hydrogen bond acceptor sites, whereas the calculated distance 
between the hydrophobic and hydrogen bond acceptor sites was between 4 and 
7 Å79-82. The two-point pharmacophore for OCT2 suggested by Zolk et al. consists of 
an ion interaction site and a hydrophobic aromatic site separated by 5 Å85. The only 
physicochemical descriptor identified was the topological polar surface area (TPSA). 
The smaller the TPSA values of a drug, the higher was its inhibitory effect on the 
transport of model cations. An influence of the log P value, pKa value, log S value 
(aqueous solubility) and solvent accessible surface area (SASA) on inhibition of the 
transport of the model cations could not be demonstrated85. However, Suhre et al. 
found an influence of hydrophobicity on the OCT2-drug interaction83. Contrary to 
OCT1 and OCT2, information on OCT3-drug interaction is still limited. 
Role in oxaliplatin influx. Recent results suggested that human organic cation 
transporters (hOCT1-3) may play an important role in the influx of oxaliplatin41,86-89. In 
different cell systems a higher accumulation of oxaliplatin in hOCT1-, hOCT2- and/or 
hOCT3-transfected cells was observed41,87,88,90. Only one study failed to demonstrate 
an involvement of hOCT2 in the transport of oxaliplatin91. 
Influence on cytotoxicity. The crucial question, if the impaired or increased 
accumulation of oxaliplatin influences cytotoxicity, was also investigated. In most of 
the hOCT1-3-transfected cell lines a higher oxaliplatin accumulation led to a higher 
cytotoxicity41,87,88,90. 
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Influence on resistance. The contribution of the transporters to resistance has been 
less investigated and the results are contradictory. Upregulation of hOCT1 and 
hOCT2, as well as downregulation of hOCT3 were observed in the resistant cell 
line73. 
1.2.3 Intracellular biotransformation 
Once inside the cell, the activation mechanism of oxaliplatin is unclear. The oxalate 
leaving group might be displaced by chloride under formation of Pt(DACH)Cl292. 
However, it was shown that the percentage of Pt(DACH)Cl2 in the cytosolic 
ultrafiltrate after incubation with oxaliplatin is similar to that observed in the culture 
medium. This implies that the intracellular conversion of oxaliplatin to Pt(DACH)Cl2 is 
low92. Consistent with these results, Mauldin et al. demonstrated the intracellular 
displacement of the malonato leaving group in the oxaliplatin analogue 
Pt(DACH)(mal) with chloride to be very slow (< 5 % in 24 h)93. Moreover, they 
suggested an activation of platinum complexes with bidentate leaving groups by the 
intermediate formation of highly reactive bicarbonato or phosphato complexes93,94. 
But the low reactivity of oxaliplatin with bicarbonate or phosphate under physiological 
conditions is in disagreement with this hypothesis45. 
Other important reactants in the intracellular environment are sulfur-containing 
nucleophiles. Oxaliplatin exhibits a higher reactivity towards sulfur-containing 
compounds than cisplatin95. The reaction rate with glutathione and cysteine was 
about six times higher for oxaliplatin, whereas the rate with methionine was only 
about twice as fast for oxaliplatin as compared to cisplatin. At the intracellular 
concentration of sulfhydryl groups up to 10 mM a half-live of oxaliplatin of less than 
15 min was estimated95. The fate of the platinum complexes bound to sulfur is largely 
unknown. The complexes might be inactive or serve as drug reservoirs10,96. However, 
it has to be taken into account that the experiments have not been conducted in the 
intracellular environment. 
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1.2.4 Efflux 
The copper transporters ATP7A and ATP7B might contribute to the cellular efflux of 
oxaliplatin. An increased expression of ATP7A in ovarian cancer cells rendered cells 
resistant to oxaliplatin97. However, cellular accumulation was not reduced as 
expected, but an enhanced sequestration of the drug into the vesicular fraction was 
shown. It was suggested that ATP7A sequesters oxaliplatin and keeps it thereby 
away from the DNA97. Furthermore, some other studies also point at the contribution 
of ATP7A and ATP7B to oxaliplatin resistance due to an increased efflux or 
sequestration38,74. ATP7A was overexpressed in response to oxaliplatin exposure in 
sensitive and oxaliplatin-resistant cells74. Analysis of tumors from colorectal cancer 
patients treated with oxaliplatin/5-FU revealed that patients with lowest mRNA 
expression levels of ATP7B had significantly longer time to progression than patients 
with highest levels38. Nevertheless, the results are cell line specific. Fibroblasts 
transfected with ATP7A or ATP7B were hypersensitive to oxaliplatin98. The fact, that 
oxaliplatin-resistant cells exhibited only basal expression of ATP7A and ATP7B 
compared to their sensitive counterparts also point at the cell line specifity of the 
results74.  
A contribution of two members of the multidrug and toxin extrusion family (MATE1 
and MATE2-K) to the efflux of oxaliplatin in renal proximal tubular cells has also been 
reported99. hMATE1 and in particular hMATE2-K can mediate the H+-dependent anti-
port of oxaliplatin. This mechanism of efflux mainly plays a role in renal cells, 
because these transporters are primarily expressed in the kidney. 
1.2.5 Mechanism of action 
Oxaliplatin shows another spectrum of efficacy and resistance than cisplatin and 
carboplatin. The oxalate ligand as the leaving group leads to a slightly reduced 
reactivity compared to cisplatin. The bulky 1,2-diaminocyclohexane (DACH) ligand is 
probably responsible for the improved water solubility as well as the altered profile of 
activity7,100. Using equimolar and equitoxic concentrations of cisplatin and oxaliplatin, 
it was found that the extent of DNA platination is substantially lower after treatment 
with oxaliplatin7,8,101. However, the rate of single-strand breaks is higher8. It is still 
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unknown, whether these single-strand breaks are induced as a result of primary DNA 
lesions or are due to rapid induction of apoptosis8.  
The activity profiles of oxaliplatin and cisplatin might be different, because mismatch 
repair proteins, damage-recognition proteins and translesion DNA polymerases 
differentiate between cisplatin- and oxaliplatin-DNA adducts4. 
Mismatch repair proteins. The DACH ligand reduces the affinity of MMR proteins 
for oxaliplatin-DNA adducts4,7,8. However, this does not reduce the cytotoxic effect of 
oxaliplatin, to wit, the cytotoxic effect of oxaliplatin is independent of the MMR 
system. This enables oxaliplatin to be active in MMR-deficient cells, which are 
resistant to cisplatin, and might be the reason for the absence of cross-resistance to 
cisplatin4,7,8.  
Damage-recognition proteins. HMG box proteins (e.g. HMG1, HMG2, Ixr1, tsHMG, 
SRY, LEF-1, hUBF) and non-HMG box proteins (e.g. TBP, histone H1, p53, XPE, Ku, 
XPA, RPA) bind with high affinity to platinum-DNA adducts (see 1.1.1). A difference 
in the affinity of these proteins in binding to cisplatin-DNA adducts compared to 
oxaliplatin-DNA could be demonstrated. Especially HMG box proteins bind more 
tightly to cisplatin-DNA adducts than to oxaliplatin-DNA adducts. However, the 
biological consequences of the different binding behavior are unclear4,7. 
Translesion DNA polymerases. Polymerases are involved in the translesion 
synthesis of platinum-GG intrastrand adducts and are able to discriminate between 
cisplatin- and oxaliplatin-DNA adducts4. Of the human polymerases tested in 
previous studies, both pol η and pol β bypass oxaliplatin-GG adducts with higher 
efficiency than cisplatin-GG adducts. Both polymerases are suggested to mediate 
error-free bypass of lesions. The results of the study of Yang et al. are consistent 
with this suggestion102. They observed that cells deficient of pol β were 
hypersensitive to oxaliplatin treatment102. Another translesion DNA polymerase, 
pol ζ, also discriminates between cisplatin- and oxaliplatin-DNA adducts. However, 
contrary to pol η and pol β, pol ζ is involved in error-prone translesion synthesis. It 
was shown that loss of pol ζ confers greater sensitivity to cisplatin than to oxaliplatin4. 
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1.3 Overcoming platinum resistance by chemical optimization 
As outlined in chapter 1.1.4, toxicity and resistance of cancer cells to platinum-based 
drugs remain a significant impediment to successful chemotherapy. Nevertheless, 
antitumor platinum compounds exhibit a broad spectrum of activity and high 
antitumor activity. Therefore, efforts have been ongoing to design new antitumor 
platinum compounds with 
• superior efficacy 
• reduced toxicity 
• lack of cross-resistance 
• and improved pharmacological properties compared to the parent compound, 
cisplatin, e.g., providing oral bioavailability. 
However, after the introduction of cisplatin in chemotherapy only two platinum 
complexes have received worldwide approval: carboplatin and oxaliplatin. 
Carboplatin differs from cisplatin by the nature of the leaving group, cyclobutan-1,1-
dicarboxylate instead of two chloride moieties. The new leaving group leads to 
increased water solubility and stability compared to cisplatin. Toxicity was decreased. 
However, cisplatin and carboplatin show cross-resistance, which points to a similar 
mechanism of action100. Oxaliplatin shows another spectrum of efficacy and 
resistance. The oxalate ligand as the leaving group leads to a slightly reduced 
reactivity compared to cisplatin100. The bulky 1,2-diaminocyclohexane (DACH) ligand 
is probably responsible for the reduced water solubility as well as the changed profile 
of activity23. 
The differences in toxicity and anticancer activity between the above-mentioned 
approved platinum complexes can be explained by structure-activity relationships. 
The leaving group of a platinum compound largely determines its reactivity103. 
Reactivity is defined as the ability to exchange the leaving group(s) upon interaction 
with nucleophiles. In the case of cisplatin and carboplatin, which only differ in the 
structure of their leaving group, one would expect differences in reactivity. In fact, in 
vitro determination of reactivity towards calf thymus DNA showed higher reactivity of 
cisplatin than of carboplatin104. It could be demonstrated that equal binding was 
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followed by equal cytotoxicity. Therefore, once the compounds are bound to DNA, 
they exhibit equal cytotoxicity. However, to achieve equal binding the dose of 
carboplatin has to be 20 to 40-fold higher than that of cisplatin which points at an 
altered biodistribution of carboplatin104,105. A positive effect of the reduced reactivity is 
the advantageous toxicological profile of carboplatin106,107. In general, the stability of 
a platinum complex regarding leaving group(s) can be increased by introduction of 
chelated, dicarboxylate-containing moieties with the reactivity decreasing in the order 
oxalate > malonate > phenylmalonate > cyclobutan-1,1-dicarboxylate100. Inert 
platinum complexes usually exhibit low cytotoxic potency and low toxicity, whereas 
reactive platinum complexes are often of high potency and toxicity103,105.  
It is believed that reactivity also influences platinum influx67,108-110. Pereira-Maia et al. 
investigated the relationship between the concentration of the extracellular cisplatin-
aquated species and the rate of cellular influx109. It was hypothesized that only the 
aquated species were transported by an active influx mechanism. More reactive 
platinum complexes, like cisplatin, produce higher amounts of aquated species. 
Therefore, they are taken up faster than less reactive platinum complexes, like 
carboplatin109. However, the hypothesis that the first step in influx of cisplatin is the 
formation of the aquated species in a Cl--deficient space at the level of the plasma 
membrane is in disagreement with the knowledge about the bioactivation of cisplatin, 
because according to the results of the previous studies the formation of the aquated 
species takes place not before cisplatin has entered the cell (see 1.1.1)3. In another 
study, a relationship between reactivity of different diammine/diaminocyclohexane 
platinum(II) complexes and cellular influx rates could be demonstrated110. However, 
in this case reactivity was determined based on interaction with G-actin, which is not 
likely to be relevant in vivo, and influx experiments were carried out in human 
erythrocytes110. Furthermore, the relevance of reactivity for influx mediated by the 
human copper transporter 1 (hCTR1) has been discussed. It has been suggested 
that platinum complexes stabilize a homotrimer of hCTR1 by cross-linking hCTR1 
subunits via methionine-rich clusters108. The extent of the formation of the 
homotrimer depended on the reactivity of the platinum complex. Consequently, 
trimerization was less efficient after treatment with oxaliplatin compared to cisplatin 
and even slower after treatment with carboplatin108. Nevertheless, besides reactivity, 
which seems to be important for binding to methionine-rich clusters, the bulky 
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diaminocyclohexane amine ligand was suggested to mediate the influx of oxaliplatin 
by a CTR1-independent mechanism67. 
It should be mentioned that not only the leaving group determines the reactivity of 
platinum complexes but also the carrier ligand is able to modify the reactivity, in an 
indirect manner, by steric, electronic and basicity effects103,111. Furthermore, the 
carrier ligand determines the structure of the platinum-DNA adduct. Because cisplatin 
and carboplatin form the same platinum-DNA adducts, their sensitivity and resistance 
pattern is similar4. However, platinum-DNA adducts formed by oxaliplatin are bulkier 
and more hydrophobic13. The different structure of the platinum-DNA adducts 
appears to contribute to the lack of cross-resistance with cisplatin and carboplatin5. 
Comparable to oxaliplatin a circumvention of cisplatin resistance could also be 
demonstrated with carboplatin analogues with 1,3-diaminepropane and 1,4-
diaminebutane as carrier ligands. It was proposed that the circumvention of cisplatin 
resistance was related to the steric hindrance of the diamine chelate ring and the 
thereby increased level of DNA interstrand crosslinks112. Consequently, modification 
of the carrier ligand results in the formation of structurally different platinum-DNA 
adducts and influences thereby the anticancer properties105.  
Another important feature, which is determined by both leaving group(s) and carrier 
ligand(s) is lipophilicity113. Among other factors, lipophilicity has been shown to affect 
absorption, transmembrane transport, bioavailability, cellular drug accumulation, 
lipophilic drug-receptor interactions, metabolism, pharmacological activity, as well as 
the toxicity of molecules. Lipophilicity of a drug has been related to its ability to cross 
cell membranes by means of passive diffusion and reflects the relative solubility of 
the drug in lipid-like (e.g., lipid bilayers of a cell membrane) and aqueous (the fluid in 
and out of the cells) environments.  
With respect to platinum compounds, it has been suggested that increasing 
lipophilicity may help to overcome accumulation defects and consequently to 
enhance cytotoxicity in resistant cell lines114. Moreover, lipophilicity was shown to 
correlate with cytotoxic activity115-117. In other studies a strong relationship between 
intracellular platinum concentrations and lipophilicity of platinum complexes was 
demonstrated114,118-120. Most of the reported investigations have been carried out with 
platinum(IV) complexes or with a panel of structurally very different platinum 
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complexes. In order to draw convincing conclusions regarding the influence of 
lipophilicity on cellular accumulation, other factors like oxidation state or reactivity 
should be comparable between the complexes. 
.
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2 Aims of the investigation 
Oxaliplatin is a widely used third-generation anticancer drug with a better safety 
profile and a lack of cross-resistance to cisplatin, especially in colorectal cancer7,13. 
Nevertheless, tumor cells can develop resistance to oxaliplatin as well57. In contrast 
to the mechanisms of cisplatin resistance, which have been extensively studied, the 
mechanisms of resistance to oxaliplatin are less well established. This applies also 
for the reduced influx as a frequently documented resistance mechanism of tumor 
cells to platinum complexes.57,121. To further elucidate the contribution of reduced 
influx to oxaliplatin resistance, it is necessary to understand the underlying 
mechanisms of oxaliplatin influx. 
One aim of this study was to explore general influx mechanism(s) of oxaliplatin and 
structurally related compounds by investigation of the influence of lipophilicity and 
reactivity on influx. Furthermore, it was planned to reveal, to which extent lipophilicity 
and reactivity influence cytotoxicity of platinum compounds and whether it is possible 
to overcome reduced influx in resistant cells by alteration of these physicochemical 
properties. For that purpose, two panels of oxaliplatin derivates were used: one panel 
of derivates with different amine ligands and another panel with different leaving 
groups. The experiments were carried out in the ileocecal colorectal adenocarcinoma 
cell line HCT-8 and its oxaliplatin-resistant variant HCT-8ox. 
The following experiments were conducted for this purpose: 
• Determination of lipophilicity of the platinum compounds 
• Determination of reactivity of the platinum compounds towards nucleotides 
• Determination of influx, efflux and cytotoxicity of the platinum compounds in 
HCT-8 and HCT-8ox cells 
• Determination of resistance of HCT-8ox cells to the platinum compounds 
• Determination of DNA platination and repair of platinum-DNA adducts 
Another aim was to investigate the transporter-mediated influx of oxaliplatin in more 
detail, particularly the contribution of the transport proteins hCTR1 and hOCT1-3. 
Therefore, the following additional experiments were performed: 
26  Aims of the investigation 
• Determination of influx of oxaliplatin after preincubation and coincubation with 
different substrates and/or inhibitors of the transport proteins 
• Determination of cytotoxicity of oxaliplatin after preincubation and coincubation 
with different substrates and/or inhibitors of the transport proteins 
• Determination of gene expression levels of the transport proteins with and 
without oxaliplatin treatment 
• Determination of subcellular localization of the transport proteins with and 
without oxaliplatin treatment 
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3 Materials and methods 
3.1 Material 
3.1.1 Chemicals and reagents 
ALEXA Fluor™ 488-conjugated chicken Invitrogen, Karlsruhe 
anti-goat antibody 
2-Amino-2-hydroxymethyl- Sigma-Aldrich, Steinheim 
propane-1,3-diol (Tris-HCl) 
Argon 4.6 Air Product, Hattingen 
Atropine sulfate salt monohydrate Fagron, Barsbüttel 
BCA™ Albumin Standard Ampules Pierce, Bonn 
(containig 2 mg/mL bovine serum albumin) 
BCA™ Reagent A Pierce, Bonn 
(containing bicinchoninic acid) 
BCA™ Reagent B Pierce, Bonn 
(containing 4 % cupric sulfate) 
Boric acid  Fluka Chemie, Neu-Ulm 
Bovine serum albumin (BSA) Sigma-Aldrich, Steinheim 
Buffer AE (elution buffer) Qiagen, Hilden 
Buffer AL (lysis buffer) Qiagen, Hilden 
Buffer AW 1, concentrate (wash buffer) Qiagen, Hilden 
Buffer AW 2, concentrate (wash buffer) Qiagen, Hilden 
Buffer HS, concentrate (wash buffer) Bio-Budget Technologies, Krefeld 
Buffer LS, concentrate (wash buffer) Bio-Budget Technologies, Krefeld 
Buffer RL (lysis buffer) Bio-Budget Technologies, Krefeld 
CASYton, isotonic diluting solution Schärfe System, Reutlingen 
Cimetidine Sigma-Aldrich, Steinheim 
Copper sulfate · 5 H2O Sigma-Aldrich, Steinheim 
2'-Deoxyadenosine 5'-monophosphate Sigma-Aldrich, Steinheim 
sodium salt (dAMP) 
2'-Deoxyguanosine 5'-monophosphate Sigma-Aldrich, Steinheim 
sodium salt (dGMP) 
Dietyhl pyrocarbonate (DEPC) Sigma-Aldrich, Steinheim 
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4´,6-Diamidino-2-phenylindole Sigma-Aldrich, Steinheim 
dihydrochloride (DAPI) 
Dimethylsulfoxide (DMSO) Riedel-de Haën, Seelze 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl- AppliChem, Darmstadt 
2H-tetrazolium bromide (MTT) 
Disodium hydrogen phosphate · 2 H2O  Merck, Darmstadt 
Ethanol 96-100 % (V/V) Merck, Darmstadt 
2,2',2'',2'''-(Ethane-1,2-diyldinitrilo) Sigma-Aldrich GmbH, Steinheim 
tetraacetic acid disodium salt  
(EDTA, dinatriumsalz)  
1-Ethyl-2-[(1-ethyl-2(1H)-quinolinylidene) Sigma-Aldrich, Steinheim 
methyl]quinolinium iodide (decynium-22) 
Fetal calf serum (FCS)  Sigma-Aldrich, Steinheim 
Fluoromount™  Sigma-Aldrich, Steinheim 
aqueous mounting medium 
Formaldehyde 37 % (m/V) Riedel de Haën AG, Seelze 
Goat antibodies to hCTR1, hOCT1, Santa Cruz Biotechnology, Santa Cruz, 
hOCT2 and hOCT3 [200 µg/mL] CA, USA 
Helium Praxair, Oevel 
Hydrochloric acid [0.1 M and 1.0 M]  Riedel de Haën AG, Seelze 
Hydrochloric acid 37 % (m/V) Merck, Darmstadt 
Isopropanol 100 %  Merck, Darmstadt 
L-Glutamin solution [200 mM] Sigma-Aldrich, Steinheim 
Methanol Merck, Darmstadt 
Monosodium phosphate Fluka Chemie, Neu-Ulm 
Nitric acid 65 % (V/V), suprapur  Merck, Darmstadt 
1-Octanol  Sigma-Aldrich, Steinheim 
Penicillin streptomycin solution  Sigma-Aldrich, Steinheim 
[10,000 I.E./mL, 10 mg/mL] 
Potassium chloride  Merck, Darmstadt 
Potassium dihydrogen phosphate  Fluka Chemie GmbH, Neu-Ulm 
Propidium iodide solution [1.5 mM] Invitrogen, Karlsruhe 
Ribonuclease A (RNase A) Sigma-Aldrich, Steinheim 
RPMI-1640 medium Sigma-Aldrich, Steinheim 
Sodium chloride Fluka Chemie, Neu-Ulm 
Sodium dihydrogen phosphate · H2O 
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Sodium hydroxide [0.1 M and 1.0 M]  Riedel de Haën AG, Seelze 
Tetraethylammonium chloride (TEA) Sigma-Aldrich, Steinheim 
Thymidine 5'-monophosphate Sigma-Aldrich, Steinheim 
disodium salt (TMP) 
Triton X-100 Sigma-Aldrich, Steinheim 
Trypsin-EDTA solution Sigma-Aldrich, Steinheim 
[0.5 g porcine trypsin and  
 0.2 g EDTA in 100 ml] 
Ultrapure water  Obtained by Purlab Plus™ system 
 
Platinum complexes 
Cisplatin  Sigma-Aldrich, Steinheim 
Carboplatin Sigma-Aldrich, Steinheim 
Oxaliplatin Sigma-Aldrich, Steinheim 
Oxaliplatin analogues Synthesis of the oxaliplatin analogues was 
carried out by the working group of Prof. Dr. 
Bernhard K. Keppler according to the 
procedures previously published122-128. 
 
An overview of the structures is presented in Tab. 3-1. 
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Tab. 3-1: Structure, stereochemistry and lipophilicity of the investigated platinum 
complexes (n.a., not applicable; *, chiral centre). 
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(Cont.) Structure, stereochemistry and lipophilicity of the investigated platinum 
complexes (n.a., not applicable; *, chiral centre). 
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3.1.2 Buffers and solutions 
Capillary electrophoresis 
Borate buffer [0.4 M, pH 9.1] 
 Boric acid   2.473 g 
 Ultrapure water   ad 100.0 mL 
 (adjusted to pH 9.1 with 1 M sodium hydroxide)   
 
dAMP stock solution [3 mM] 
 dAMP    12.88 mg 
 Ultrapure water   ad 10.0 mL 
 
dGMP stock solution [3 mM] 
 dGMP    13.09 mg 
 Ultrapure water   ad 10.0 mL 
 
Phosphate buffer [40 mM, pH 7.4] 
 Sodium dihydrogen phosphate · H2O   552 mg 
 Ultrapure water   ad 100.0 mL 
 (adjusted to pH 7.4 with 1 M sodium hydroxide)   
 
Sodium chloride buffer [40 mM, pH 7.4] 
 Sodium chloride   234 mg 
 Ultrapure water   ad 100.0 mL 
 (adjusted to pH 7.4 with 1 M sodium hydroxide)   
 
TMP stock solution [3 mM] 
 TMP    11.88 mg 
 Ultrapure water   ad 10.0 mL 
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Platinum analysis 
Cisplatin stock solution [1 mg/mL platinum] 
 Cisplatin    15.4 mg 
 Ultrapure water   ad 10.0 mL 
 
Cisplatin working solution 1 [10 µg/mL platinum] 
 Cisplatin stock solution   0.1 mL 
 Ultrapure water   ad 10.0 mL 
 
Cisplatin working solution 2 [1 µg/mL platinum] 
 Cisplatin working solution 1   1.0 mL 
 Ultrapure water   ad 10.0 mL 
 
MTT assay 
MTT solution 
 MTT   500.0 mg 
 Phosphate buffered saline    ad 100.0 mL 
 
Incubation experiments 
Atropine sulfate [160 mM] 
 Atropine sulfate salt monohydrate    44.47 mg 
 Ultrapure water    ad 0.4 mL 
 
Carboplatin [800 µM] 
 Carboplatin    2.97 mg 
 Ultrapure water    ad 10.0 mL 
 
Cell culture medium 
 RPMI-1640 medium    500.0 mL 
 Fetal calf serum    50.0 mL 
 Penicillin streptomycin solution   5.0 mL 
 
Cimetidine [15 mM] 
 Cimetidine    3.75 mg 
 Ultrapure water    ad 1.0 mL 
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Cisplatin [800 µM] 
 Cisplatin    2.40 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 4 [800 µM] 
 Complex 4    3.29 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 5 [800 µM] 
 Complex 5    3.40 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 6 [800 µM] 
 Complex 6    3.79 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 7 [800 µM] 
 Complex 7    3.63 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 8 [800 µM] 
 Complex 8    3.04 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 9 [800 µM] 
 Complex 9    3.68 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 10 [800 µM] 
 Complex 10    3.29 mg 
 Ultrapure water    ad 10.0 mL 
 
Complex 11 [800 µM] 
 Complex 11    3.45 mg 
 Ultrapure water    ad 10.0 mL 
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Complex 12 [800 µM] 
 Complex 12    5.05 mg 
 Ultrapure water    ad 10.0 mL 
 
Copper sulfate solution [500 µM] 
 Copper sulfate · 5 H2O   124.8 mg 
 Ultrapure water   ad 1.0 mL 
 
Decynium-22 stock solution [12 mM] 
 Decynium-22   54.5 mg 
 Dimethylsulfoxide   ad 10.0 mL 
 
Decynium-22 working solution [500 µM] 
 Decynium-22 stock solution   41.7 µL 
 Ultrapure water   ad 1 mL 
 
Oxaliplatin solution [12 mM] 
 Oxaliplatin    47.7 mg 
 Ultrapure water   ad 10.0 mL 
 
Oxaliplatin solution [800 µM] 
 Oxaliplatin    3.18 mg 
 Ultrapure water    ad 10.0 mL 
 
Phosphate buffered saline (PBS) 
 Sodium chloride    8.0 g 
 Disodium hydrogen phosphate · 2 H2O   1.4 g 
 Potassium dihydrogen phosphate    0.2 g 
 Potassium chloride    0.2 g 
 Ultrapure water   ad 1000.0 mL 
 
TEA solution [300 mM] 
 TEA    49.71 mg 
 Ultrapure water    ad 1.0 mL 
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Isolation of DNA 
Buffer AE (elution buffer) [pH 9.0] 
 Tris-HCl   10.0 mM 
 EDTA   0.5 mM 
 
Buffer AW 1 (wash buffer) 
 AW 1 concentrate*    95.0 mL 
 Ethanol 96 % (V/V)    ad 220.0 mL 
 * The manufacturer does not provide information about the exact composition. 
 
Buffer AW 2 (wash buffer) 
 AW 2 concentrate*    66.0 mL 
 Ethanol 96 % (V/V)    ad 226.0 mL 
 * The manufacturer does not provide information about the exact composition. 
 
Isolation of RNA 
Buffer HS (wash buffer) 
 HS concentrate*    15.0 mL 
 Ethanol 96 % (V/V)    ad 30.0 mL 
 * The manufacturer does not provide information about the exact composition. 
 
Buffer LS (wash buffer) 
 LS concentrate*    8.0 mL 
 Ethanol 96 % (V/V)    ad 40.0 mL 
 * The manufacturer does not provide information about the exact composition. 
 
DEPC water [0.1 %] 
 DEPC   1.0 g 
 Ultrapure water   ad 1.0 L 
 
Immunohistochemical staining 
ALEXA Fluor™ 488-conjugated chicken anti-goat antibody solution 
 ALEXA Fluor™ 488-conjugated chicken anti-goat antibody 10.0 µL 
 Ethanol 96 % (V/V)    ad 1.0 mL 
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BSA solution [1 %] 
 BSA   0.5 g 
 Phospate buffered saline   ad 50.0 mL 
 
DAPI stock solution [1 mg/mL] 
 DAPI   1.0 mg 
 Methanol   ad 1.0 mL 
 
DAPI working solution [5 µg/mL] 
 DAPI stock solution   5.0 µL 
 Ultrapure water   ad 1.0 mL 
 
Ethanol [90 %] 
 Ethanol 96-100 %   9.0 mL 
 Ultrapure water   ad 10.0 mL 
 
Ethanol [70 %] 
 Ethanol 96-100 %   7.0 mL 
 Ultrapure water   ad 10.0 mL 
 
Formaldehyde [3.7 %] 
 Formaldehyde 37 %   5.0 mL 
 Phosphate buffered saline   ad 50.0 mL 
 
Goat antibody solution (hCTR1, hOCT1, hOCT2 or hOCT3) 
 Goat antibody   100 µL 
 BSA solution 1 %   ad 1.0 mL 
 
Propidium iodide solution [5 µM] 
 Propidium iodide   3 µL 
 Phosphate buffered saline   ad 0.9 mL 
 
RNase A stock solution [1 mg/mL] 
 RNase A   1 mg 
 Phosphate buffered saline   ad 1.0 mL 
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RNase A working solution [100 µg/mL] 
 RNase A stock solution   100 µL 
 Phosphate buffered saline   ad 1.0 mL 
 
Triton® X-100 [0.5 %] 
 Triton® X-100   234 µL 
 Phosphate buffered saline   ad 50.0 mL 
3.1.3 Cell lines 
The human ileocecal colorectal adenocarcinoma cell lines HCT-8 and HCT-8ox 
(kindly provided by Dr. R.A. Hilger, University of Essen, Germany) were used in the 
study. The resistant variant (HCT-8ox) was obtained by incubation with stepwise 
increasing oxaliplatin concentrations. In detail, oxaliplatin was added to HCT-8 cells 
to a final concentration equal to the EC50 for 24 h. Afterwards, the cells were 
incubated in drug-free cell culture medium. At the point that treated cells grew as fast 
as untreated cells, a higher concentration of oxaliplatin was added to the cells. 
However, the concentration of oxaliplatin did not exceed 3- to 4-fold of the EC50. 
3.1.4 Consumption materials 
BCA™ Protein Assay Kit Pierce, Bonn 
BIO-CERT® pipette tips Brand GmbH & Co., Wertheim 
Capillaries, uncoated Beckman Coulter, Fullerton, USA 
(fused silica, 75 µm ID, 365 µm OD) 
Cellstar® Cell Culture Flasks 175 cm2  Greiner Labortechnik, Frickenhausen 
Cellstar® Cell Culture Flasks 75 cm2  Greiner Labortechnik, Frickenhausen 
Cellstar® Cell Culture Flasks 25 cm2  Greiner Labortechnik, Frickenhausen 
Cellstar® conical centrifuge tubes (15 mL) Greiner Labortechnik, Frickenhausen 
Cellstar® conical centrifuge tubes (50 mL) Greiner Labortechnik, Frickenhausen 
Cellulose acetate membrane filters  Macherey-Nagel, Düren 
(0.22 µm) 
Cover slips Carl Roth GmbH & Co., Karlsruhe 
Cryovials Sarstedt, Nümbrecht 
Disposable syringe (10 mL) B. Braun Melsungen AG, Melsungen 
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Graphite tubes  Varian, Darmstadt 
Microscope slides Carl Roth GmbH & Co., Karlsruhe 
MycoAlert® Mycoplasma Detection Kit Lonza Rockland, Rockland, USA 
my-Budget RNA Mini Kit Bio-Budget Technologies, Krefeld 
Pasteur pipettes Brand GmbH & Co., Wertheim 
Petri dishes Greiner Labortechnik, Frickenhausen 
Pipette tips Brand GmbH & Co., Wertheim 
Pipettes of glass Labomedic GmbH, Bonn 
Platinum hollow cathode lamps  Varian, Darmstadt 
(UltrAA® lamps) 
QIAamp® DNA Mini Kit  Qiagen, Hilden 
Reaction tubes (0.5, 1.5, 2 mL)  Greiner Labortechnik, Frickenhausen 
Sample vials (2 mL, conical)  Varian, Darmstadt 
Tissue culture plates, 96 wells  Greiner Labortechnik, Frickenhausen 
Tissue culture plates, 6 wells  Greiner Labortechnik, Frickenhausen 
3.1.5 Equipment 
Axiovert® 25 inverted microscope Carl Zeiss, Oberkochen 
CASY®1 cell counter  Schärfe System, Reutlingen 
CO2 incubator  Thermo Scientific, Waltham, USA 
GENESYS 6 UV/VIS spectrophotometer Thermo Scientific, Waltham, USA 
Hellma® absorption cuvettes Hellma, Mülheim 
(Suprasil® quartz) 
Incubator shaker Unimax® 1010 Heidolph, Schwabach 
inoLab® pH level 2 pH Meter WTW, Weilheim 
Kern 770 analytical balance Gottlieb Kern & Sohn, Albstadt 
Laminar flow workstation Heraeus, Hanau 
Magnetic stirrer RMH71 Gerhardt GmbH & Co. KG, Königswinter 
Microfuge® Lite centrifuge Beckman Coulter, Brea, USA 
MIKRO 200R microliter centrifuge Hettich, Beverly, USA 
Multiskan Ascent microplate photometer  Thermo Scientific, Waltham, USA 
Purelab Plus water purification system ELGA Labwater, Celle 
40  Materials and methods 
Transferpette® -12 electronic, multi-chanel BRAND, Wertheim 
pipettes (variable volume, 0.5 - 300 µL) 
Transferpette® S, single-channel pipettes BRAND, Wertheim 
(variable volume, 0.5 - 1000 µL) 
Ultrasonic water bath Bandelin, Berlin 
Universal 32R centrifuge Hettich, Beverly, USA 
Vortexer Gesellschaft für Laborbedarf, Würzburg 
Water bath Büchi 461  Büchi, Switzerland 
 
Atomic absorption spectrometry 
Spectrometer SpectrAA® Zeeman 220  Varian, Darmstadt 
Graphite tube atomizer GTA 100   Varian, Darmstadt 
Programmable sample dispenser PSD 100 Varian, Darmstadt 
Software SpectrAA® 220, version 2.20  Varian, Darmstadt 
 
Capillary electrophoresis 
P/ACE® 5510  Beckman Coulter, Fullerton, USA 
UV detector  Beckman Coulter, Fullerton, USA 
 
Immunohistochemical staining 
Leica TCS SP2 confocal system  Leica Microsystems, Wetzlar 
Zeiss ApoTome Axiovert 200M system Carl Zeiss, Oberkochen 
3.1.6 Software 
Adobe® Photoshop® 6.0  Adobe Systems, San Jose, USA 
GraphPad Prism™  GraphPad Software, San Diego, USA 
MVA 2.0  NOVIA, Frankfurt am Main 
Software P/ACE® Station, version 1.21 Beckman Coulter, Fullerton, USA 
SPSS® Statistics 17  SPSS Inc., Chicago, USA 
WinNonlin® Professional 5.0.1  Pharsight Corporation, Mountain View,  
  USA 
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3.2 Determination of log P 
Lipophilicity of the platinum complexes was quantified as log P (logarithm of 
1-octanol/water partition coefficient). The log P values were determined according to 
the OECD guideline using the shake-flask method129. Weighted amounts of platinum 
complexes were partitioned between an aqueous and 1-octanol phase. Platinum 
concentrations in the aqueous phase were measured by flameless atomic absorption 
spectrometry. Based on these results, the partition coefficients were calculated.  
 
3.3 Assessment of reactivity towards nucleotides 
For the investigation of reactivity of platinum complexes towards the nucleotides 
dAMP and dGMP, a previously described method for capillary electrophoresis was 
modified and validated130,131. Briefly, 150 µM (platinum complexes with different 
amine ligands) or 300 µM (platinum complexes with different leaving groups) of each 
platinum complex were incubated with 150 µM dGMP and 150 µM dAMP under 
physiological conditions (4 mM NaH2PO4, 4 mM NaCl, pH 7.4, 37 °C) up to 72 h. A 
platinum-nucleotide ratio of 1:1 was chosen in case of the assessment of reactivity of 
platinum complexes with different leaving groups in order to estimate the rate 
constants of the formation of the monofunctional platinum-nucleotide adducts. The 
samples were collected after 0, 12, 24, 48 and 72 h of incubation (n = 3). To enhance 
the precision of nucleotide analysis, 4 µL internal standard (TMP, 3 mM in buffer 
containing 4 mM NaH2PO4, 4 mM NaCl, pH 7.4) were added to 100 µL sample. The 
measurement was carried out on a P/ACE™ 5510 instrument controlled by the 
P/ACE™ station software. An uncoated capillary (75 µm ID, effective separation 
length 57 cm) was assembled in the P/ACE™ cartridge. The capillary was 
thermostated at 19 °C. Injections were performed at 5 psi for 5 s. A voltage of 20 kV 
was applied for all experiments. Detection was performed using UV absorption at 
254 nm. Prior to each analysis the capillary was flushed with running buffer (400 mM 
borate buffer, pH 9.1) for 1 min. After each analysis the capillary was rinsed with 
sodium hydroxide (0.1 M) for 1 min, followed by ultrapure water for 1 min. 
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3.4 Determination of the rate constants 
The rate constants for the reaction between the platinum complexes ([Pt(DACH)Y2], 
Y2 being the leaving group) and the nucleotides, dGMP and dAMP, were calculated 
based on a second-order reaction. To simplify the calculations, it was focused 
exclusively on the formation of the monofunctional platinum-nucleotide adducts. 
Consequently, for the rates (ν1 and ν2) and the rate constants (k1 and k2) the 
following relationship holds (Eqs. 1 and 2): 
     (1) 
     (2) 
Under the condition that at any time of the reaction  
       (3) 
the rate constants k1 and k2 were estimated by non-linear regression of the 
nucleotide concentration-time data using WinNonlin® Professional 5.0.1. 
 
3.5 Platinum analysis 
The platinum concentrations were measured by flameless atomic absorption 
spectrometry using a modification of the procedure described by Kloft et al., which 
was validated by Dr. Anne C. Pieck132,133. Because the validation was carried out on 
the same instrument used in this study a revalidation was not necessary. In brief, an 
atomic absorption spectrometer equipped with a graphite tube atomizer, a 
programmable sample dispenser and a platinum hollow cathode lamp were used. 
The temperature program included an ashing step at 1,300 °C and an atomization 
step at 2,700 °C. The lower limit of quantification (LLOQ) was 1 ng/mL. 
Samples with platinum concentrations below the LLOQ of the flameless atomic 
absorption spectrometry were analyzed using a validated adsorptive stripping 
voltammetry method134. With this method the detection limit could be reduced to 
0.4 pg/mL. In brief, after drying the samples were mineralized by a high-pressure 
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asher (HPA, Kürner, Rosenheim, Germany)135. Platinum was then quantified by 
adsorptive stripping voltammetry using a Metrohm Polarecord 693 VA Processor with 
694 VA Stand (Metrohm, Herisau, Switzerland). The standard addition technique was 
used to determine the platinum concentrations134. The measurements were 
performed in the working group of Dr. Günther Weber. 
In the course of time, a faster method of determination of platinum in samples below 
the LLOQ of flameless atomic absorption spectrometry was available: the inductively 
coupled plasma mass-spectrometry (ICP-MS)136. Samples were lyzed with an 
aqueous solution containing 1 % nitric acid for 24 h on a water bath at 78 °C. For the 
quantification of platinum a Varian 820 ICP-MS detector was used and volumes of 
1.0 mL were injected. Accuracy and precision of the method were determined during 
the analysis. Each ICP-MS analysis resulted from five replicate measurements 
consisting of 20 scans of the isotops of interest. Quality control samples were used to 
insure the accuracy of the measurements. The measurement of the samples was 
carried out in the working group of Dr. Ralf A. Hilger. 
 
3.6 NMR spectroscopy 
Oxaliplatin (10 mM) and cimetidine (150 mM) were incubated in PBS/DMF mixture 
(1:1) at 37 °C. After 1 h, 2 h, 3 h and 16 h, 195Pt NMR spectra of the reaction mixture 
were recorded on a Bruker DPX 300 spectrometer with a 5 mm multinucleus probe. 
The spectra were calibrated with respect to external K2PtCl4 at δ = - 1,614 ppm. The 
working group of Prof. Dr. Jan Reedijk carried out the measurements. 
 
3.7 Cell culture 
Cells were grown in RPMI-1640 medium after adding 10 % fetal calf serum, 
100 I.E./mL penicillin and 0.1 mg/mL streptomycin and cultivated as monolayers at 
37 °C in a humidified atmosphere containing 5 % CO2. Cells were routinely checked 
for mycoplasma contamination by DAPI staining and using MycoAlert® Mycoplasma 
Detection Kit. Backups of all cells were frozen with 10 % DMSO and stored in liquid 
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nitrogen. Every 12 passages, a new backup of cells was thawed to ensure that the 
resistance status was unchanged during long-time cultivation. 
The advantages of this cell model were the high sensitivity of HCT-8 cells to 
oxaliplatin and the high level of resistance of HCT-8ox cells to oxaliplatin. The 
HCT-8ox cell line acquired resistance after oxaliplatin treatment bearing the 
advantage of developing oxaliplatin-specific characteristics. 
Cell count was carried out using a Casy™1 cell counter, which works via electronic 
pulse area analysis. Beside the number of cells, cell volume, aggregation and 
viability were determined. 
 
3.8 Cytotoxicity assay 
Cytotoxicity of the platinum complexes was assessed using an MTT-based assay137. 
Briefly, cells were plated in 96-well microtiter plates (approximately 5,000 cells/well) 
and pre-incubated with growth medium for up to six hours. Then medium was 
removed. Stock solutions of platinum complexes in ultrapure water (0.8 mM) were 
diluted in medium and nine subsequent dilutions were added to the cells in triplicate 
(100 µL/well). In some experiments cells were pre- or coincubated with copper 
sulfate (coincubation: 50 and 100 µM), TEA (coincubation: 10 µM, 1 and 10 mM), 
atropine sulfate (Fig. 3-1A, preincubation: 1 h, 1 mM; coincubation: 0.1 and 1 mM), 
cimetidine (Fig. 3-1B, preincubation: 6 h, 1.5 mM; coincubation: 0.1 mM or 1 mM) or 
decynium-22 (Fig. 3-1C, coincubation: 0.1 and 1 µM).  
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Fig. 3-1 Structure of A atropine sulfate, B cimetidine and C decynium-22. 
After 72 h of incubation, 20 µL of a 5 mg/mL MTT solution was added to each well, 
and the cells were incubated at 37 °C for about 1 h. Subsequently, medium was 
discarded and 100 µL DMSO was added to dissolve the formazan crystals. 
Absorbance of the converted dye was measured at 570 nm with background 
subtraction at 690 nm using a microplate photometer. The results were analyzed and 
the pEC50 values (pEC50 = -log EC50, EC50 is the drug concentration that produces 
50 % of the maximum possible response) were estimated with the GraphPad 
Prism™ analysis software package using non-linear regression (sigmoidal dose 
response, variable slope). The resistance factor (RF) was calculated by dividing the 
EC50 in the resistant variant by the EC50 in the respective sensitive cell line. 
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3.9 Measurement of intracellular platinum concentration 
3.9.1 Influx of oxaliplatin analogues 
In order to characterize the influx of the oxaliplatin analogues, 1 x 106 cells per well 
were seeded in six-well plates. After attachment (5 – 6 h), cells were incubated with 
100 µM platinum complex up to 2 h. After certain time points the medium was 
discarded quickly and cells were washed with 1 mL ice-cold PBS (phosphate 
buffered saline, pH adjusted to 7.4). Then cells were trypsinized, resuspended in 
fresh drug-free medium and centrifuged for 1 min at 4 °C and 1,520 g. The 
supernatant was discarded and the pellet was washed twice in 1 mL ice-cold PBS. 
After centrifugation for 1 min at 18,620 g the supernatant was discarded again and 
the cell pellet was frozen at -20 °C until further analysis. Immediately after thawing 
the cells were lyzed with concentrated nitric acid for 1 h on a water bath at 80 °C. 
Then intracellular platinum concentrations were measured by flameless atomic 
absorption spectrometry or adsorptive stripping voltammetry. Platinum 
concentrations were calculated in relation to the mean cell volume (as measured with 
Casy™1 cell counter). 
3.9.2 Influx of oxaliplatin 
In order to characterize the influx of oxaliplatin, three different types of influx 
experiments were conducted. In each experiment 1 x 106 cells per well were seeded 
in six-well plates. After the attachment (5 – 6 h), cells were incubated with oxaliplatin 
under different conditions.  
In the first set of experiments cells were treated with different concentrations of 
oxaliplatin (0.02, 0.1, 0.5, 1.0, 1.5 mM) over a period of 2 h. In the second set of 
experiments cells were incubated with 100 µM oxaliplatin up to 2 h. In the third set of 
experiments cells were pre- or coincubated with substrates and/or inhibitors of 
transport proteins. In general, preincubation experiments were only performed if an 
effect was found in coincubation experiments. Cells were treated with copper sulfate 
(substrate of hCTR1; coincubation: 50 and 100 µM), TEA (substrate of hOCT1-3; 
coincubation: 10 µM, 1 mM and 10 mM), atropine sulfate (Fig. 3-1A, inhibitor of 
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hOCT1; preincubation: 1 h, 1 mM; coincubation: 1 mM), cimetidine (Fig. 3-1B, 
inhibitor of hOCT2; preincubation: 1 h, 1.5 mM, coincubation: 0.15 and 1.5 mM) or 
decynium-22 (Fig. 3-1C, inhibitor of hOCT3; coincubation: 0.1 and 1 µM).60,77,78,138 In 
each experiment, cells were incubated with oxaliplatin for 2 h. Afterwards, cells were 
collected as described above (see 3.9.1). 
3.9.3 Long-term influx of oxaliplatin in presence of cimetidine 
To characterize the influence of cimetidine on the influx of oxaliplatin in more detail, 
long-term experiments were performed. In each experiment 5 x 105 cells per well 
were seeded in six-well plates. After the attachment (5 – 6 h), cells were 
preincubated with 1.5 mM cimetidine for 12 h and subsequently incubated with 20 µM 
oxaliplatin up to 24 h or cells were coincubated with 1.5 mM cimetidine and 20 µM 
oxaliplatin up to 24 h. After 2, 4, 6, 8, 10, 12 and 24 h of oxaliplatin treatment cells 
were collected as described above (see 3.9.1). In contrast to the above-described 
collection of the cells, after the first centrifugation step at 1,520 g and the subsequent 
resuspension of the cell pellet in ice-cold PBS an aliquot of 20 µL was removed for 
protein determination (see 3.10.3). Both, cell pellet and aliquot, were frozen at -20 °C 
until further analysis. 
3.9.4 Efflux 
In order to characterize the efflux of platinum, 1 x 106 cells per well were seeded in 
six-well plates and allowed to attach for 5 to 6 h. Afterwards they were incubated with 
100 µM platinum complex for 2 h. One part of the cells was collected as described 
above. The other part of the cells was washed two times with 1 mL PBS and 
incubated for 2, 5, 10, 60 and 120 min with drug-free medium. Subsequently, the 
cells were collected as described above (see 3.9.1). 
 
3.10 Protein determination 
In some influx experiments time after plating cells was too long to act on the 
assumption that the number of cells remained unchanged. The doubling time of both 
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cell lines determined prior to the experiments was about 14 h. Therefore, in all 
experiments, in which cells grew longer than 14 h, the intracellular platinum 
concentration was calculated in ng/mg protein. 
The protein concentration was determined using the bicinchoninic assay (BCA™ 
Protein Assay Kit) according to the manufacturers instructions. A validation with 
respect to the calibration curve (linearity and working range, precision and accuracy, 
lower limit of quantification) was already conduced in our working group131. 
Therefore, the validation in this study was restricted to the examination of the 
conditions of the sample preparation. The most important step during the sample 
preparation is the solubilization of the cell suspension. To get reliable results it is 
important that the cells are completely solubilized. 
3.10.1 Standards and quality control samples 
Six non-zero standard concentrations were prepared out of the albumin standard 
(SL) ampule provided by the manufacturer (Tab. 3-2). Ultrapure water was used as 
diluent. Standards and quality control samples were prepared out of different charges 
of stock solution. 
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Tab. 3-2 Preparation of standards and quality control samples. 
 Volume of diluent 
[µL] 
Volume and source 
of BSA [µL] 
Final BSA 
concentration 
[µg/mL] 
Standards 
SL1 -- -- 2,000 
S1 1,600 400 of SL 400 
S2 250 750 of S1 300 
S3 500 500 of S1 200 
S4 600 300 of S2 100 
S5 625 375 of S3 75 
S6 300 300 of S4 50 
  Quality control samples 
SL2 -- -- 2,000 
QC1 825 175 of SL2 350 
QC2 875 125 of SL2 250 
QC3 925 75 of SL2 150 
 
3.10.2 Experimental procedure 
Protein samples (20 µL) were thawed. Standards and quality control samples were 
prepared and 40 µL of each concentration was pipetted into a vial. To assure that the 
experimental conditions were the same for samples, standards and quality control 
samples, all solutions were treated in the same way. 10 µL of sodium hydroxide (1 M) 
was added to each sample and 20 µL to each standard and quality control. All 
solutions were sonicated for 30 min at room temperature. Afterwards, the solutions 
were neutralized by addition of the same volume of hydrochloric acid (1 M) as before 
of sodium hydroxide. Dilutions with ultrapure water were performed where necessary 
in order to bring the protein concentration of the samples within the calibration range. 
20 µL of each solution was transferred to a 96-well microtiter plate. Standards were 
determined in triplicate, quality control samples and samples in duplicate. The 
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subsequent procedure was carried out as described by the manufacturer (microplate 
procedure).  
If the following conditions were met, the experiment was accepted139: 
• The deviation of standards was ≤ 15 % and the deviation of the LLOQ 
≤ 20 % from nominal concentration. 
• At least four out of six standards met the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. 
• The coefficient of correlation was ≥ 0.99 (weighted linear regression, 1/x). 
• At least 67 % (two out of three) of the quality control samples were within 
± 15 % of their respective nominal values. 
3.10.3 Partial validation of the sample preparation 
Aliquots for the determination of proteins were removed during the collection of cells 
after long-term incubation with oxaliplatin and/or cimetidine (see 3.9.3). The time 
after seeding cells varied in this experiment between 7 and 48 h. Consequently, the 
concentration of cells in the aliquots differed within a wide range. Therefore, cell lysis 
became a crucial factor in the determination of the concentration of proteins. To be 
sure that even in samples with a high concentration of cells all cells were lyzed, the 
method of sample preparation was validated. Under optimal cell lysis conditions one 
would expect a linear relationship between protein and cell concentration. 
Suspension of HCT-8 and HCT-8ox cells with 1 x 106, 2 x 106, 3 x 106, 4 x 106 
cells/mL were prepared. Aliquots of 20 µL were removed and frozen at -20 °C for 
further analysis. At six different days six aliquots of each cell concentration were 
thawed and the protein concentration was determined as described above. Finally, 
the protein concentration was related to the cell concentration. 
 
3.11 Measurement of platinum-DNA adduct formation and repair 
For the determination of the platinum-DNA adduct formation 5 x 106 cells were 
incubated with 100 µM platinum complex up to 4 h and subsequently washed with 
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1 mL ice-cold PBS. Afterwards, cells were trypsinized, resuspended in fresh drug-
free medium and centrifuged for 1 min at 4 °C and 1,520 g. The supernatant was 
discarded and the pellet was washed twice in 1 mL ice-cold PBS. After centrifugation 
for 1 min at 18,620 g the supernatant was discarded again. The cell pellet was frozen 
at -20 °C until further analysis. 
Repair experiments were performed by incubating 1 x 106 cells for 4 h with 
oxaliplatin. HCT-8 cells were incubated with 100 µM oxaliplatin and HCT-8ox cells 
with 200 µM oxaliplatin. The different concentrations were chosen to achieve a 
comparable extent of platinum-DNA adducts in each cell line at the beginning of the 
experiment. Subsequent to the incubation with oxaliplatin, cells were washed once in 
1 mL ice-cold PBS and afterwards, drug-free cell culture medium was added to each 
well. After 0, 2, 4 or 6 h cells were collected as described above. 
DNA platination was determined using a previously published method adapted to 
tumor cells140: Subsequent to the isolation with solid-phase extraction (QIAmp® DNA 
Mini Kit) DNA concentrations were measured by UV photometry and platinum 
concentrations by flameless atomic absorption spectrometry, adsorptive stripping 
voltammetry or ICP-MS, as appropriate. Based on these results the platinum-
nucleotide ratio [platinum atoms/106 nucleotides] was calculated as a measure of the 
extent of DNA platination. The platinum-nucleotide ratio reflects the net rate of adduct 
formation and repair. 
DNA quantification and determination of platinum in adduct samples using flameless 
atomic absorption spectrometry was validated by Dr. A. Pieck with respect to 
accuracy and precision133.  
 
3.12 Gene expression analysis 
In each experiment 1.2 x 105 cells per well were seeded in six-well plates. On the 
next day oxaliplatin (20 µM) was added to some wells. After another 2 h or 24 h 
oxaliplatin-containing medium was removed and cells were further cultured in 
platinum-free medium for 24 h. Cells treated for 24 h with oxaliplatin without a 
subsequent wash-out phase and untreated cells were maintained in parallel. The 
experiment, in which cells were treated for 24 h with oxaliplatin without a wash-out 
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phase, was included to secure that the effect of the incubation with oxaliplatin was 
not masked by the wash-out phase. Afterwards, treated and untreated cells were 
harvested by trypsinization and RNA was isolated using my-Budget RNA Mini Kit. 
The optical density ratio (260/280 nm) of all RNA samples was between 2.08 and 
2.36. RNA integrity was confirmed by agarose gel electrophoresis (2 % in HEPES 
buffer containing 10 mM EDTA, 50 mM CH3COONa x 3 H2O, 200 mM HEPES, 
pH 7.2, and 1.7 % formaldehyde). 2 µg of RNA was mixed with 6x loading dye and 
heated to 65 °C for 5 min. Then 2 µL of SYBR® Green II (Applied Biosystems, Foster 
City, USA) was added and the samples were loaded onto the gel. Reverse 
transcription was performed with 1 µg RNA by using the High-Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, USA) and 35 pM oligo(dT)23 anchored primer. 
Reverse transcription was performed at 37 °C for 2 h. Reverse transcription mixtures 
were diluted with 1x Tris-EDTA buffer pH 7.4, and quantitative real-time PCR (qRT-
PCR) was performed using the Power SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City, USA) according to the manufacturer´s instructions. 
Sequences of the used primers are listed in Tab. 3-3. Housekeeping genes were 
identified using geNorm141,142. Analysis of differential gene expression was carried 
out using the ∆∆Ct-method143. After normalization to the gene of interest (GOI) the 
results were rescaled by setting the normalized mRNA expression of the relevant 
transporter in untreated HCT-8 cells to 1 (= rescaled normalized expression). 
Verification of RNA integrity, qRT-PCR, identification of housekeeping genes and 
analysis of differential gene expression were performed in the working group of Prof. 
Dr. Matthias Kassack. 
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Tab. 3-3 Sequences of the primers used in qRT-PCR. 
Gene Accession number Left 5´→ 3´ Right 5´→ 3´ 
ß-Actin (ACTB) AY582799 
 
TCCTTCCTGGGC
ATGGAGT 
GCACTGTGTTGG
CGTACAG 
Beta-2-
microglobulin (B2M) 
BC064910 
 
CACCCCCACTGA
AAAAGATG 
CAAACCTCCATGA
TGCTG 
Glucuronidase beta 
(GUS) 
NM_000181 
 
TTCACCAGGATC
CACCTCTG 
AGCACTCTCGTC
GGTGACTG 
Hypoxanthine-
phosphoribosyltrans
-ferase 1 (HPRT1) 
NM_000194 
 
CTGGCGTCGTGA
TTAGTG 
CACACAGAGGGC
TACAATG 
60S (Human) Acidic 
ribosomal protein 
P1 (HUPO) 
BC070194 
 
AGCTCTGGAGAA
ACTGCTG 
CAGCAGCTGGCA
CCTTATTG 
Phospholipase A2 
(PhosA2) 
M86400 
 
GACAGCTTTTGAT
GAAGCCATTG 
TCCACAATGTCAA
GTTGTCTCTCAG 
Ribosomal protein 
L13 (RPL13) 
BC071929 
 
GCTCATGAGGCT
ACGGAAAC 
TATTGGGCTCAG
ACCAGGAG 
Transferrin receptor 
(p90, CD71) (TFR) 
BC001188 
 
GACTTTGGATCG
GTTGGTG 
CAGTAACCGGAT
GCTTCAC 
Ubiquitin-
conjugating enzyme 
E2D2 (UBE2D2) 
NM_003339 
 
ACCACCTAAGGTT
GCATTTAC 
TAGATCCGAGCA
ATCTCAGG 
Human copper 
transporter 1 
(hCTR1) 
BC061924 
 
AGCTGGAGAAAT
GGCTGGAG 
AGGTGAGGAAAG
CTCAGCATC 
Human organic 
cation transporter 1 
(hOCT1) 
NM_003057 ACCTCGGAGTGA
TGGTGTGTTC 
CCAACACCGCAA
ACAAAATG 
Human organic 
cation transporter 2 
(hOCT2) 
NM_003058 CACCGAGTTTAAC
CTGGTATGTG 
GGCCAAACCTGT
CTGCTATG 
Human organic 
cation transporter 3 
(hOCT3) 
NM_021977 GTCAGCGAGTTT
GACCTTGTC 
CCATACCTGTCTG
CTGCATAG 
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3.13 Immunohistochemical staining 
Immunohistochemical staining was done one day after seeding cells on cover slips. 
In some experiments, cells were pre-treated with either 20 µM oxaliplatin for 2 h, 
sometimes followed by a subsequent wash-out phase of 2 h. After three rinses with 
PBS, cells were fixed with 3.7 % formaldehyde in PBS for 15 min at room 
temperature. After fixation, cells were washed three times with PBS and 
permeabilized with 0.5 % Triton X-100 in PBS for 30 min. In some cases, 0.02 % 
Triton X-100 was used for permeabilization in parallel experiments. No differences in 
the staining results depending on Triton X-100 concentration were observed. Cells 
were again rinsed three times with PBS and afterwards unspecific binding was 
blocked with 1 % BSA in PBS for 1 h. An incubation for 90 min at 37 °C with a 
primary antibody against the respective transport protein (hCTR1, hOCT1, hOCT2, 
hOCT3) was followed. Subsequently, cells were washed three times with PBS and 
incubated for 90 min at 37 °C with the secondary ALEXA Fluor™ 488-conjugated 
antibody. Antibody solutions were diluted in PBS containing 1 % BSA. To stain the 
nucleus with propidium iodide, cells were treated with RNase A (100 µg/mL in PBS) 
for 30 min at 37°C, washed with PBS and incubated with 5 µM propidium iodide in 
PBS for 15 min at 37 °C. After the final washing steps, cells were gradually 
dehydrated in an ethanol series of 70 %, 90 %, 100 %, for 1 min each. The cover 
slips were mounted in Fluoromount™ medium for microscopic observations. Images 
were recorded using a Leica TCS SP2 confocal system or a Zeiss ApoTome Axiovert 
200M system for brightfield images at the Laboratory for Molecular Developmental 
Biology, LIMES Institute, University of Bonn. Images were normalized to the 
fluorescence of cells stained only with the secondary antibody. Each image is a 
representative of six images. 
 
3.14 Statistical analysis 
Although the results of the Kolmogorov-Smirnov test suggested a Gaussian 
distribution of the data from the cell culture experiments, the sample number was too 
small to exclude a non-Gaussian distribution. Therefore, the median was chosen as 
measure of central tendency. Consequently, differences were analyzed using the 
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non-parametric Mann-Whitney U test or the Kruskal-Wallis test, as appropriate. 
Correlation analyses were performed using the non-parametric Kendall tau rank 
correlation. In contrast, the EC50 values are generally accepted to be log-normally 
distributed. In this case, it was regarded as appropriate to calculate the mean pEC50 
values and to compare the results by performing Student’s t-test. The results of the 
investigation of the gene expression were first analyzed using ANOVA. When a 
significant difference was found, Tukey's test was used to determine which of the 
means differed. P values of ≤ 0.05 were considered significant. 
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4 Results 
4.1 Oxaliplatin analogues with different amine ligands 
4.1.1 Platinum complexes 
The introduction of substituents at position 4 of the cyclohexane ring creates an 
additional chiral center. Thus, compounds 4, 6 and 7 contain alkyl groups in 
equatorial and/or in axial position. The synthesized complexes 4 and 7 feature 
exclusively equatorial substitution, and 6 is mainly axially substituted (Tab. 
3-1)124,125,144. 
4.1.2 Determination of log P 
The results of the log P determination are shown in Tab. 4-1131. As expected 
lipophilicity of the compounds with different amine ligands increases in the following 
order: cisplatin < carboplatin < oxaliplatin < 4 < 5 < 6 < 7. 
 
Tab. 4-1  log P values of the investigated platinum complexes. 
Compound log P 
Cisplatin -2.53 
Carboplatin -2.30 
Oxaliplatin -1.76 
4 -1.28 
5 -0.68 
6 -0.28 
7 0.42 
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4.1.3 Reactivity towards nucleotides 
During the incubation of the platinum complexes with nucleotides, platinum-
nucleotide adducts were formed. The reactivity of the platinum complexes was 
determined based on the decrease in the amount of free nucleotide (Fig. 4-1 and Fig. 
4-2)131. 
A faster decrease in the concentration of dGMP compared to the concentration of 
dAMP was observed in presence of all tested platinum complexes. Oxaliplatin and its 
analogues with different amine ligands showed a comparable reactivity towards the 
nucleotides. For comparison, the reactivity of carboplatin and cisplatin was also 
determined. Cisplatin turned out to be the most reactive and carboplatin the least 
reactive compound. 
 
 
Fig. 4-1 Reduction of the corrected peak area of the nucleotide dAMP during 
incubation with platinum complex: cisplatin (), carboplatin (), 
oxaliplatin (), 4 (), 5 (), 6 (), 7 () (n = 3, mean ± SD). 
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Fig. 4-2 Reduction of the corrected peak area of the nucleotide dGMP during 
incubation with platinum complex: cisplatin (), carboplatin (), 
oxaliplatin (), 4 (), 5 (), 6 (), 7 () (n = 3, mean ± SD). 
4.1.4 Platinum accumulation 
4.1.4.1 Influx 
During the incubation experiments the platinum accumulation within the cells was 
measured. The platinum accumulation reflects the net rate of influx and efflux. 
Because of the infeasibility to determine each process separately, conditions were 
chosen to enhance one of the processes. Thus, a high extracellular concentration of 
platinum complex was used to boost the influx. 
During the incubation with oxaliplatin and its analogues up to 2 h platinum 
accumulation exhibited an approximately linear increase (except 7) (Fig. 4-3 and Fig. 
4-4).  
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Fig. 4-3 Intracellular platinum concentration in HCT-8 cells during incubation with 
100 µM platinum complex: oxaliplatin (), 4 (), 5 (), 6 (), 7 () 
(n = 6 - 18, median, for reasons of clarity a measure of variation is not 
shown). 
 
Fig. 4-4  Intracellular platinum concentration in HCT-8ox cells during incubation with 
100 µM platinum complex: oxaliplatin (), 4 (), 5 (), 6 (), 7 () 
(n = 6 - 18, median; for reasons of clarity a measure of variation is not 
shown). 
60  Results 
A reduction of the platinum accumulation in the resistant cell line was found for all 
compounds except 7. This compound showed a higher platinum accumulation in the 
resistant cell line after 2 h of incubation compared to the sensitive cell line.  
For comparison of the concentration-time profiles of the different platinum 
compounds, it was differentiated between early and late influx. The influx rate within 
10 min of incubation was used as an indicator for early influx (early influx rate). Due 
to the approximately linear increase of the platinum accumulation between the 10th 
and 120th min observed in both cell line pairs a linear regression of the median 
concentration-time profile was performed for each complex. The slope obtained 
reflected the influx rate in the late influx phase (late influx rate) and was used as an 
indicator for late influx. 
The relationship between lipophilicity and early influx rate is shown in Fig. 4-5.  
 
 
Fig. 4-5 Dependence of the early influx rate in HCT-8 () and HCT-8ox (◊) cells after 
incubation with 100 µM platinum complex for 10 min on lipophilicity of 
oxaliplatin and platinum complexes 4 - 7 (n = 6 - 18, median; for reasons of 
clarity a measure of variation is not shown). 
Already after 10 min of incubation a reduced influx rate of some complexes in the 
resistant cell lines was observed. The difference was statistically significant for 
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oxaliplatin, 4 and 7. Moreover, good to relatively strong correlations were found in 
both cell lines (0.80 ≤ r ≤ 1.00). These findings suggest an influence of lipophilicity on 
the early influx of the platinum complexes.  
In Fig. 4-6 the calculated late influx rates of the complexes are displayed.  
 
 
Fig. 4-6 Dependence of the late influx rate in HCT-8 () and HCT-8ox (◊) cells after 
incubation with 100 µM platinum complex on lipophilicity of oxaliplatin and 
the platinum complexes 4 - 7 (n = 2 - 6, median; for reasons of clarity a 
measure of variation is not shown). 
Late influx rates of a given compound in resistant cells were slower compared to the 
sensitive cell line. The only exception was 7 exhibiting a higher late influx rate in the 
resistant cell line. No significant correlation between lipophilicity and late influx rates 
was found in the investigated cell lines. 
4.1.4.2 Efflux 
Investigation of efflux was important for two reasons. Firstly, the reduced platinum 
accumulation in the resistant cell lines may be a result of increased efflux. Secondly, 
efflux may contribute to the striking differences in platinum accumulation after 
incubation with 7 as compared to oxaliplatin (Fig. 4-3 and Fig. 4-4).  
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Therefore, efflux rate of oxaliplatin as the least lipophilic compound and 7 as the 
most lipophilic compound was assessed by measuring the platinum accumulation 
after incubation with the complexes and subsequent incubation in drug-free medium 
(Fig. 4-7 and Fig. 4-8). 
In the ileocecal colorectal adenocarcinoma cell line pair oxaliplatin efflux was slow, 
only after 1 h the efflux rate seemed to be enhanced. The efflux of 7 was fast only in 
the first minutes. Neither the efflux of oxaliplatin nor the efflux of 7 differed 
noteworthy between HCT-8 and HCT-8ox cells. 
These results suggest that differences in efflux of oxaliplatin and 7 between sensitive 
and resistant cells are negligible. Therefore, the different cellular accumulation of 
both compounds in the resistant cell line seems to be due to differences in influx 
rather than efflux. 
 
 
Fig. 4-7 Intracellular platinum concentration in HCT-8 () and HCT-8ox (◊) cells after 
2 h of incubation with oxaliplatin and subsequent incubation with drug-free 
medium (n = 6, median ± IQR). The median platinum concentration at the 
end of the 2 h incubation period was set to 100 %. 
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Fig. 4-8 Intracellular platinum concentration in HCT-8 () and HCT-8ox (◊) cells after 
2 h of incubation with complex 7 and subsequent incubation with drug-free 
medium (n = 6, median ± IQR). The median platinum concentration at the 
end of the 2 h incubation period was set to 100 %. 
4.1.5 Cytotoxicity 
The sensitivity of each cell line to oxaliplatin and its analogues is presented in Tab. 
4-2.  
Tab. 4-2 pEC50 values and resistance factors (RF) of oxaliplatin and the platinum 
complexes 4 - 7 in the HCT-8 cell line pair (n = 3, mean ± SE). 
pEC50 (EC50) Compound 
HCT-8 HCT-8ox 
RF 
Oxaliplatin 6.11 ± 0.03 
(0.8 µM) 
5.11 ± 0.03 
(7.8 µM) 
10.0 
4 5.31 ± 0.09 
(4.9 µM) 
4.45 ± 0.01 
(35.5 µM) 
7.3 
5 5.19 ± 0.05 
(6.5 µM) 
4.58 ± 0.06 
(26.3 µM) 
4.0 
6 4.51 ± 0.06 
(30.9 µM) 
4.16 ± 0.01 
(69.2 µM) 
2.2 
7 4.14 ± 0.05 
(72.4 µM) 
4.10 ± 0.05 
(79.4 µM) 
1.1 
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The low cytotoxicity of the most lipophilic compound 7 compared to the other 
compounds is remarkable. Furthermore, HCT-8ox cells did not show any resistance 
against 7. 
The determined pEC50 values were inversely correlated with the lipophilicity of the 
complexes. A strong correlation was found in both investigated cell lines The 
correlation was found to be at least good for both investigated cell lines (-0.80 ≤ r ≤ -
1.00). Increased lipophilicity of the oxaliplatin analogues is hence associated with 
lower cytotoxicity. 
In order to investigate the possibility to overcome resistance using more lipophilic 
platinum complexes, correlation between lipophilicity and the resistance factor was 
also tested. A strong inverse correlation was observed in the ileocecal colorectal 
adenocarcinoma cell line pair (r = -1.00, p < 0.01). 
4.1.6 DNA platination 
In order to address the question to which extent oxaliplatin and 7 (as the least and 
the most lipophilic complex, respectively) form DNA adducts, the DNA platination 
was analyzed (Fig. 4-9).  
 
Fig. 4-9 DNA platination in HCT-8 (unfilled column) and HCT-8ox (striped column) 
cells after incubation with oxaliplatin and 7 for 4 h (n = 6, median ± IQR; 
Mann-Whitney U test). 
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A 2.4-fold higher level of oxaliplatin-DNA adducts was found in HCT-8 as compared 
to HCT-8ox cells, whereas the extent of DNA platination by 7 was only 1.6-fold higher 
and did not differ significantly between HCT-8 and HCT-8ox cells. Comparison of 
DNA platination in presence of oxaliplatin and 7 shows that oxaliplatin formed on 
average 4.6-fold more adducts in HCT-8 and 3.1-fold more adducts in HCT-8ox cells. 
4.1.7 Repair of platinum-DNA adducts 
The reason for the low degree of DNA platination in HCT-8ox compared to HCT-8 
cells after incubation with oxaliplatin might be a result of an enhanced repair of 
platinum-DNA adducts in HCT-8ox cells. To figure out, if enhanced repair represents 
a resistance mechanism of HCT-8ox cells, the changes in the amount of platinum-
DNA adducts in both cell lines after incubation with oxaliplatin and subsequent 
incubation in drug-free medium were investigated (Fig. 4-10).  
 
 
Fig. 4-10 DNA platination in HCT-8 () and HCT-8ox (◊) cells after incubation with 
oxaliplatin for 4 h (n = 6, median ± IQR). 
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As shown in Fig. 4-10, the amount of platinum-DNA adducts was comparable 
between sensitive and resistant cells and remained nearly constant. Even after 6 h of 
incubation in drug-free medium, no significant changes could be observed. 
 
4.2 Oxaliplatin analogues with different leaving groups 
4.2.1 Determination of log P 
The results of the log P determination are shown in Tab. 4-3. As expected lipophilicity 
of the compounds with different leaving groups increases in the order: 
12 < 11 < oxaliplatin < 10 < 8 < 9. 
Tab. 4-3  log P values of the investigated platinum complexes. 
Compound log P 
Oxaliplatin -1.76 
8 -1.30 
9 -0.86 
10 -1.56 
11 -2.34 
12 -2.67 
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4.2.2 Reactivity towards nucleotides 
During the incubation of the platinum complexes with nucleotides, platinum-
nucleotide adducts were formed. Reactivity of the platinum compounds was 
determined based on the decrease in the amount of free nucleotide (Fig. 4-11 and 
Fig. 4-12) and the respective rate constants were estimated (Tab. 4-4). For 
comparison, reactivity of carboplatin and cisplatin was studied as well. The order of 
the rate constants of the reaction between the platinum complex and dGMP (k1) and 
dAMP (k2), respectively, was cisplatin > 8 > oxaliplatin > 10 > 9 ≈ carboplatin. 
In general, the rate constant k1 was at least 2-fold higher compared to the rate 
constant k2, which means that each platinum complex preferentially bound to dGMP. 
Reactivity of the platinum(IV) complexes was negligible. 
 
 
Fig. 4-11 Reduction of the corrected peak area of the nucleotide dAMP during 
incubation with platinum complex: cisplatin (), carboplatin (), 
oxaliplatin (), 8 (), 9 (), 10 (), 11 (◊), 12 () (n = 3, mean ± SD; 
some error bars are smaller than data points). 
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Fig. 4-12 Reduction of the corrected peak area of the nucleotide dGMP during 
incubation with platinum complex: cisplatin (), carboplatin (), 
oxaliplatin (), 8 (), 9 (), 10 (), 11 (◊), 12 () (n = 3, mean ± SD; 
some error bars are smaller than data points). 
Tab. 4-4  Rate constants of the reaction between platinum complexes with different 
leaving ligands and nucleotides dGMP (k1) and dAMP (k2), respectively, 
(n = 3, mean ± SE). 
Compound k1 [10-6•M-1 • h-1] 
k2 
[10-6•M-1 • h-1] 
Cisplatin 270 ± 24.0 102 ± 10.0 
Carboplatin 7 ± 1.0 3 ± 1.0 
Oxaliplatin 48 ± 2.0 25 ± 2.3 
8 89 ± 2.9 26 ± 2.0 
9 13 ± 1.5 7 ± 1.2 
10 28 ± 0.6 13 ± 0.3 
11 n.a. n.a. 
12 n.a. n.a. 
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4.2.3 Platinum accumulation 
As already explained, the platinum accumulation was measured within cells after 
incubation with high extracellular concentrations of platinum compound, because 
under these conditions the influx was supposed to govern the measured 
concentration-time profiles (see 4.1.4.1). 
During incubation with oxaliplatin and its analogues up to 2 h, platinum accumulation 
increased approximately linear in the investigated cell lines (Fig. 4-13 and Fig. 4-14). 
A reduction of platinum accumulation in the resistant cell line (Fig. 4-14) was found 
for all compounds except 9 and 11. The platinum(IV) complexes (11 and 12) 
accumulated only to a small extent in both cell lines. 
 
 
Fig. 4-13  Intracellular platinum concentration in HCT-8 cells during incubation with 
100 µM platinum complex up to 2 h: oxaliplatin (), 8 (), 9 (), 10 (), 
11 (◊), 12 () (n = 6 - 18, median ± IQR; some error bars are smaller than 
data points). 
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Fig. 4-14  Intracellular platinum concentration in HCT-8ox cells during incubation with 
100 µM platinum complex up to 2 h: oxaliplatin (), 8 (), 9 (), 10 (), 
11 (◊), 12 () (n = 6 - 18, median ± IQR; some error bars are smaller than 
data points). 
In the next step, the influence of both, lipophilicity and reactivity, on the influx rate of 
the oxaliplatin analogues in the early and late influx phase was investigated (Fig. 
4-15, Fig. 4-16, Fig. 4-17 and Fig. 4-18). 
The oxaliplatin analogues with different amine ligands (4 - 7) described in chapter 4.1 
were included in the examination of the influence of lipophilicity, but excluded from 
the reactivity studies due to their similar reactivity. Firstly, the observations in the 
early influx phase are described in detail (Fig. 4-15 and Fig. 4-16).  
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Fig. 4-15 Dependence of the early influx rate in HCT-8 () and HCT-8ox (◊) cells 
after incubation with 100 µM platinum complex for 10 min on lipophilicity of 
oxaliplatin and 4 - 12 (n = 6 - 18, median; for reasons of clarity a measure of 
variation is not shown). 
Already after 10 min of incubation a reduced early influx rate of some complexes in 
the resistant cell line was found compared to the sensitive counterpart, except 9 and 
11, where the contrary was observed. A good correlation between log P values and 
early influx rates was found in HCT-8 and HCT-8ox cells (HCT-8: r = 0.689, 
p = 0.006; HCT-8ox: r = 0.733, p = 0.003) (Fig. 4-15). 
Moreover, an increase in reactivity (k1) led to an enhanced influx rate: 
10 < oxaliplatin < 8. Despite the low reactivity of 9, the early influx rate was high (Fig. 
4-16). 
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Fig. 4-16 Dependence of the early influx rate in HCT-8 () and HCT-8ox (◊) cells 
after incubation with 100 µM platinum complex for 10 min on reactivity 
towards dGMP of oxaliplatin and 8 - 10 (n = 6 - 18, median; for reasons of 
clarity a measure of variation is not shown). 
Secondly, the late influx rates were analyzed (Fig. 4-17 and Fig. 4-18). The 
comparison of a given compound in sensitive and resistant cells showed a reduction 
of the late influx rate in the resistant cell line, apart from 7 and 9, which accumulated 
faster in HCT-8ox compared to HCT-8 cells (Fig. 4-17). Correlation between log P 
values and late influx rates was weak and not significant in HCT-8 cells, however, 
good and significant in HCT-8ox cells (r = 0.644, p = 0.009).  
In both cell lines late influx rates were influenced by the reactivity of the platinum 
complexes (Fig. 4-18). Comparable to the early influx phase, but more pronounced, 
an increase in k1 led to an increase in the late influx rate: 10 < oxaliplatin < 8. Again 
the late influx rate of the least reactive complex, 9, was high.  
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Fig. 4-17 Dependence of the late influx rate in HCT-8 () and HCT-8ox (◊) cells after 
incubation with 100 µM platinum complex on lipophilicity of oxaliplatin and 
4 - 12 (n = 2 - 6, median; for reasons of clarity a measure of variation is not 
shown). 
 
Fig. 4-18 Dependence of the late influx rate in HCT-8 () and HCT-8ox (◊) cells after 
incubation with 100 µM platinum complex on reactivity towards dGMP of 
oxaliplatin and the platinum complexes 8 - 10 (n = 2-6, median; for reasons 
of clarity a measure of variation is not shown). 
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At last, the early and late influx rates of a given compound were compared (Tab. 
4-5). The late influx rate was in general comparable or lower than the early influx 
rate. An exception represented 8 with a higher influx rate in the late phase than in the 
early phase in both cell lines. 
Tab. 4-5  Early and late influx rates of the platinum compounds in HCT-8 and 
HCT-8ox. 
HCT-8 HCT-8ox 
Compound Early influx 
rate 
Late influx 
rate 
Early influx 
rate 
Late influx 
rate 
Oxaliplatin 0.123 0.119 0.063 0.064 
4 0.157 0.119 0.070 0.046 
5 0.134 0.118 0.122 0.076 
6 0.282 0.141 0.174 0.075 
7 0.665 0.098 0.330 0.222 
8 0.181 0.210 0.084 0.105 
9 0.338 0.143 0.509 0.155 
10 0.074 0.026 0.047 0.015 
11 0.022 0.012 0.057 0.008 
12 0.031 0.003 0.026 0.004 
 
In order to investigate the influence of the amine ligands and leaving groups in more 
detail, additionally, the platinum accumulation upon incubation with cisplatin and 
carboplatin was assessed for comparison (Fig. 4-19 and Fig. 4-20).  
In Fig. 4-19 the concentration-time profiles of the platinum accumulation after 
incubation with cisplatin and its analogue 8 are presented. Despite different amine 
ligands the accumulation of both complexes was not significantly different in 
HCT-8ox cells. In HCT-8 cells the accumulation of 8 was reduced to 70 – 80 % 
(10 min: p = 0.0043, 60 min: p = 0.0043, 2 h: n.s.). Interestingly, the concentration-
time profiles of carboplatin and its analogue 9 were completely different, although 
these complexes also only differ in their amine ligands (Fig. 4-20). Carboplatin was 
taken up to a higher extent in sensitive cells, in contrast to 9. The accumulation of 9 
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compared to carboplatin was 3-fold higher in HCT-8 and more than 10-fold in 
HCT-8ox cells (10 min: p = 0.0022, 60 min: p = 0.0022, 2 h: p = 0.0022). 
 
Fig. 4-19  Intracellular platinum concentration of cisplatin (, ) and 8 (, ) in 
HCT-8 (filled symbols) and HCT-8ox (open symbols) cells after incubation 
with 100 µM platinum complex up to 2 h (n = 6, median ± IQR). 
 
Fig. 4-20 Intracellular platinum concentration of carboplatin (, ) and 9 (, ) in 
HCT-8 (filled symbols) and HCT-8ox (open symbols) cells after incubation 
with 100 µM platinum complex up to 2 h (n = 6, median ± IQR). 
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4.2.4 Cytotoxicity 
The cytotoxicity of all compounds was investigated in the ileocecal colorectal 
adenocarcinoma cell line pair and the influence of reactivity and lipophilicity on 
cytotoxicity was evaluated.  
Both platinum(IV) complexes exhibited low cytotoxicity and low resistance factors 
Tab. 4-6). The resistance of HCT-8ox cells towards cisplatin and carboplatin was 
also low, but the cytotoxic activity of carboplatin and especially cisplatin was clearly 
higher than cytotoxicity of platinum(IV) complexes. 8 was the most potent platinum 
complex followed by oxaliplatin, 10 and 9 in both cell lines. 
Tab. 4-6  pEC50 values and resistance factors (RF) of cisplatin, carboplatin, 
oxaliplatin and platinum complexes 8 - 12 in HCT-8 and HCT-8ox cells 
(n = 3 - 11, mean ± SE). 
pEC50 (EC50) Compound 
HCT-8 HCT-8ox 
RF 
Cisplatin 5.15 ± 0.09 
(7.1 µM) 
4.69 ± 0.03 
(20.4 µM) 
2.9 
Carboplatin 4.10 ± 0.06 
(79.4 µM) 
3.80 ± 0.07 
(158.5 µM) 
2.2 
Oxaliplatin 6.11 ± 0.03 
(0.8 µM) 
5.11 ± 0.03 
(7.8 µM) 
10.0 
8 6.24 ± 0.05 
(0.6 µM) 
5.38 ± 0.06 
(4.2 µM) 
7.2 
9 5.60 ± 0.03 
(2.5 µM) 
4.78 ± 0.02 
(16.6 µM) 
6.6 
10 5.94 ± 0.04 
(1.1 µM) 
5.00 ± 0.03 
(10.0 µM) 
8.6 
11 3.84 ± 0.04 
(144.5 µM) 
3.36 ± 0.04 
(437.0 µM) 
3.0 
12 3.91 ± 0.03 
(123.0 µM) 
3.28 ± 0.01 
(525.0 µM) 
4.3 
 
The hypothesis that with increased reactivity towards nucleotides cytotoxicity of the 
complexes also increases, could be confirmed for the oxaliplatin analogues (HCT-8: 
r = 1.000, p < 0.01, HCT-8ox: r = 1.000, p < 0.01) (Fig. 4-21). However, cytotoxicity of 
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all investigated platinum(II) complexes (oxaliplatin and 4 - 10) was also influenced by 
lipophilicity (HCT-8: r = -0.714, p = 0.013; HCT-8ox: r = -0.786, p = 0.006) (Fig. 4-22). 
 
Fig. 4-21 Relationship between reactivity (k1: , k2: , mean ± SE) and cytotoxicity of 
oxaliplatin and 8, 9 and 10 (pEC50 values, n = 3 - 11, mean ± SE) in HCT-8 
(filled symbols) and HCT-8ox (open symbols) cells. 
 
Fig. 4-22 Relationship between lipophilicity (log P values) and cytotoxicity (pEC50 
values, n = 3 - 11, mean ± SE) of oxaliplatin and 4 - 10 in HCT-8 () and 
HCT-8ox (◊) cells. 
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The log P values of the oxaliplatin analogues inversely correlated with resistance 
factors (r = -0.929, p = 0.001) (Fig. 4-23), resulting in a loss of resistance against 
platinum compounds with positive log P values. Additionally, resistance of HCT-8ox 
cells against platinum complexes with low reactivity was reduced. Resistance against 
complexes with high reactivity is at least comparable to resistance against oxaliplatin 
or even lower (Fig. 4-24). 
 
 
Fig. 4-23 Relationship between lipophilicity (log P values) and resistance factors 
(n = 3 - 11, mean ± SD) of oxaliplatin and 4 - 10. 
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Fig. 4-24  Relationship between reactivity (k1 values) and resistance factors  
(n = 3 - 11, mean ± SD) of oxaliplatin and 8 - 10. 
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4.3 Role of transport proteins 
4.3.1 Platinum accumulation 
To estimate the contribution of passive diffusion to the influx of oxaliplatin, 
intracellular platinum concentration was determined as a function of the oxaliplatin 
concentration administered to the cell culture medium and as a function of time (Fig. 
4-25 and Fig. 4-26).  
Fig. 4-25 shows that the intracellular platinum concentration increased linearly with 
the concentration of oxaliplatin in the medium (linear regression analysis: HCT-8: 
r = 0.9996, HCT-8ox: r = 0.9994). 
 
 
Fig. 4-25 Platinum accumulation after incubation of HCT-8 () and HCT-8ox (x) cells 
with various concentrations of oxaliplatin for 2 h (n = 6, median ± IQR; some 
error bars are smaller than data points). 
The intracellular platinum concentration in HCT-8ox cells was reduced to 35 % (at 
1.5 mM extracellular oxaliplatin) compared to HCT-8 cells. 
As shown in Fig. 4-26, intracellular platinum concentration also increased linearly 
with time (linear regression analysis: HCT-8: r = 0.9996, HCT-8ox: r = 0.9961). 
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Fig. 4-26 Platinum accumulation after incubation of HCT-8 () and HCT-8ox (x) cells 
with 100 µM oxaliplatin up to 4 h (n = 6, median ± IQR; some error bars are 
smaller than data points). 
A reduction of the intracellular platinum concentration in HCT-8ox cells to 46 % (at 
2 h of incubation) compared to HCT-8 cells was also found. 
To investigate the influence of hCTR1 and hOCT1-3, various inhibitors of the 
transporters or their substrates were used (Tab. 4-7). As hCTR1 is the main copper 
importer, competitive inhibition of the influx of oxaliplatin by copper sulfate could be 
expected, if oxaliplatin is a substrate of hCTR1 as well. During coincubation with 
100 µM copper sulfate a reduction of the platinum accumulation was detected in both 
cell lines. Co-exposure to 50 µM copper sulfate did not influence the platinum 
accumulation. Coincubation with TEA as a substrate of hOCT1-3 caused an impaired 
accumulation of platinum in both cell lines at the highest TEA concentration (10 mM) 
and at 100 µM TEA in HCT-8 cells. To further investigate which organic cation 
transporters might be responsible for this effect, various inhibitors were used. The 
hOCT1 inhibitor atropine reduced the platinum accumulation only in HCT-8 cells 
during coincubation and even after preincubation. Cimetidine, known to mainly inhibit 
hOCT2, led to a decreased platinum accumulation in both cell lines during 
coincubation as well as after preincubation. The hOCT3 inhibitor decynium-22 did not 
influence the accumulation of platinum, neither in HCT-8 nor in HCT-8ox cells. 
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Tab. 4-7  Platinum accumulation in HCT-8 and HCT-8ox cells, respectively, after pre- 
or coincubation of different substrates and inhibitors of hCTR1 and 
hOCT1-3 and oxaliplatin (2 h of incubation) as a percentage of the platinum 
accumulation after incubation with oxaliplatin alone (n = 6 - 12, median 
(IQR); Mann Whitney U test). 
 HCT-8 HCT-8ox 
 
Platinum 
accumulation 
[%] 
p 
value 
Platinum 
accumulation 
[%] 
p 
value 
Oxaliplatin, 100 µM, 2 h 100 n.a. 100 n.a. 
+ Copper sulfate     
coincubation, 100 µM 78.7  (74.3 – 86.2) 0.0020 
71.3  
(64.8 – 75.3) 0.0028 
coincubation, 50 µM 103.5  (96.4 – 110.2) n.s. 
98.9  
(93.9 – 105.3) n.s. 
+ TEA     
coincubation, 10 mM 65.9  (57.3 – 66.8) 0.0022 
77.6  
(73.5 – 86.9) 0.0260 
coincubation, 100 µM 69.7  (63.2 – 76.4) 0.0152 
84.9  
(76.4 – 95.3) n.s. 
coincubation, 1 µM 78.9  (68.2 – 89.9) n.s. 
85.4  
(74.6 – 100.7) n.s. 
+ Atropine     
coincubation, 1 mM 72.1  (64.2 – 83.9) 0.0120 
99.9  
(91.1 – 108.9) n.s. 
preincubation, 1 mM, 1 h 81.4  (68.5 – 92.5) 0.0106 
85.2  
(79.9 – 93.3) n.s. 
+ Cimetidine     
coincubation, 1.5 mM 73.8  (70.5 – 82.7) 0.0002 
74.1  
(71.1 – 95.2) 0.0360 
preincubation, 1.5 mM, 1 h 78.4  (74.1 – 83.8) 0.0016 
78.4  
(74.1 – 83.8) 0.0017 
+ Decynium-22     
coincubation, 1 µM 94.1  (91.5 – 102.8) n.s. 
93.9  
(86.4 – 104.4) n.s. 
coincubation, 0.1 µM 96.8  (91.8 – 111.5) n.s. 
113.2  
(83.3 – 121.6) n.s. 
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4.3.2 Cytotoxicity 
Following influx experiments, the influence of the various inhibitors (or transporter 
substrates) on cytotoxicity of oxaliplatin was examined. Representative sigmoidal 
dose-response curves are shown in Fig. 4-27, Fig. 4-28, Fig. 4-29, Fig. 4-30 and Fig. 
4-31.  
 
Fig. 4-27 Representative sigmoidal dose-response curves of oxaliplatin in A HCT-8 
and B HCT-8ox: oxaliplatin alone (, ◊), coincubation with 100 µM copper 
sulfate (, ) and coincubation with 50 µM copper sulfate (, ). Survival 
is expressed in terms of % of survival of untreated cells. 
 
Fig. 4-28 Representative sigmoidal dose-response curves of oxaliplatin in A HCT-8 
and B HCT-8ox: oxaliplatin alone (, ◊), coincubation with 10 mM 
TEA (, ), with 1 mM TEA (, ) and with 10 µM TEA (, ). Survival 
is expressed in terms of % of survival of untreated cells. 
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Fig. 4-29 Representative sigmoidal dose-response curves of oxaliplatin in A HCT-8 
and B HCT-8ox: oxaliplatin alone (, ◊), preincubation with 1 mM atropine 
for 1 h and subsequent incubation with oxaliplatin alone (, ), 
coincubation with 1 mM atropine (, ) and coincubation with 0.1 mM 
atropine (, ). Survival is expressed in terms of % of survival of untreated 
cells. 
 
Fig. 4-30 Representative sigmoidal dose-response curves of oxaliplatin in A HCT-8 
and B HCT-8ox: oxaliplatin alone (, ◊), preincubation with 1.5 mM 
cimetidine for 6 h and subsequent incubation with oxaliplatin alone (, ), 
coincubation with 1.5 mM cimetidine (, ) and coincubation with 0.15 mM 
cimetidine (, ). Survival is expressed in terms of % of survival of 
untreated cells. 
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Fig. 4-31 Representative sigmoidal dose-response curves of oxaliplatin in A HCT-8 
and B HCT-8ox: oxaliplatin alone (, ◊), coincubation with 1 µM 
decynium-22 (, ) and coincubation with 0.1 µM decynium-22 (, ). 
Survival is expressed in terms of % of survival of untreated cells. 
Based on the sigmoidal dose-response curves pEC50 values were calculated. The 
pEC50 values of oxaliplatin and the influence of substrates or inhibitors of hCTR1 and 
hOCT1-3 on sensitivity of HCT-8 and HCT-8ox cells to oxaliplatin are presented in 
Tab. 4-8. HCT-8ox cells were found highly resistant to oxaliplatin with a resistance 
factor of 20. 
Copper sulfate, TEA and decynium-22 did not affect cytotoxicity of oxaliplatin. 
However, coincubation with 1 mM atropine and 1.5 mM cimetidine significantly 
reduced the cytotoxicity of oxaliplatin. 
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Tab. 4-8  pEC50 values of oxaliplatin alone in comparison with pEC50 values of 
oxaliplatin after pre- or coincubation with different substrates or inhibitors of 
hCTR1 and hOCT1-3 (copper sulfate, TEA, atropine, cimetidine, 
decynium-22) in HCT-8 and HCT-8ox (n = 3, mean ± SE; unpaired 
Student’s t-test). 
 HCT-8 HCT-8ox 
 pEC50 (EC50) 
p 
value pEC50 (EC50) 
p 
value 
Oxaliplatin 6.08 ± 0.03  (0.8 µM) n.a. 
4.77 ± 0.03  
(16.8 µM) n.a. 
+ Copper sulfate     
coincubation, 100 µM 6.14 ± 0.06  (0.7 µM) n.s. 
4.87 ± 0.07  
(13.6 µM) n.s. 
coincubation, 50 µM 6.15 ± 0.10  (0.7 µM) n.s. 
4.83 ± 0.02  
(14.6 µM) n.s. 
+ TEA     
coincubation 10 mM 6.06 ± 0.04  (0.9 µM) n.s. 
4.63 ± 0.06  
(23.4 µM) n.s. 
coincubation, 1 mM 6.07 ± 0.02  (0.9 µM) n.s. 
4.76 ± 0.03  
(17.3 µM) n.s. 
coincubation, 10 µM 6.12 ± 0.01  (0.8 µM) n.s. 
4.76 ± 0.04  
(17.4 µM) n.s. 
+ Atropine     
coincubation, 1 mM 5.06 ± 0.18 (8.7 µM) 0.0045 
4.26 ± 0.05  
(54.9 µM) 0.0040 
coincubation, 0.1 mM 6.08 ± 0.04  (0.8 µM) n.s. 
4.72 ± 0.08  
(19.1 µM) n.s. 
preincubation, 1 mM, 1 h 6.04 ± 0.04  (0.9 µM) n.s. 
4.79 ± 0.11  
(16.1 µM) n.s. 
+ Cimetidine     
coincubation, 1.5 mM 4.66 ± 0.02  (21.9 µM) 0.0002 
3.57 ± 0.04  
(269.2 µM) 0.0020 
coincubation, 0.15 mM 5.80 ± 0.84  (1.6 µM) n.s. 
4.41 ± 0.07  
(39.0 µM) n.s. 
preincubation, 1.5 mM, 6 h 5.90 ± 0.06  (1.3 µM) n.s. 
4.56 ± 0.05  
(27.4 µM) n.s. 
+ Decynium-22     
coincubation, 1 µM 6.18 ± 0.03  (0.7 µM) n.s. 
4.72 ± 0.07  
(19.1 µM) n.s. 
coincubation, 0.1 µM 6.27 ± 0.05  (0.5 µM) n.s. 
4.87 ± 0.06  
(13.5 µM) n.s. 
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4.3.3 Gene expression profile 
The expression levels of hCTR1 and hOCT1-3 were examined in untreated HCT-8 
and HCT-8ox cells as well as in both cell lines after treatment with oxaliplatin. Among 
a set of 9 possible housekeeping genes (Tab. 3-3), the two most stably expressed 
genes were identified by GENORM145,146: β-Actine and GUS. Expression of the 
transporters was normalized to the expression levels of the respective housekeeping 
genes, and is presented in a rescaled way so that untreated sensitive cells obtained 
a normalized expression value of 1 (Fig. 4-32, Fig. 4-33, Fig. 4-34 and Fig. 4-35). 
Oxaliplatin concentrations of > 20 µM were avoided in the expression experiments to 
prevent a possible interference of oxaliplatin with RNA and subsequent reverse 
transcription and PCR. Furthermore, the concentration used (20 µM) is within the 
range of those attainable in plasma of patients receiving oxaliplatin therapy (7.8 – 
24.7 µM)44. 
 
 
Fig. 4-32 Rescaled normalized expression of hCTR1 in HCT-8 and HCT-8ox cells, 
not treated with oxaliplatin (0 + 0) and after oxaliplatin treatment (labeling of 
x axis: first row = duration of treatment in h, second row = duration of 
subsequent wash-out phase in h). The significance of difference between 
untreated and treated cells within a single cell line was analyzed (n = 2 - 4, 
mean ± SE; Tukey´s test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)). 
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The level of hCTR1 was lower in resistant cells than in sensitive cells (Fig. 4-32, 
p < 0.001). Treatment of HCT-8 cells with oxaliplatin resulted in downregulation of 
hCTR1, already detectable after 2 h of incubation (p < 0.05), most lucid after 24 h of 
incubation without a subsequent wash-out phase (p < 0.001). Interestingly, treatment 
of HCT-8ox cells with oxaliplatin caused a slight upregulation of hCTR1 (p < 0.05). 
The expression of hOCT1 in untreated HCT-8 and HCT-8ox cells was similar. A 
significant increase was observed in HCT-8 cells after 24 h of oxaliplatin treatment 
without a wash-out phase compared to untreated HCT-8 cells (Fig. 4-33). However, 
no significant differences in hOCT1 expression in HCT-8 and HCT-8ox cells under 
other treatment conditions compared to the respective untreated cells were 
observed.  
 
 
Fig. 4-33 Rescaled normalized expression of hOCT1 in HCT-8 and HCT-8ox cells, 
not treated with oxaliplatin (0 + 0) and after oxaliplatin treatment (labeling of 
x axis: first row = duration of treatment in h, second row = duration of 
subsequent wash-out phase in h). The significance of difference between 
untreated and treated cells within a single cell line was analyzed (n = 2 - 4, 
mean ± SE; Tukey´s test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)). 
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The hOCT2 expression in sensitive cells was comparable to that in resistant cells 
(Fig. 4-34).  
 
 
Fig. 4-34 Rescaled normalized expression of hOCT2 in HCT-8 and HCT-8ox cells, 
not treated with oxaliplatin (0 + 0) and after oxaliplatin treatment (labeling of 
x axis: first row = duration of treatment in h, second row = duration of 
subsequent wash-out phase in h). The significance of difference between 
untreated and treated cells within a single cell line was analyzed (n = 2 - 4, 
mean ± SE; Tukey´s test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)). 
Treatment of HCT-8 cells with oxaliplatin resulted in a reduced expression of hOCT2. 
The contrary was observed in HCT-8ox cells, in which incubation with oxaliplatin for 
24 h and a subsequent wash-out phase led to an increased hOCT2 expression. 
However, no significant changes in the expression level were recognized after 24 h 
of treatment with oxaliplatin without a wash-out phase.  
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In HCT-8ox cells the expression of hOCT3 was significantly reduced compared to 
HCT-8 cells (Fig. 4-35, p < 0.01). 
 
 
Fig. 4-35 Rescaled normalized expression of hOCT3 in HCT-8 and HCT-8ox cells, 
not treated with oxaliplatin (0 + 0) and after oxaliplatin treatment (labeling of 
x axis: first row = duration of treatment in h, second row = duration of 
subsequent wash-out phase in h). The significance of difference between 
untreated and treated cells within a single cell line was analyzed (n = 2 - 4, 
mean ± SE; Tukey´s test, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***)). 
Furthermore, the expression of hOCT3 in HCT-8 cells was reduced after treatment 
with oxaliplatin over 24 h. However, no changes were observed after 2 and 24 h of 
incubation and a subsequent wash-out phase. During the wash-out phase of 24 h the 
effect of oxaliplatin on the gene expression seemed to be reversed. In HCT-8ox cells 
the expression of hOCT3 was increased after 24 h of oxaliplatin treatment and a 
subsequent wash-out phase. Surprisingly, no changes were determined after 24 h of 
incubation without a wash-out phase.  
In summary, the expression of hCTR1 and hOCT3 was significantly lower in 
untreated resistant cells than in sensitive cells. Treatment with oxaliplatin influenced 
the expression of all the transporters studied, but in a different way. 
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4.3.4 Subcellular localization of transporters 
To further investigate the role of hCTR1 and hOCT1-3 in the influx of oxaliplatin and 
their contribution to resistance, the subcellular localization of the transporters in 
untreated and oxaliplatin-treated HCT-8 and HCT-8ox cells was analyzed using 
confocal laser-scanning microscopy after immunohistochemical staining. The 
concentration of oxaliplatin used in these experiments was within the range of those 
attainable in plasma of patients receiving oxaliplatin therapy (7.8 – 24.7 µM)44. 
Representative images are shown in Fig. 4-36, Fig. 4-38, Fig. 4-40 and Fig. 4-42. 
The results are summarized in Tab. 4-9. To support the interpretation of the 
fluorescence images brightfield images are shown (Fig. 4-37, Fig. 4-39, Fig. 4-41, 
Fig. 4-43). 
In HCT-8 cells hCTR1 was located in both plasma membrane and cytoplasm (Fig. 
4-36, Fig. 4-37). Treatment with oxaliplatin did not influence the localization of the 
transporter. In untreated HCT-8ox cells hCTR1 was also detectable in the plasma 
membrane and in the cytoplasm. However, after treatment with oxaliplatin the protein 
moved close to the nucleus and a subsequent wash-out phase caused a 
redistribution in the direction of the plasma membrane. 
In HCT-8 cells the human organic cation transporter hOCT1 was located in the 
cytoplasm (Fig. 4-38, Fig. 4-39). Oxaliplatin did not change the distribution of the 
hOCT1 protein. In HCT-8ox cells hOCT1 was partially found in plasma membrane 
and also cytoplasm. After oxaliplatin treatment the protein was no longer detectable 
in the plasma membrane. A subsequent wash-out phase provoked a redistribution to 
the plasma membrane. 
Subcellular localization of human organic cation transporter hOCT2 was comparable 
in sensitive and resistant cells (Fig. 4-40, Fig. 4-41). In both untreated cell lines the 
protein was dispersed throughout the cytoplasm. After treatment with oxaliplatin 
hOCT2 was found close to the nucleus. After a subsequent wash-out phase the 
protein was again present throughout the cytoplasm. 
hOCT3 was localized throughout the cytoplasm and in the plasma membrane in both 
sensitive and resistant cells (Fig. 4-42, Fig. 4-43). Treatment with oxaliplatin did not 
influence the localization of this protein. 
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Fig. 4-36 Immunofluorescence localization of hCTR1 (green) in HCT-8 (A, B, C) and 
HCT-8ox (D, E, F) without oxaliplatin treatment (A, D), after 2 h of 
incubation with oxaliplatin (B, E), after a subsequent wash-out phase of 2 h 
(C, F). Arrows indicate hCTR1 located in the plasma membrane. Nuclei 
were stained with propidium iodide (red). Scale bars represent 10 µm. 
 
Fig. 4-37 Immunofluorescence localization of hCTR1 (green) in HCT-8 (A, B) and 
HCT-8ox (C, D) cells without oxaliplatin treatment (A, C), after 2 h of 
incubation with oxaliplatin (B, D). Arrows indicate hCTR1 located in the 
plasma membrane. Scale bars represent 10 µm. 
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Fig. 4-38 Immunofluorescence localization of hOCT1 (green) in HCT-8 (A, B, C) and 
HCT-8ox (D, E, F) without oxaliplatin treatment (A, D), after 2 h of 
incubation with oxaliplatin (B, E), after a subsequent wash-out phase of 2 h 
(C, F). Arrows indicate hOCT1 located in the plasma membrane. Nuclei 
were stained with propidium iodide (red). Scale bars represent 10 µm. 
 
Fig. 4-39 Immunofluorescence localization of hOCT1 (green) in HCT-8 (A, B) and 
HCT-8ox (C, D) cells without oxaliplatin treatment (A, C), after 2 h of 
incubation with oxaliplatin (B, D). Arrows indicate hOCT1 located in the 
plasma membrane. Scale bars represent 10 µm. 
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Fig. 4-40 Immunofluorescence localization of hOCT2 (green) in HCT-8 (A, B, C) and 
HCT-8ox (D, E, F) without oxaliplatin treatment (A, D), after 2 h of 
incubation with oxaliplatin (B, E), after a subsequent wash-out phase of 2 h 
(C, F). Nuclei were stained with propidium iodide (red). Scale bars 
represent 10 µm. 
 
Fig. 4-41 Immunofluorescence localization of hOCT2 (green) in HCT-8 (A, B) and 
HCT-8ox (C, D) cells without oxaliplatin treatment (A, C), after 2 h of 
incubation with oxaliplatin (B, D). Scale bars represent 10 µm. 
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Fig. 4-42 Immunofluorescence localization of hOCT3 (green) in HCT-8 (A, B, C) and 
HCT-8ox (D, E, F) without oxaliplatin treatment (A, D), after 2 h of 
incubation with oxaliplatin (B, E), after a subsequent wash-out phase of 2 h 
(C, F). Arrows indicate hOCT3 located in the plasma membrane. Nuclei 
were stained with propidium iodide (red). Scale bars represent 10 µm. 
 
Fig. 4-43 Immunofluorescence localization of hOCT3 (green) in HCT-8 (A, B) and 
HCT-8ox (C, D) cells without oxaliplatin treatment (A, C), after 2 h of 
incubation with oxaliplatin (B, D). Arrows indicate hOCT3 located in the 
plasma membrane. Scale bars represent 10 µm. 
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A summary of the subcellular localization of the investigated proteins is given in Tab. 
4-9. 
Tab. 4-9  Overview of the subcellular localization of hCTR1 and hOCT1-3 in HCT-8 
and HCT-8ox cells without treatment of oxaliplatin (- oxaliplatin), after 
incubation with oxaliplatin (+ oxaliplatin) and after incubation with oxaliplatin 
followed by a wash-out phase (+ wash-out). 
 
Protein Treatment HCT-8 HCT-8ox 
- oxaliplatin plasma membrane, cytoplasm 
+ oxaliplatin close to the nucleus hCTR1 
+ wash-out 
plasma membrane, 
cytoplasm 
plasma membrane, 
cytoplasm 
- oxaliplatin plasma membrane, cytoplasm 
+ oxaliplatin cytoplasm hOCT1 
+ wash-out 
cytoplasm 
plasma membrane, 
cytoplasm 
- oxaliplatin cytoplasm, dispersed cytoplasm, dispersed 
+ oxaliplatin close to the nucleus close to the nucleus hOCT2 
+ wash-out cytoplasm, dispersed cytoplasm, dispersed 
- oxaliplatin 
+ oxaliplatin hOCT3 
+ wash-out 
plasma membrane, 
cytoplasm 
plasma membrane, 
cytoplasm 
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4.4 Interaction between oxaliplatin and cimetidine 
4.4.1 Cytotoxicity 
Firstly, the effect of cimetidine on cytotoxicity of oxaliplatin was studied (Tab. 4-10).  
Tab. 4-10 pEC50 values of oxaliplatin alone in comparison with pEC50 values of 
oxaliplatin after pre- or coincubation with cimetidine in HCT-8 and HCT-
8ox cells (n = 3, mean ± SE; unpaired Student´s t-test). 
 HCT-8 HCT-8ox 
 pEC50 (EC50) p value pEC50 (EC50) p value 
Oxaliplatin 5.99 ± 0.05 (1.0 µM) n.a. 
4.69 ± 0.06 
(20.4 µM) n.a. 
Preincubation, 6 h 5.90 ± 0.06 (1.3 µM) n.s. 
4.56 ± 0.05 
(27.5 µM) n.s. 
Preincubation, 12 h 5.91 ± 0.07 (1.2 µM) n.s. 
4.59 ± 0.05 
(25.7 µM) n.s. 
Coincubation 4.66 ± 0.02 (21.9 µM) 0.0002 
3.57 ± 0.04 
(269.2 µM) 0.0020 
 
Pretreatment with cimetidine for 6 and 12 h did not affect the cytotoxic potency of 
oxaliplatin. However, coincubation significantly reduced cytotoxicity of oxaliplatin in 
both HCT-8 and HCT-8ox cells.  
4.4.2 Long-term influx experiments 
4.4.2.1 Protein determination 
In the long-term influx experiments intracellular platinum concentration should be 
expressed in ng platinum/mg protein, because a calculation based on a fixed number 
of cells was not appropriate due to the growing of the cells during the experiment. It 
is commonly known that a linear relationship between protein and cell concentration 
exists. However, it had to be assured that the conditions of the preparation of the 
samples were chosen in a way, which guaranteed a complete lysis of the cells even 
at high cell concentrations. 
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Addition of 1 mM sodium hydroxide and subsequent sonication of the samples for 
30 min turned out to lyse the cells completely (Fig. 4-44). 
 
 
Fig. 4-44 Relationship between cell and protein concentration in HCT-8 () and 
HCT-8ox (◊) cells (calibration curve: continuous line; 95 % confidence 
interval: broken line; n = 6, mean ± SD). 
A linear relationship between protein and cell concentration was observed. The mean 
protein content of a sensitive cell was 276 ± 29 pg and of a resistant cell 502 ± 31 pg. 
Within-day precision ranged between 3.4 and 14.3 % and between-day precision 
between 5.2 and 13.6 % (see Appendix D2). 
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4.4.2.2 Influx experiments 
In accordance with the results of the determination of cytotoxicity, a reduction of the 
intracellular platinum accumulation during coincubation, but not during preincubation 
with cimetidine was observed (Fig. 4-45). 
 
 
Fig. 4-45 Intracellular platinum concentration after incubation with 20 µM oxaliplatin 
up to 24 h (, HCT-8, , HCT-8ox), after coincubation with 20 µM 
oxaliplatin and 1.5 mM cimetidine (, HCT-8, , HCT-8ox) and after 
preincubation with 1.5 mM cimetidine for 12 h and subsequent incubation 
with 20 µM oxaliplatin alone (, HCT-8, , HCT-8ox), (n = 3-9, 
median ± IQR; some error bars are smaller than data points). 
Since preincubation with cimetidine had no effect and coincubation significantly 
affected intracellular platinum concentrations and cytotoxicity, it was presupposed 
that oxaliplatin could react with cimetidine in culture medium, thereby resulting in the 
reduced cellular accumulation and hence in reduced cytotoxicity. 
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4.4.3 Chemical interaction between oxaliplatin and cimetidine 
Monitoring the reaction between oxaliplatin and cimetidine showed that interaction 
between the compounds was fast, as no peak of oxaliplatin at δ = – 1970 ppm could 
be detected already after 1 h. Instead, a peak at δ = – 3245 ppm corresponding to 
the product of the reaction was found (Fig. 4-46). 
 
 
Fig. 4-46 195Pt NMR spectrum of 10 mM oxaliplatin in PBS/DMF (1:1) at 37 °C (A) 
and 195Pt NMR spectrum of a mixture of 10 mM oxaliplatin and 150 mM 
cimetidine in PBS/DMF at 37 °C after coincubation for 1 h (B). 
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5 Discussion 
In chapter 5.1 and 5.2 the results of the systematic investigation on the relationships 
between lipophilicity, reactivity, influx and cytotoxicity of oxaliplatin and its analogues 
in human carcinoma cells are discussed. In chapter 5.3 the role of the transporters 
hCTR1 and hOCT1-3 in influx and cellular processing of oxaliplatin and in oxaliplatin 
resistance is elucidated. 
 
5.1 Oxaliplatin analogues with different amine ligands 
5.1.1 Influx 
The first objective of this investigation was to reveal whether it is possible to 
overcome one of the main oxaliplatin resistance mechanisms – a reduced influx – by 
enhancing the lipophilicity of the complex. For this purpose, the influence of 
lipophilicity on the influx kinetics of oxaliplatin analogues was assessed in different 
tumor cell lines. Reactivity towards nucleophiles is also supposed to play a major role 
in the influx, especially in the influx mediated by CTR1108,110. Despite possessing the 
same leaving group, differences in reactivity of the investigated platinum complexes 
were possible due to altered steric hindrance. However, all investigated oxaliplatin 
analogues showed a comparable reactivity. Therefore, it had to be assumed that 
differences in cellular accumulation are mainly related to different lipophilicity of 
platinum complexes. Nonetheless, the influence of other so far unknown properties of 
platinum complexes with relevance for influx cannot be excluded. 
Within the first minutes of incubation a correlation between log P values and influx 
rates was observed, suggesting a lipophilicity-dependent early influx phase. Most 
likely passive diffusion of the complexes in or across the plasma membrane 
dominates in the early influx phase. 
Passive diffusion should still proceed in the late influx phase, however with a reduced 
rate because of the reduced concentration gradient. In fact, the late influx rate was 
lower than the early influx rate, but no longer determined by lipophilicity. It was 
therefore supposed that reactivity mainly influences the influx rate. This may 
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correspond to a reactivity-dependent binding of the platinum complexes to transport 
proteins, e.g. CTR1 or OCT1-33,54,147. In the resistant cell line a reduction of the influx 
rate, even in the early influx phase, was found. As previously described for the 
ovarian carcinoma cell line (A2780/A2780cis) this may be associated with the 
reduced expression of CTR1148. 
In contrast, the late influx rate of the most lipophilic platinum compound 7 was 
increased in the resistant cell line compared to the sensitive counterpart while efflux 
of 7 was not altered. Therefore, the higher accumulation may be a result of an 
increased influx. If lipophilicity of this complex is the only reason for increased late 
influx rate, the influx rate in the sensitive cell line would also be increased, which was 
not the case. One may speculate that the biophysical properties of the plasma 
membrane of resistant cells are altered leading to a favored transport of lipophilic 
complexes in or across the membrane. Changes in the membrane composition of the 
resistant cell lines have been associated with reduced influx3,54. In a cisplatin-
resistant cell line lower membrane fluidity due to a tighter packing of phospholipid 
molecules, an altered dynamic character of lipid molecules and a lower index of 
unsaturated fatty acids were observed149. On the contrary, more “fluid” plasma 
membranes were found in another cisplatin-resistant cell line150. The changes appear 
to be cell line specific and their contribution to resistance has been discussed 
controversially. 
5.1.2 Cytotoxicity 
The increased accumulation of the more lipophilic complexes found in each cell line 
leads to the question whether it is possible to increase the cytotoxic potency of a 
platinum complex in a given cell line by increasing lipophilicity. 
Given the observed differences in the accumulation of the platinum complexes in the 
early influx phase, an increase in cytotoxicity with increasing lipophilicity could be 
expected. This has already been described for other platinum complexes116,117,151. 
Surprisingly, an inverse correlation between lipophilicity and cytotoxicity was found in 
both cell lines. A lower cytotoxic potency of the complexes with bulky substituents at 
position 4 of the cyclohexane ring was previously reported in different human cancer 
cell lines124,125. In order to understand the reduced cytotoxic potency of the more 
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lipophilic complexes the intracellular fate of oxaliplatin and 7 as the least and the 
most lipophilic complexes was investigated in more detail. 
The reduced cytotoxicity of 7 was accompanied by a reduced DNA platination 
compared with oxaliplatin although the cellular accumulation of this complex was 
higher. On the one hand, changes in reactivity of the platinum complexes with bulky 
substituents once they have entered the cell cannot be completely excluded. The 
reduced DNA platination might be a result of a reduced reactivity of 7 towards DNA 
compared to the reactivity towards single nucleotides. On the other hand, this 
observation might suggest that 7 is trapped in the cytoplasm, either by binding to 
nucleophiles and therefore inactivation or by sequestration in subcellular 
compartments152-155. There is already evidence for sequestration of lipophilic 
platinum complexes. A platinum complex with a lipophilic anthraquinone carrier 
ligand was found to accumulate in lysosomes. It has been discussed that 
amphiphilicity of this platinum complex leads to partitioning in the plasma membrane 
without diffusion through the membrane followed by internalization by endosomes 
and accumulation in lysosomes152. Mitochondria may represent another cellular 
organelle capable of sequestration of platinum complexes. The increased 
mitochondrial membrane potential in tumor cells compared to normal epithelial cells 
could result in an increased accumulation of lipophilic cations156. According to a 
predictive model, strong bases and permanent cations with intermediate lipophilicity 
(log P between -2 and 2 with an optimum at 0) tend to accumulate in mitochondria of 
tumor cells157. Although there is some evidence of an involvement of lysosomes and 
mitochondria in sequestration of platinum complexes, the exact subcellular 
localization of 7 needs further clarification.  
To summarize, increasing lipophilicity of oxaliplatin by introducing substituents to the 
DACH carrier ligand failed to enhance cytotoxicity in the investigated cell lines. 
5.1.3 Resistance 
In a previous study a correlation between the expression of copper transporter 1, 
intracellular platinum concentration, DNA platination and cell death in the ovarian 
carcinoma cell line pair (A2780/A2780cis) was observed148. Resistance of A2780cis 
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cells to cisplatin was mainly based on a reduced intracellular platinum concentration 
due to a reduced influx, which was followed by reduced DNA platination148.  
Consequently, a circumvention of the reduced influx should result in a diminution of 
resistance114,115. In the ileocecal colorectal adenocarcinoma cell line pair 7 was able 
to bypass the reduced influx in the resistant cell line. To estimate the impact of the 
increased influx of 7 on DNA platination and resistance, these processes were 
quantified and compared with those after oxaliplatin treatment (Tab. 5-1).  
Tab. 5-1 Contribution of cellular accumulation and DNA platination to resistance. 
HCT-8ox vs. HCT-8 
 
Oxaliplatin 7 
Fold resistance 10.0 1.1 
Fold decrease in accumulation after 2 h 1.8 0.6 
Fold decrease in DNA platination 2.4 1.6 
 
In the ileocecal colorectal adenocarcinoma cell line pair the expected correlation 
between intracellular platinum concentration, DNA platination and resistance was 
observed. In HCT-8ox cells a decreased platinum-DNA adduct formation was 
observed upon a decreased accumulation after treatment with oxaliplatin. However, 
other processes might be involved, as the resistance factor was rather high. No 
significant repair of platinum-DNA adducts in both ileocecal colorectal 
adenocarcinoma cell lines was found. Thus it is entirely conceivable that enhanced 
adduct tolerance represents a second resistance mechanism in this cell line, which 
has often been detected in cells with acquired resistance to oxaliplatin57. A closer 
look to the relationship between influx rate of 4, 5 and 6 and the resistance factor 
showed that despite their lower accumulation in HCT-8ox cells compared to their 
sensitive counterpart, the resistance factor diminished with increasing lipophilicity. 
These results suggest that reduction of resistance was either due to decreased 
inactivation of oxaliplatin analogues or mediated by mechanisms occurring after DNA 
binding. For instance, cellular processing of the platinum-DNA adducts generated by 
more lipophilic as well as bulkier carrier ligands might be altered in this cell line pair. 
Differences in the processing of cisplatin- and oxaliplatin-DNA adducts are well 
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known, e.g. the failure of recognition of the more lipophilic and bulkier oxaliplatin-
DNA adducts by proteins of the MMR system and other damage recognition proteins 
like HMG domain proteins4,7,158. Thus, an influence of the substituents of the DACH 
carrier ligand on cellular processing is conceivable. 
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5.2 Oxaliplatin analogues with different leaving groups 
5.2.1 Reactivity 
Until now a broad spectrum of nucleophiles has been used to quantify the reactivity 
of platinum complexes, e.g. G-actin110, L-methionine159,160, glutathione96,96,159,161, calf 
thymus DNA104,162 and guanosine-5'-monophosphate159,160,163. The choice of the 
model compound depends on the underlying question. For the investigation of the 
relationship between reactivity and cytotoxicity, the determination of reactivity 
towards nucleophiles seems to be appropriate. However, it is more difficult to identify 
an appropriate model compound for investigating the influence of reactivity on 
cellular accumulation, because of a lack of knowledge about the involved transport 
mechanism(s). Some evidence exists that the copper transporter hCTR1 contributes 
to the influx of platinum complexes, especially to the influx of cisplatin3. However, a 
contribution of hCTR1 to the influx of oxaliplatin at concentrations higher than 2 µM is 
unlikely67. Therefore, the assessment of reactivity was restricted to the reaction 
between the platinum compound and nucleotides as targets inside the cell. In 
general, one should keep in mind that the reactivity depends on the nucleophile as 
well as on the conditions under which the reaction takes place160.  
The reduced reactivity of all platinum complexes towards dAMP compared to dGMP 
is well documented164. The degree of reactivity of the complexes is determined by the 
structure of the leaving group and steric aspects. 8 might be less reactive than 
cisplatin because of the steric hindrance of the amine ligand. The formation of a 
chelate complex increases the stability, which might explain the reduced reactivity of 
oxaliplatin, 9 and 10 compared to 8165. The higher the electron density of the leaving 
group, the less reactive the complexes are: oxalate > malonato > cyclobutane-1,1-
dicarboxylato. The high stability and, therefore, low reactivity of the complexes with a 
cyclobutane-1,1-dicarboxylato leaving group is well known109,163. The reactivity of 
platinum(IV) compounds depends on their reduction potential. The binding is 
accelerated by an increase in the reduction potential and the ease of reduction 
depends on the axial ligands with X = Cl > OAc > OH166-168. Therefore, the inertness 
of 11 and 12 might be a consequence of their low reduction potential168.  
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5.2.2 Influx 
According to the previous results, more lipophilic complexes should enter the cells 
more rapidly in the early influx phase, in which lipophilicity is the rate-determining 
influx mechanism. Furthermore, the hypothesis that more reactive compounds should 
enter the cells faster than inert compounds by triggering protein-mediated transport 
was generated. 
By increasing lipophilicity the early influx rate increased, further strengthening the 
above drawn conclusion (see 5.1). Most likely, passive diffusion dominates in the 
early influx phase. The results of the correlation analysis also point to a contribution 
of passive diffusion in the late influx phase in HCT-8ox cells. Passive diffusion is a 
continuously ongoing process only slowed down by a decreasing concentration 
gradient. From this point of view it is obvious to detect an influence of lipophilicity 
also on the late influx rate. However, influence of lipophilicity was negligible in the 
sensitive cell line indicating the existence of another influx mechanism. 
Reactivity is supposed to be an important factor in the influx via a lipophilicity-
independent mechanism. In fact, beside lipophilicity, reactivity of the complexes 
influenced both early influx rate and late influx rate. Increasing reactivity led to a 
higher influx rate: 10 < oxaliplatin < 8 (the influx of 9 will be discussed below). A 
comparable relationship was also determined during incubation with oxaliplatin, 
Pt(DACH)Cl2 and Pt(DACH)(H2O)292. However, the exact role of the exchange of the 
leaving ligand in the influx of platinum complexes still remains unanswered, because 
it is unknown which platinum species are taken up by the cell. Either the ligand 
exchange already occurs within the cell culture medium and reactive chloro or aqua 
complexes are formed, which are transported into the cell, or the exchange occurs by 
direct interaction with proteins in the plasma membrane responsible for the influx of 
platinum complexes 108,109,160. The up to 50 % reduced influx of most of the 
compounds in the resistant cell line might be a result of both a downregulation of 
transport proteins and changes in the membrane lipid composition 3. 
The most lipophilic oxaliplatin analogue 9 deserves closer examination. Despite the 
low reactivity, cellular accumulation of 9 was relatively high and even higher in the 
resistant than in the sensitive cell line. To evaluate the influence of the structure of 
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the amine ligand and leaving group, the cellular accumulation of 9, the least reactive 
oxaliplatin analogue, and carboplatin as well as 8, the most reactive oxaliplatin 
analogue, and cisplatin was compared. Interestingly, the concentration-time profiles 
of cisplatin and 8 were similar, suggesting a minor influence of the amine ligand. 
Reactivity seems to be crucial for the influx. On the contrary, the concentration-time 
profiles of carboplatin and 9 were completely different, in spite of bearing the same 
leaving group. In this case lipophilicity has an exceptionally high impact on the influx 
of 9 compared to reactivity. This property apparently allows the complex to bypass 
the resistance mechanism, which leads to a reduced influx of the other investigated 
complexes. In the first part of this study of oxaliplatin analogues with different amine 
ligands a similar behavior of the most lipophilic compound 7 was observed. A change 
in the biophysical properties of the plasma membrane of the resistant cells leading to 
a favored transport of lipophilic complexes in or across the membrane was 
suggested. This might not only explain the influence of lipophilicity on the late influx 
phase in the resistant cells but also the high accumulation of 9. The comparison of 
the cellular accumulation of these complexes demonstrates the relative importance of 
lipophilicity versus reactivity. 
Unlike 9, the cellular accumulation of the platinum(IV) complexes (11 and 12) was 
very low. A low cellular accumulation of platinum(IV) compounds with axial hydroxo 
ligands, especially of 11, was already described167,169. Either the hydroxo ligand itself 
affects the influx or a low reduction potential is responsible for the reduced influx169. 
A high reduction potential accelerates the influx, however, a preceding reduction in 
the extracellular medium does not seem to be essential for the influx154,167,170. 
Therefore, a small amount of 11 still enters the cell. Regarding the influx of 12, a 
deprotonation of the axial ligand at physiological pH was presumed to be responsible 
for the low cellular accumulation of this complex119. These negatively charged 
species are possibly not able to permeate the plasma membrane. 
5.2.3 Cytotoxicity and resistance 
Cytotoxic potency was influenced by lipophilicity and reactivity. High lipophilicity led 
to a reduced cytotoxicity, despite an increased influx of more lipophilic complexes in 
the early influx phase. The reason might be an impaired formation of platinum-DNA 
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adducts by lipophilic platinum complexes, which could already be demonstrated for 
oxaliplatin and 7. In this second part of this study it was demonstrated that an 
increase in reactivity leads to a higher cytotoxicity, maybe due to a higher influx. In 
summary, if lipophilicity of the investigated oxaliplatin analogues is moderate, 
reactivity seems to be the most decisive property. Thus, based on these results, 
lipophilicity of the compound should be as low as possible and reactivity as high as 
possible for a high cytotoxic potential. 
Nevertheless, the more lipophilic oxaliplatin analogues had the potential of 
overcoming resistance. Regarding the platinum complexes with different amine 
ligands (oxaliplatin and 4 – 7) a different recognition and processing of the platinum-
DNA adducts due to their different structure was proposed. The platinum(II) 
compounds oxaliplatin and 8 – 10 possess the same amine ligand. Consequently, 
the structure of the platinum-DNA adducts will probably be the same. Therefore, 
reactions occurring before, and not after DNA binding might be more relevant.  
Which processes taking place before binding to the DNA might be altered in the 
resistant cells? First of all, a reduction of the influx might contribute to resistance. 
However, no correlation between the fold decrease in accumulation after 2 h and 
resistance factors was observed. Therefore, changes in the influx might only 
contribute to a minor extent to resistance. Processes and reactions occurring in the 
cytoplasm might also participate in the emergence of resistance. As already 
discussed, increased sequestration of lipophilic platinum complexes might be 
responsible for the reduced cytotoxicity (see 5.1). Hence, diminished sequestration of 
the lipophilic complexes in the resistant cells might increase the amount of platinum 
compound reaching the DNA and therefore reduce the resistance factor. Changes in 
cellular organelles in resistant tumor cells such as reduction of the lysosomal 
compartment to 40 % and an altered cellular distribution and function of mitochondria 
have been described and may contribute to the lower degree of resistance against 
lipophilic compounds171,172.  
Beside lipophilicity, reactivity also represents an important property of platinum 
complexes regarding the reactions occurring in the cytoplasm. An increased 
inactivation by sulfur-containing molecules, like glutathione, metallothionein, but also 
sulfur-containing high molecular mass molecules, is commonly assumed to represent 
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one of the major resistance mechanisms of tumor cells5. Accordingly, less reactive 
platinum complexes are expected to be less affected and platinum complexes of 
higher reactivity are expected to be more affected by metabolic reactions. 
Consequently, resistance of the investigated cell line pair against less reactive 
platinum complexes was lower than resistance against more reactive compounds. 
Therefore, in order to overcome resistance lipophilicity of the platinum compounds 
should be high, presumably a log P value of approximately 0, and reactivity should 
be low. The slightly reduced resistance of cells against 8 also points at the ability of 
highly reactive complexes to overcome resistance. However, further investigations 
are needed to confirm this hypothesis. 
Now the question arises, which properties should a platinum compound possess to 
exhibit a well-balanced relationship between cytotoxic potency and toxicity and to 
overcome the resistance mechanisms in cancer cells at the same time. According to 
the results of the experiments with the oxaliplatin analogues the log P value should 
be approximately 0 and reactivity should be low. Though compounds of low reactivity 
are less cytotoxic, they bear the advantage of producing less side effects103. If the 
hypothesis that also highly reactive compounds might be able to overcome platinum 
resistance turns out to be true a platinum complex with a 4-tert-butyl-cyclohexane-
1,2-diamine amine ligand and two chloro leaving groups might be a good candidate 
for optimization studies. 
In the following, the results of the experiments with the platinum(IV) compounds are 
discussed. Despite the low reactivity and influx, the platinum(IV) complexes 
developed a certain cytotoxicity, which was even comparable to the cytotoxic 
potential of carboplatin. That a low cellular accumulation does not necessarily result 
in a low cytotoxicity, was also demonstrated with platinum(IV) compounds having the 
general structure DACH-Pt(IV)-X2Y2 with X = Cl, OAc or TFA as axial ligands and 
Y = Cl as equatorial ligand173. Although a direct interaction of platinum(IV) 
compounds with DNA or nucleotides was described, the intracellular reduction seems 
to be crucial for the cytotoxicity of the complexes173-175. Resistance of HCT-8ox cells 
against 11 and 12 was lower than against oxaliplatin and 8 – 10, but a direct 
comparison is not possible because of the structural differences. 
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5.3 Role of transport proteins 
It is reported here on the contribution of passive diffusion as well as protein-mediated 
transport on the influx of oxaliplatin. The investigations were focused on the copper 
transporter 1 (hCTR1) and the organic cation transporters 1-3 (hOCT1-3). When 
indicated, the contribution of these transporters to reduced influx and to resistance 
was elucidated. An overview of the key points of the discussion is presented in Tab. 
5-2. 
5.3.1 Passive diffusion 
The data show that oxaliplatin enters the cells partly via passive diffusion. The 
hallmarks of passive diffusion were observed in the cell system: influx was linear, 
concentration dependent and nonsaturable within a wide concentration range. 
However, there are some arguments against passive diffusion as the only influx 
mechanism. Firstly, accumulation of oxaliplatin was reduced in resistant cells. This 
might be caused by changes in the plasma membrane composition, though it is 
doubtful that these changes provoke a reduction in the influx to about 50 %3. The 
second argument for the involvement of other transport mechanisms are the results 
of the investigation of the structure-transport relationship (see 5.1 and 5.2), which 
point at a protein-mediated transport of oxaliplatin.  
5.3.2 Copper transporter hCTR1 
The localization of hCTR1 in the plasma membrane of both sensitive and resistant 
cells possibly points at the contribution of hCTR1 to the influx of oxaliplatin. 
Furthermore, the reduced platinum accumulation after coincubation of oxaliplatin and 
copper might be provoked by mutual inhibition of the transport of copper and 
oxaliplatin or by degradation of hCTR1 following copper exposure. Although 
treatment with extensive concentrations of copper was followed by a marked 
reduction of hCTR1 levels in the plasma membrane in transfected cell lines, this 
observation could not be verified in cell lines endogenously expressing 
hCTR172,108,176-178. Therefore, a mutual inhibition of the transport of copper and 
oxaliplatin is likely. Further, due to the reduced cellular accumulation of platinum, 
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reduced cytotoxicity of oxaliplatin during coincubation with copper sulfate was also 
expected. However, this was not the case. A possible explanation is that the fraction 
of oxaliplatin, which has been transported by hCTR1, does not reach its 
pharmacological target, the DNA72. One might even speculate that the binding of 
oxaliplatin to the Met-rich extracellular domain of hCTR1 is already 
irreversible45,163,179. On the other hand, the effect of coincubation with copper sulfate 
on the influx of oxaliplatin might have been not sufficient to affect cytotoxicity of 
oxaliplatin. An indirect evidence of contribution of hCTR1 to influx and/or cellular 
processing of oxaliplatin has been adduced by investigation of the influence of 
oxaliplatin on subcellular localization and gene expression of hCTR1. Both alterations 
in localization of hCTR1 in HCT-8ox cells and in expression in HCT-8 and HCT-8ox 
cells during incubation with oxaliplatin hint at the involvement of hCTR1 in oxaliplatin 
transport. Redistribution of hCTR1 in HCT-8ox cells might be partly responsible for 
reduced influx of the drug in these cells compared to sensitive cells. Additionally, the 
a priori reduced expression of hCTR1 in resistant cells may contribute to the reduced 
influx. The increased mRNA expression in resistant cells after oxaliplatin treatment 
may be caused by the need of the cells to have sufficient amounts of copper. 
Because hCTR1 disappeared from the plasma membrane in HCT-8ox cells upon 
oxaliplatin exposure, the copper supply might be hindered. Therefore, HCT-8ox cells 
might counteract by upregulation of the expression of hCTR1180,181. Taken together, 
the data point out at the relevance of hCTR1 for reduced influx of oxaliplatin in HCT-
8ox cells. However, contribution of the transporter to resistance in this cell line needs 
further clarification. 
5.3.3 Organic cation transporters hOCT1-3 
In order to evaluate the influence of organic cation transporters on influx of oxaliplatin 
the model OCT substrate TEA was used77. At the highest concentration of TEA 
applied in this study the maximum transport rate of hOCT1, hOCT2 and even 
hOCT3, which has the lowest affinity to TEA, can be achieved77. The reduction of 
oxaliplatin influx in both cell lines after coincubation with TEA let one assume that at 
least one of these transporters participates in the influx of oxaliplatin. However, the 
reduced influx did not affect cytotoxicity of oxaliplatin, possibly due to the same 
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reasons as discussed above, the inability to reach the DNA or an insufficient effect of 
TEA. The contribution of the each particular transporter was investigated using 
specific inhibitors.  
Atropine inhibits hOCT1 with the highest known affinity77,78. The influence of atropine 
on the influx of oxaliplatin in HCT-8 cells may reflect a contribution of hOCT1 to 
oxaliplatin transport across the plasma membrane. However, the protein appeared to 
be not located in the plasma membrane. Nevertheless, hOCT1 might steadily cycle 
through different compartments of the cells and be localized intracellular by a 
process of continuous retrieval from the cell surface178. The evidence of the 
contribution of this transporter to influx was further strengthened by the reduced 
cytotoxicity of oxaliplatin during coincubation with atropine. Nonetheless, it should be 
noted that survival of the atropine-treated cells was in general diminished. Reduced 
cytotoxicity of oxaliplatin might simply be a result of the retarded cell growth. This 
might also explain the reduction of cytotoxic activity of oxaliplatin in HCT-8ox cells, 
despite an unchanged influx in presence of atropine. Interestingly, in HCT-8ox cells 
hOCT1 was detected in the plasma membrane. Nevertheless, in contrast to the 
sensitive cells it is suggested that hOCT1 is not involved in the influx of oxaliplatin in 
resistant cells, because the influx was not influenced by co-/preincubation with 
atropine. The absence of oxaliplatin influx via hOCT1 in HCT-8ox cells might 
contribute to the reduced influx in this cell line compared to the sensitive cell line and 
contribute to resistance of HCT-8ox cells. Furthermore, the protein may in some way 
be directly or indirectly involved in cellular processing of oxaliplatin, as indicated by 
the increased gene expression after treatment of sensitive cells with oxaliplatin and 
the lucid alterations of the cellular localization of the protein in resistant cells after 
treatment with oxaliplatin.  
The influence of organic cation transporter hOCT2 on influx of platinum drugs has 
often been studied using cimetidine, which acts mainly as an inhibitor of hOCT2, 
under the assumption that it does not chemically interact with the platinum drugs87,88. 
However, an interaction between platinum drugs and cimetidine cannot be 
completely ruled out. Therefore, this question was studied in more detail182. Reduced 
cytotoxicity of oxaliplatin and reduced intracellular platinum accumulation during long-
term coincubation of oxaliplatin and cimetidine, but not during long-term 
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preincubation, could be on the one hand a result of an inhibition of hOCT2 by 
cimetidine. On the other hand this could also be due to an interaction of oxaliplatin 
and cimetidine already in the cell culture medium, with the consequence that this new 
platinum complex is not taken up by the cell. The behavior of a mixture of oxaliplatin 
and cimetidine was investigated using 195Pt NMR. The chemical shift of the peak 
indicates a Pt ion to be in an [N3S] coordination surrounding, suggesting that 
[Pt(DACH)(cimetidine)]2+ was formed (Fig. 5-1). 
 
 
Fig. 5-1 Proposed product of the interaction between oxaliplatin and cimetidine. 
Thus, under the conditions of coincubation experiments oxaliplatin is bound to 
cimetidine. This is the first report about interaction between oxaliplatin and cimetidine 
under physiological conditions. The data clearly show that the results of the studies, 
in which a platinum complex is coincubated with a transporter inhibitor, should be 
treated with caution. For example, a recent publication reported that coincubation 
with cimetidine significantly reduced oxaliplatin accumulation but did not affect 
cisplatin and carboplatin accumulation88. Given rapid interaction between oxaliplatin 
and cimetidine, reaction of cisplatin and carboplatin with the inhibitor of hOCT2 is 
also likely. At first glance, one would expect reduction of cisplatin and carboplatin 
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accumulation, as well as their cytotoxicity. However, it is possible that the product of 
reaction of cisplatin and carboplatin with cimetidine [Pt(NH3)2(cimetidine)]2+ is readily 
taken up by the cell, whereas [Pt(DACH)(cimetidine)]2+ is not. Since organic cation 
transporters (e.g. OCT1) mostly transport molecules with molecular weight below 
500 Da, [Pt(NH3)2(cimetidine)]2+ (M = 481 Da) might be a better substrate for them 
than [Pt(DACH)(cimetidine)]2+ (M = 561 Da)77. However, even if this would be the 
case, it remains unclear whether [Pt(NH3)2(cimetidine)]2+ species can platinate 
genomic DNA and thereby exert cytotoxic action. 
Despite the evidence of a direct interaction between oxaliplatin and cimetidine, in 
short-term experiments not only coincubation but also preincubation leads to 
diminished influx. Therefore, it is suggested that reduction in the influx of oxaliplatin 
by cimetidine is a result of direct binding between the substances in the cell culture 
medium as well as of inhibition of hOCT2-mediated influx. However, the organic 
cation transporter hOCT2 was not located in the plasma membrane but in an 
intracellular compartment in both cell lines. For that reason one would exclude 
initially a contribution of this transporter to the influx of oxaliplatin. It is hypothesized 
that hOCT2 contributes to the influx of oxaliplatin in both cell lines and that the 
missing membrane localization might be due to the continuous cycling of the protein 
through different cellular compartments178. Since cytotoxicity of oxaliplatin was only 
decreased upon coincubation with cimetidine, it was not possible to determine to 
which extent each effect, binding between the substances in the cell culture medium 
and inhibition of hOCT2-mediated transport, contributed to the reduced cytotoxicity. 
Involvement of hOCT2 in the reduced influx in resistant cells seems to be unlikely, 
because neither the localization nor the gene expression of hOCT2 differed between 
untreated resistant and sensitive cells. However, there is evidence that hOCT2 may 
contribute to cellular processing of oxaliplatin, since the localization and the gene 
expression of the protein changed after treatment with oxaliplatin. 
The organic cation transporter hOCT3 was located in the cytoplasm as well as in the 
plasma membrane in untreated sensitive and resistant cells. However, the hOCT3-
inhibitor decynium-22 did neither inhibit the influx of oxaliplatin nor its cytotoxicity, to 
wit, either (1) the inhibitor was not potent enough or (2) the inhibitor binds hOCT3 in 
a way that the transport of model cations is inhibited, but the transport of oxaliplatin is 
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not, or (3) hOCT3 is not involved in the transport of oxaliplatin. The first explanation 
seems improbable, because decynium-22 is one of the most potent inhibitors of 
hOCT3138. However, due to lack of knowledge regarding mechanisms of influx of 
platinum complexes via organic cation transporters, the second explanation cannot 
be ruled out. Therefore, an involvement of hOCT3 should not be precluded until this 
issue is clarified. The results of the expression analysis imply a contribution of 
hOCT3 to the transport of oxaliplatin, as the expression of hOCT3 in HCT-8ox cells 
was reduced compared to HCT-8 cells and the expression levels were influenced by 
treatment with oxaliplatin. 
The key points of the discussion are summarized in Tab. 5-2. 
Tab. 5-2 Contribution of hCTR1 and hOCT1-3 to influx, cellular processing and 
cytotoxicity of oxaliplatin (+, involved; (+), possibly involved; -, not involved). 
Influx Cellular processing 
Protein 
HCT-8 HCT-8ox HCT-8 HCT-8ox 
Resistance 
hCTR1 + + (+) (+) (+) 
hOCT1 + - (+) (+) + 
hOCT2 + + (+) (+) - 
hOCT3 (+) (+) (+) (+) (+) 
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6 Conclusions and outlook 
Within the scope of this study new insights in general influx mechanisms and in 
transporter-mediated influx of oxaliplatin could be gained. The investigated structure-
transport and structure-activity relationships of oxaliplatin analogues serve as a basis 
for the development of new platinum compounds. However, to manifest the 
conclusions reached in this study more oxaliplatin analogues should be included in 
the investigation. Especially compounds of higher reactivity and higher lipophilicity 
might provide added value. 
The examination of the role of transport proteins in influx of oxaliplatin suggest that a 
number of transporters are probably capable of accommodating oxaliplatin influx. In 
general, this kind of studies are very dependent on the inhibitors used. Therefore, for 
future investigations it is desirable to have more specific and potent inhibitors 
available. Furthermore, investigation of the protein expression and conduction of 
colocalization studies of fluorescent oxaliplatin analogues and transport proteins 
might help to clarify the exact role of hCTR1 and hOCT1-3 in influx of oxaliplatin and 
its contribution to resistance.  
To be able to interpret the results of this study in a more sophisticated way, the 
mechanisms of resistance of the HCT-8/HCT-8ox cell model should be examined in 
more detail, e.g. investigation of the membrane composition, the degree of 
sequestration and, more generally, the intracellular inactivation of oxaliplatin 
analogues and the investigation of the mechanisms occurring after binding to DNA. 
The transferability of the results to other cell models should be also verified. 
In summary, this study makes a valuable contribution to the elucidation of the influx 
of oxaliplatin and provides ideas for the development of new platinum compounds. 
Nevertheless, due to the complexity of the reactions taking place within a cell there 
are still many open questions to be faced. 
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7 Summary 
This thesis describes the first systematic investigation of the relationship between 
lipophilicity and reactivity on the one hand and cellular accumulation and cytotoxic 
activity on the other hand of a new class of oxaliplatin derivatives with different 
substituents at position 4 of the cyclohexane ring and different leaving ligands. 
Furthermore, the contribution of hCTR1 and hOCT1-3 on the influx of oxaliplatin was 
investigated. Information regarding the influence of oxaliplatin on the expression of 
these transporters, as well as on their localization inside cancer cells is still limited. In 
contrast to the studies conducted in the past, in this study no transfected cell lines 
were used.  
Lipophilicity and reactivity are important determinants of the platinum influx. In 
contrast to the early influx phase, in which lipophilicity predominantly governs the 
influx rate, the late influx phase is mainly controlled by the reactivity of a platinum 
compound. Passive diffusion is suggested as the preponderant influx mechanism in 
the early influx phase and protein-mediated transport as the major influx mechanism 
in the late influx phase. 
Lipophilicity and reactivity are also determinants of the cytotoxic potency of platinum 
compounds and of tumor resistance. Although lipophilicity enhances the influx of 
platinum complexes, especially in the early influx phase, an increased lipophilicity 
leads to a reduction of cytotoxic potency of the investigated oxaliplatin analogues. 
This might be due to alterations in the reactivity of platinum complexes with bulky 
substituents in the intracellular environment or increased intracellular sequestration 
of lipophilic complexes. On the other hand, an increased lipophilicity is associated 
with the advantage of overcoming resistance. This does not seem to be related to 
increased influx. Changes in the reactions occuring before binding to the DNA, as 
well as different recognition and processing of the formed DNA adducts due to the 
variation of the carrier ligand might be another explanation for this phenomenon 
which, however, requires clarification in future investigations. Contrary to lipophilicity, 
an increase in reactivity enhances the cytotoxic potency of a platinum compound. 
Furthermore, resistance against platinum complexes of low reactivity appears to be 
reduced, possibly because these compounds are less affected by cytosolic 
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inactivation. Therefore, a well-balanced relationship between lipophilicity and 
reactivity may be a starting point for optimization of the oxaliplatin structure. A log P 
value of approximately 0 and a low reactivity should support (a) passive diffusion as 
well as (b) the possibility of overcoming resistance. 
In any event, passive diffusion represents an important mechanism of oxaliplatin 
influx. Furthermore, it is supposed that oxaliplatin is transported by hCTR1 and that 
this transport is reduced in resistant cells. It is questionable whether the thereby 
decreased influx contributes to resistance. Influx of oxaliplatin via hOCT1 occurs in 
sensitive cells, however is unlikely in resistant cells. This fact might partly account for 
the reduced influx of oxaliplatin in resistant cells and contribute to resistance of HCT-
8ox cells. hOCT2 is assumed to be involved in the influx of oxaliplatin in both cell 
lines to a similar extent suggesting no major relevance of this transporter for 
resistance. It could be demonstrated that cimetidine, routinely used as inhibitor of 
hOCT2 in influx studies, interacts with oxaliplatin under physiological conditions. The 
data strongly suggest that the results of studies, in which a platinum complex is 
coincubated with a transporter inhibitor, should be reinterpreted. hOCT3 may 
participate in cellular processing of oxaliplatin. However, its involvement in the influx 
of the platinum drug remains questionable. The relevance of this transporter for 
oxaliplatin resistance cannot be ruled out, but requires more detailed investigation.  
The results of this thesis contribute to the elucidation of influx of platinum compounds 
and of resistance provoked by reduced influx. Based on these results platinum 
complexes with improved activity against oxaliplatin-resistant tumor cells can be 
developed. Additionally, the results may support the efforts to refine individualized 
chemotherapy by consideration of the expression profile of the investigated transport 
proteins. 
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Appendix A 
 
Results of the investigation on oxaliplatin analogues with different 
amine ligands 
 
A1 Influx 
Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM platinum complex up to 120 min. 
 HCT-8  HCT-8ox 
Oxaliplatin 
Time Median IQR n Median IQR n 
10 1.23 0.29 12 0.63 0.28 18 
60 8.17 0.65 12 3.12 1.68 18 
120 14.47 1.23 12 7.86 2.97 18 
Compound 4 
10 1.57 0.17 6 0.70 0.29 6 
60 5.99 1.00 6 3.44 1.96 6 
120 14.28 5.75 6 5.81 2.60 6 
Compound 5 
10 1.33 0.17 6 1.22 0.13 6 
60 5.69 0.97 6 5.58 1.51 6 
120 14.28 1.49 6 9.64 0.47 6 
Compound 6 
10 3.95 2.31 6 1.90 0.56 6 
60 13.57 5.70 6 7.02 3.55 6 
120 17.96 0.04 6 10.13 3.31 6 
Compound 7 
10 6.65 1.10 6 3.30 0.81 6 
60 11.82 6.70 6 10.50 5.83 6 
120 17.20 5.42 6 27.59 5.37 6 
n, number of experiments; IQR, interquartile range 
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Early and late influx rate in HCT-8 and HCT-8ox cells after incubation with 100 µM 
platinum complex [µM/min]. 
  Early influx rate Late influx rate 
Compound HCT-8 HCT-8ox HCT-8 HCT-8ox 
Oxaliplatin 0.12 0.06 0.12 0.08 
4 0.16 0.07 0.12 0.05 
5 0.13 0.12 0.12 0.08 
6 0.40 0.19 0.14 0.07 
7 0.67 0.33 0.10 0.22 
 
A2 Efflux 
Intracellular platinum concentration in HCT-8 and HCT-8ox cells after 120 min 
incubation with oxaliplatin or 7 and subsequent incubation with drug-free medium up 
to 120 min (n = 6). The median platinum concentration at the end of the 120 min 
incubation period was set to 100 %. 
 Oxaliplatin Compound 7 
 HCT-8 HCT-8ox HCT-8 HCT-8ox 
Time Median IQR Median IQR Median IQR Median IQR 
0 100.0 6.5 100.0 4.8 100.0 5.9 100.0 3.3 
2 109.6 26.7 110.9 12.2 76.9 7.4 83.0 15.9 
5 86.6 36.8 83.5 4.4 53.2 23.7 76.0 3.3 
10 85.2 6.6 80.9 11.4 74.7 6.2 79.0 9.2 
60 82.1 14.7 80.7 12.0 75.2 9.0 74.8 10.4 
120 53.7 29.4 50.6 45.4 68.0 5.1 74.8 32.3 
IQR, interquartile range 
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A3 Cytotoxicity 
Survival of HCT-8 and HCT-8ox cells after incubation with different concentrations of 
platinum complex. The mean absorption determined in a representative experiment 
is indicated in the table (n = 3). The absorption of untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 2.8 0.891 0.025 100.0 9.4 0.449 0.042 
-7.5 106.3 1.9 0.947 0.017 -- -- -- -- 
-7.0 99.6 7.7 0.887 0.069 128.4 14.3 0.577 0.064 
-6.5 90.9 5.9 0.809 0.053 134.3 3.8 0.603 0.017 
-6.0 53.5 4.3 0.477 0.038 123.0 1.9 0.552 0.009 
-5.7 35.8 3.9 0.319 0.035 99.7 6.8 0.448 0.030 
-5.3 33.3 2.3 0.288 0.020 89.0 5.9 0.400 0.027 
-5.0 29.9 2.8 0.266 0.025 53.7 1.2 0.241 0.005 
-4.5 25.0 0.7 0.223 0.006 36.2 1.0 0.163 0.005 
-3.5 4.9 0.2 0.044 0.002 11.00 0.3 0.049 0.001 
-3.0 -- -- -- -- 10.8 0.3 0.048 0.001 
Compound 4 
Untreated 100.0 8.2 0.721 0.059 100.0 3.5 0.634 0.022 
-7.5 106.4 2.1 0.651 0.015 92.6 2.8 0.587 0.018 
-6.5 94.5 5.7 0.630 0.041 94.4 1.0 0.598 0.006 
-5.5 56.1 2.2 0.444 0.016 93.0 7.1 0.589 0.045 
-5.2 34.7 3.4 0.298 0.025 87.8 6.7 0.556 0.042 
-4.9 30.4 1.8 0.237 0.013 78.0 4.4 0.494 0.028 
-4.6 23.5 1.4 0.213 0.010 58.4 3.8 0.370 0.024 
-4.3 15.1 1.2 0.179 0.009 28.5 4.4 0.180 0.028 
-4.1 6.9 0.9 0.100 0.007 9.5 0.4 0.060 0.003 
-4.0 6.1 0.5 0.086 0.004 8.8 1.6 0.056 0.010 
-3.7 5.4 0.7 0.074 0.005 8.3 2.0 0.052 0.012 
Compound 5 
Untreated 100.0 8.4 0.633 0.053 100.00 3.2 0.665 0.021 
-7.5 81.7 3.0 0.517 0.019 101.75 2.6 0.677 0.018 
-6.5 79.2 16.8 0.501 0.106 91.93 0.9 0.612 0.006 
-5.5 66.9 12.1 0.423 0.077 78.56 3.5 0.523 0.023 
-5.2 38.5 3.7 0.243 0.023 82.11 1.6 0.546 0.011 
-4.9 28.3 4.5 0.179 0.028 59.87 6.2 0.398 0.041 
-4.6 19.7 1.2 0.124 0.008 42.08 4.3 0.280 0.029 
-4.3 16.5 2.0 0.104 0.013 31.76 1.0 0.211 0.007 
-4.1 7.1 0.2 0.045 0.001 18.64 1.2 0.124 0.008 
-4.0 6.7 0.6 0.042 0.004 14.58 0.9 0.097 0.006 
-3.7 6.7 0.3 0.042 0.002 12.12 1.1 0.081 0.008 
 
  Appendix 138 
(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with different 
concentrations of platinum complex. The mean absorption determined in a 
representative experiment is indicated in the table (n = 3). The absorption of 
untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Compound 6 
Untreated 100.0 4.4 0.567 0.025 100.0 1.9 0.556 0.011 
-7.5 86.7 1.9 0.491 0.011 90.5 2.8 0.503 0.015 
-6.5 79.2 2.7 0.449 0.015 87.4 9.4 0.485 0.052 
-5.5 77.8 1.3 0.441 0.007 79.1 12.7 0.440 0.071 
-5.2 70.5 1.2 0.400 0.007 93.0 7.5 0.517 0.042 
-4.9 62.4 3.2 0.353 0.018 83.6 5.9 0.464 0.033 
-4.6 49.1 4.9 0.278 0.028 76.3 9.7 0.424 0.054 
-4.3 39.0 3.0 0.221 0.017 51.5 5.4 0.286 0.030 
-4.1 23.7 1.6 0.134 0.009 42.3 3.9 0.235 0.022 
-4.0 14.7 3.5 0.083 0.020 33.0 3.8 0.183 0.021 
-3.7 4.0 0.3 0.023 0.002 7.2 0.5 0.040 0.003 
Compound 7 
Untreated 100.0 2.3 0.471 0.011 100.0 2.7 0.460 0.012 
-7.5 98.4 10.3 0.464 0.049 99.1 9.7 0.456 0.045 
-6.5 89.5 7.0 0.422 0.033 89.7 3.7 0.413 0.017 
-5.5 90.6 6.7 0.427 0.031 86.5 10.8 0.398 0.049 
-5.2 76.1 7.3 0.359 0.034 88.2 0.8 0.406 0.003 
-4.9 90.5 11.1 0.426 0.052 85.3 2.2 0.393 0.010 
-4.6 82.5 11.6 0.398 0.055 88.8 2.2 0.409 0.010 
-4.3 66.3 8.0 0.312 0.038 76.3 7.3 0.351 0.034 
-4.1 53.5 5.5 0.252 0.026 49.9 0.8 0.230 0.004 
-4.0 38.3 5.7 0.181 0.027 39.1 4.0 0.180 0.018 
-3.7 5.8 0.2 0.027 0.001 17.3 3.0 0.080 0.014 
SD, standard deviation; --, concentration was not used 
 
A4 DNA platination 
DNA platination in HCT-8 and HCT-8 ox cells after incubation with oxaliplatin and 7 
for 4 h [Platinum atoms/106 nucleotides]. 
 Oxaliplatin Compound 7 
 HCT-8 HCT-8ox HCT-8 HCT-8ox 
Median 36.33 15.06 7.82 4.88 
IQR 21.78 6.53 5.32 2.06 
n 6 6 6 6 
n, number of experiments; IQR, interquartile range 
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A5 Repair of platinum-DNA adducts 
Amount of platinum-DNA adducts in HCT-8 and HCT-8ox cells after 4 h of incubation 
with oxaliplatin and subsequent incubation with drug-free medium [Platinum 
atoms/106 nucleotides]. 
 HCT-8  HCT-8ox  
Time Median IQR n Median IQR n 
0 28.64 22.22 6 29.06 12.64 6 
2 30.47 14.57 6 31.19 10.09 6 
4 35.31 25.22 6 28.36 10.05 6 
6 36.75 22.35 6 31.82 8.59 6 
n, number of experiments; IQR, interquartile range 
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Appendix B 
 
Results of the investigation on oxaliplatin analogues with different 
leaving groups 
 
B1 Determination of log P 
log P values of the investigated platinum complexes. 
Volume ratio  
(V1-octanol:Vwater) 
Ptwater [µM]  Pt1-octanol [µM]  log P 
Compound 8 
1:1 9.25 0.48 -1.28 
1:1 9.40 0.51 -1.27 
1:2 8.96 0.51 -1.25 
1:2 9.71 0.52 -1.27 
2:1 8.47 0.36 -1.38 
2:1 8.98 0.39 -1.37 
Compound 9 
1:1 6.24 0.92 -0.83 
1:1 6.79 0.86 -0.90 
1:2 6.88 0.91 -0.88 
1:2 6.97 0.98 -0.85 
2:1 5.40 0.69 -0.89 
2:1 5.51 0.86 -0.81 
Compound 10 
1:1 4.67 0.12 -1.58 
1:1 4.77 0.15 -1.51 
1:2 4.15 0.12 -1.54 
1:2 4.43 0.10 -1.63 
2:1 4.63 0.13 -1.55 
Compound 11 
1:1 8.06 0.05 -2.24 
1:1 8.38 0.04 -2.28 
1:2 7.92 0.03 -2.41 
2:1 7.35 0.03 -2.41 
2:1 7.53 0.03 -2.35 
Compound 12 
1:1 7.70 0.02 -2.58 
1:2 8.38 0.02 -2.71 
1:2 8.54 0.02 -2.67 
2:1 6.75 0.01 -2.67 
2:1 7.57 0.01 -2.70 
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B2 Reactivity towards nucleotides 
Reduction of the corrected peak area of the nucleotides dAMP and dGMP during 
incubation with platinum complex (n = 3, mean ± SD). The initial concentration of the 
nucleotides was set to 100 %. 
Time [h] dAMP [%] SD [%] dGMP [%] SD [%] 
Oxaliplatin 
0 100.0 5.3 100.0 2.6 
12 97.6 4.9 94.4 1.6 
24 83.5 1.7 79.6 2.0 
48 74.8 5.8 60.7 2.8 
72 66.5 3.7 46.6 0.3 
Compound 8 
0 100.0 6.6 100.0 7.3 
12 78.5 5.4 65.2 4.4 
24 76.1 5.5 53.9 2.8 
48 70.0 5.0 38.3 2.0 
72 65.0 5.1 32.6 2.9 
Compound 9 
0 100.0 6.4 100.0 7.0 
12 105.4 7.8 101.9 7.5 
24 95.8 8.9 99.5 9.1 
48 91.5 7.8 85.7 7.4 
72 88.3 7.0 80.2 6.6 
Compound 10 
0 100.0 0.2 100.0 2.3 
12 98.8 4.4 96.5 2.2 
24 90.9 3.0 91.3 4.9 
48 87.3 1.0 73.8 0.9 
72 81.1 1.6 63.3 1.6 
Compound 11 
0 100.0 2.1 100.0 0.9 
12 102.6 3.0 105.5 5.0 
24 98.7 5.9 99.24 4.8 
48 108.2 2.4 109.9 2.1 
72 97.1 1.1 98.5 2.4 
Compound 12 
0 100.0 2.3 100.0 1.1 
12 94.3 3.2 99.2 1.3 
24 95.1 1.4 97.0 3.4 
48 94.6 1.2 98.6 3.3 
72 89.2 0.7 93.2 3.0 
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(Cont.) Reduction of the corrected peak area of the nucleotides dAMP and dGMP 
during incubation with platinum complex (n = 3, mean ± SD). The initial concentration 
of the nucleotides was set to 100 %. 
Time [h] dAMP [%] SD [%] dGMP [%] SD [%] 
Cisplatin 
0 100.0 3.2 100.0 0.9 
12 80.1 2.1 52.2 2.6 
24 60.6 3.7 25.6 3.1 
48 43.1 4.6 10.6 2.3 
72 42.2 9.6 7.4 3.1 
Carboplatin 
0 100.0 2.1 100.0 3.4 
12 95.7 5.8 97.8 5.8 
24 97.0 6.2 97.5 5.8 
48 94.6 2.1 94.1 2.8 
72 92.8 2.9 84.4 4.7 
SD, standard deviation 
 
B3 Influx 
Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM platinum complex up to 120 min. 
 HCT-8 HCT-8ox 
Time [min] Median IQR n Median IQR n 
Oxaliplatin 
10 1.23 0.29 12 0.63 0.28 18 
60 8.14 0.65 15 3.12 1.68 18 
120 14.05 1.23 15 7.86 2.97 18 
Compound 8 
10 1.81 0.10 6 0.84 0.67 6 
60 13.58 2.72 6 5.90 2.38 6 
120 24.68 3.66 6 12.35 3.89 6 
Compound 9 
10 3.38 2.04 6 5.09 0.50 6 
60 13.08 0.86 6 18.81 2.22 6 
120 18.45 1.27 6 21.44 2.29 6 
Compound 10 
10 0.74 0.60 6 0.47 0.54 6 
60 2.69 0.40 6 1.70 0.59 6 
120 4.02 2.01 6 2.27 0.92 6 
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(Cont.) Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after 
incubation with 100 µM platinum complex up to 120 min. 
Time [min] Median IQR n Median IQR n 
Compound 11 
10 0.22 0.05 6 0.57 0.24 6 
60 0.70 0.03 6 0.60 0.33 6 
120 1.26 0.63 6 1.30 0.32 6 
Compound 12 
10 0.31 0.33 6 0.36 0.21 6 
60 0.44 0.04 6 0.42 0.01 6 
120 0.80 0.09 6 0.70 0.07 6 
Cisplatin 
10 5.31 3.78 6 1.79 1.67 6 
60 18.73 4.44 6 5.75 1.48 6 
120 30.61 10.25 6 10.62 1.57 6 
Carboplatin 
10 0.71 0.31 6 0.29 0.06 6 
60 4.06 0.77 6 1.22 0.15 6 
120 6.07 1.10 6 2.37 0.24 6 
n, number of experiments; IQR, interquartile range 
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B4 Cytotoxicity 
Survival of HCT-8 and HCT-8ox cells after incubation with different concentrations of 
platinum complex. The mean absorption determined in a representative experiment 
is indicated in the table (n = 3 - 11). The absorption of untreated cells was set to 
100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 2.8 0.891 0.025 100.0 9.4 0.449 0.042 
-7.5 106.3 1.9 0.947 0.017 -- -- -- -- 
-7.0 99.6 7.7 0.887 0.069 128.4 14.3 0.577 0.064 
-6.5 90.9 5.9 0.809 0.053 134.3 3.8 0.603 0.017 
-6.0 53.5 4.3 0.477 0.038 123.0 1.9 0.552 0.009 
-5.7 35.8 3.9 0.319 0.035 99.7 6.8 0.448 0.030 
-5.3 33.3 2.3 0.288 0.020 89.0 5.9 0.400 0.027 
-5.0 29.9 2.8 0.266 0.025 53.7 1.2 0.241 0.005 
-4.5 25.0 0.7 0.223 0.006 36.2 1.0 0.163 0.005 
-3.5 4.9 0.2 0.044 0.002 11.00 0.3 0.049 0.001 
-3.0 -- -- -- -- 10.8 0.3 0.048 0.001 
Compound 8 
Untreated 100.0 9.6 0.519 0.050 100.0 20.6 0.352 0.073 
-7.7 112.6 4.5 0.585 0.024 112.2 7.5 0.395 0.027 
-7.2 107.5 3.7 0.558 0.019 108.9 10.3 0.383 0.036 
-6.7 88.6 7.2 0.460 0.038 100.7 11.0 0.354 0.039 
-6.2 52.2 1.5 0.271 0.008 107.2 5.1 0.377 0.018 
-5.7 29.6 2.1 0.154 0.011 83.6 3.3 0.294 0.012 
-5.2 22.9 0.7 0.119 0.004 52.4 1.7 0.184 0.006 
-4.7 19.3 0.2 0.100 0.001 33.4 3.1 0.118 0.011 
-4.2 14.6 0.3 0.076 0.002 25.1 1.7 0.088 0.006 
-3.7 13.0 1.2 0.067 0.006 27.9 2.6 0.098 0.009 
Compound 9 
Untreated 100.0 2.5 0.654 0.016 100.0 6.2 0.549 0.034 
-7.7 105.3 6.3 0.688 0.041 93.6 6.7 0.514 0.037 
-7.2 103.8 4.3 0.678 0.028 95.1 3.1 0.522 0.017 
-6.7 100.7 3.7 0.658 0.024 83.3 4.0 0.457 0.022 
-6.2 87.4 4.6 0.571 0.030 84.1 3.3 0.462 0.018 
-5.7 58.6 2.7 0.383 0.018 78.5 5.6 0.431 0.031 
-5.2 32.0 1.9 0.209 0.012 66.8 12.4 0.367 0.068 
-4.7 28.2 3.0 0.184 0.020 37.4 7.7 0.205 0.042 
-4.2 22.9 0.6 0.149 0.004 23.4 9.0 0.129 0.050 
-3.7 5.5 0.3 0.036 0.002 11.1 1.0 0.061 0.006 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with different 
concentrations of platinum complex. The mean absorption determined in a 
representative experiment is indicated in the table (n = 3 - 11). The absorption of 
untreated cells was set to 100 %. 
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Compound 10 
Untreated 100.0 0.6 1.101 0.007 100.0 7.7 0.956 0.073 
-7.7 87.3 2.3 0.961 0.025 83.1 1.8 0.794 0.017 
-7.2 86.9 1.8 0.957 0.020 85.7 4.2 0.819 0.041 
-6.7 87.5 0.8 0.963 0.009 88.2 8.8 0.843 0.084 
-6.2 73.7 7.4 0.811 0.082 90.6 5.6 0.866 0.053 
-5.7 36.3 2.7 0.400 0.029 86.3 5.2 0.825 0.050 
-5.2 30.4 3.3 0.335 0.037 64.3 3.6 0.614 0.035 
-4.7 26.3 1.5 0.290 0.017 33.2 2.6 0.318 0.025 
-4.2 17.0 0.7 0.187 0.008 25.9 2.1 0.248 0.021 
-3.7 5.1 0.1 0.056 0.002 6.1 0.3 0.058 0.003 
Compound 11 
Untreated 100.0 10.1 0.618 0.063 100.0 9.1 0.549 0.050 
-4.9 85.5 9.1 0.528 0.056 79.5 3.6 0.436 0.020 
-4.7 88.0 3.7 0.544 0.023 82.6 8.2 0.453 0.045 
-4.4 83.9 2.5 0.518 0.016 90.6 0.8 0.497 0.004 
-4.2 79.5 9.8 0.491 0.061 89.3 6.7 0.490 0.037 
-3.9 59.0 3.2 0.365 0.020 79.0 5.6 0.433 0.031 
-3.7 37.9 2.3 0.234 0.014 63.8 11.5 0.350 0.063 
-3.4 31.8 1.8 0.197 0.011 46.5 4.1 0.255 0.023 
-3.2 25.2 0.8 0.155 0.005 32.8 1.7 0.180 0.010 
-2.9 9.6 0.3 0.059 0.002 17.0 0.9 0.093 0.005 
Compound 12 
Untreated 100.0 4.1 0.563 0.023 100.0 0.1 0.412 0.001 
-5.6 101.6 4.8 0.572 0.027 106.2 7.6 0.438 0.031 
-4.4 97.1 5.3 0.547 0.030 108.3 6.8 0.446 0.028 
-4.2 86.2 9.7 0.485 0.055 95.6 2.2 0.394 0.009 
-4.0 77.2 9.3 0.434 0.053 94.4 7.0 0.389 0.029 
-3.6 57.6 2.9 0.324 0.017 91.5 7.0 0.377 0.029 
-3.4 34.8 3.5 0.196 0.020 72.9 10.1 0.301 0.042 
-4.8 31.1 1.9 0.175 0.011 59.2 5.9 0.244 0.024 
-3.2 27.8 1.8 0.157 0.010 48.5 1.9 0.200 0.008 
-2.8 9.8 7.1 0.055 0.040 23.2 1.7 0.096 0.007 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with different 
concentrations of platinum complex. The mean absorption determined in a 
representative experiment is indicated in the table (n = 3 - 11). The absorption of 
untreated cells was set to 100 %. 
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Cisplatin 
Untreated 100.0 0.1 0.923 0.001 100.0 0.3 0.812 0.003 
-7.5 100.3 7.0 0.926 0.064 85.4 3.9 0.695 0.032 
-6.5 95.2 0.6 0.878 0.006 87.3 3.3 0.710 0.027 
-5.5 76.0 2.8 0.701 0.026 78.5 2.3 0.639 0.018 
-5.2 62.5 6.4 0.577 0.059 73.7 7.7 0.600 0.063 
-4.9 47.3 2.7 0.436 0.025 56.9 1.6 0.463 0.013 
-4.6 30.5 0.7 0.281 0.006 41.5 3.0 0.338 0.024 
-4.3 11.4 0.4 0.105 0.004 31.5 1.1 0.256 0.009 
-4.1 9.7 0.5 0.090 0.004 10.2 0.2 0.083 0.002 
-4.0 9.2 1.3 0.085 0.012 8.6 0.2 0.070 0.002 
-3.7 7.0 1.2 0.064 0.012 8.5 0.5 0.069 0.004 
Carboplatin 
Untreated 100.0 14.3 0.625 0.089 100.0 13.7 0.549 0.075 
-6.5 100.8 13.4 0.630 0.084 79.1 8.6 0.434 0.047 
-5.0 102.3 3.5 0.639 0.022 78.6 4.3 0.431 0.024 
-4.5 77.8 6.0 0.486 0.038 81.4 1.8 0.447 0.010 
-4.3 57.4 2.9 0.359 0.018 73.5 1.8 0.404 0.010 
-4.1 45.2 7.8 0.282 0.049 71.9 1.9 0.395 0.011 
-4.0 -- -- -- -- 64.0 3.8 0.351 0.021 
-3.9 37.8 5.3 0.236 0.033 61.2 5.6 0.336 0.031 
-3.7 23.9 3.3 0.149 0.020 47.3 7.7 0.260 0.042 
-3.5 13.7 0.7 0.086 0.004 33.6 2.5 0.185 0.014 
-3.0 9.7 0.3 0.060 0.002 12.4 0.8 0.068 0.005 
-2.4 7.8 0.7 0.049 0.004 -- -- -- -- 
SD, standard deviation; --, concentration was not used 
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Appendix C 
 
Results of the investigation on transport proteins 
 
C1 Influx 
Intracellular platinum concentration [µM] after incubation of HCT-8 and HCT-8ox cells 
with various extracellular concentrations of oxaliplatin for 2 h. 
 HCT-8  HCT-8ox 
Extracellular 
concentration [µM]  Median IQR n Median IQR n 
20 2.93 0.61 6 1.30 0.24 6 
100 16.12 1.94 6 5.77 0.76 6 
500 79.52 3.99 6 30.92 5.55 6 
1000 164.31 42.73 6 61.94 8.03 6 
1500 265.33 16.89 6 88.46 4.53 6 
n, number of experiments; IQR, interquartile range 
 
Intracellular platinum concentration [µM] after incubation of HCT-8 and HCT-8ox cells 
with 100 µM oxaliplatin up to 4 h. 
 HCT-8  HCT-8ox 
Time [min]  Median IQR n Median IQR n 
10 1.39 0.16 6 1.05 0.15 6 
60 8.61 0.44 6 4.87 0.68 6 
120 19.05 1.34 6 10.59 1.51 6 
240 39.52 2.03 6 17.95 1.36 6 
n, number of experiments; IQR, interquartile range 
 
Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM oxaliplatin and after coincubation of 100 µM oxaliplatin and 50 µM or 
100 µM copper sulfate 
 HCT-8 HCT-8ox 
Treatment Median IQR n Median IQR n 
Oxaliplatin 12.94 7.69 12 6.98 2.12 9 
Coincubation,  
100 µM copper 14.87 2.30 7 5.21 0.66 6 
Coincubation,  
50 µM copper 13.18 5.97 9 6.15 0.71 6 
n, number of experiments; IQR, interquartile range 
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Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM oxaliplatin and after coincubation of 100 µM oxaliplatin and 10 mM, 
100 µM or 1 µM. 
 HCT-8 HCT-8ox 
Treatment Median IQR n Median IQR n 
Oxaliplatin 16.49 4.39 6 6.33 0.46 6 
Coincubation,  
10 mM TEA 10.87 1.56 6 4.92 0.84 6 
Coincubation,  
100 µM TEA 11.49 2.19 6 5.38 1.20 6 
Coincubation,  
1 µM TEA 13.01 3.58 6 5.41 1.65 6 
n, number of experiments; IQR, interquartile range 
 
Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM oxaliplatin and after pre- or coincubation of 100 µM oxaliplatin and 1 mM 
atropine. 
 HCT-8 HCT-8ox 
Treatment Median IQR n Median IQR n 
Oxaliplatin 23.00 4.32 9 7.89 2.35 9 
Coincubation,  
1 mM atropine 16.58 4.54 6 7.89 1.40 6 
Preincubation, 1 h,  
1 mM atropine 18.72 5.52 9 6.73 1.05 8 
n, number of experiments; IQR, interquartile range 
 
Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM oxaliplatin and after pre- or coincubation of 100 µM oxaliplatin and 
1.5 mM cimetidine. 
 HCT-8 HCT-8ox 
Treatment Median IQR n Median IQR n 
Oxaliplatin 19.76 2.70 9 10.59 1.51 6 
Coincubation,  
1.5 mM cimetidine 14.58 2.42 9 7.90 2.55 9 
Preincubation, 1 h,  
1.5 mM cimetidine 15.49 1.92 12 6.80 2.32 10 
n, number of experiments; IQR, interquartile range 
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Intracellular platinum concentration [µM] in HCT-8 and HCT-8ox cells after incubation 
with 100 µM oxaliplatin and after coincubation of 100 µM oxaliplatin and 1 µM or 
0.1 µM decycnium-22. 
 HCT-8 HCT-8ox 
Treatment Median IQR n Median IQR n 
Oxaliplatin 16.50 1.48 9 6.18 2.28 9 
Coincubation,  
1 µM decynium-22 15.53 1.86 9 5.81 1.11 8 
Coincubation,  
0.1 µM decynium-22 15.98 3.24 9 7.00 2.37 8 
n, number of experiments; IQR, interquartile range 
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C2 Cytotoxicity 
Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
coincubation of oxaliplatin and 100 µM or 50 µM copper sulfate. The mean absorption 
determined in a representative experiment is indicated in the table (n = 3). The 
absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 5.3 0.534 0.028 100.0 9.1 0.528 0.048 
-7.5 100.9 9.1 0.539 0.049 -- -- -- -- 
-7.0 99.3 4.7 0.530 0.025 99.7 4.2 0.527 0.022 
-6.5 93.5 9.3 0.499 0.049 98.2 7.7 0.518 0.041 
-6.0 53.3 3.2 0.285 0.017 107.3 4.5 0.567 0.024 
-5.5 34.5 0.1 0.184 0.001 102.3 7.8 0.540 0.041 
-5.0 31.2 1.7 0.167 0.009 69.9 12.3 0.369 0.065 
-4.5 26.7 0.4 0.143 0.002 39.6 2.8 0.209 0.015 
-4.0 11.6 1.0 0.062 0.006 26.6 2.9 0.140 0.015 
-3.5 10.9 0.4 0.058 0.002 10.4 1.2 0.055 0.006 
 -- -- -- -- 9.8 1.2 0.052 0.006 
Coincubation, 100 µM copper sulfate 
Untreated 76.3 2.1 0.407 0.011 70.3 6.1 0.371 0.032 
-7.5 82.8 7.6 0.442 0.041 -- -- -- -- 
-7.0 83.8 11.1 0.447 0.060 66.2 14.2 0.349 0.075 
-6.5 67.6 11.3 0.361 0.060 64.4 10.3 0.340 0.054 
-6.0 32.4 4.8 0.173 0.026 65.6 10.9 0.346 0.058 
-5.5 24.2 1.4 0.129 0.007 59.5 7.8 0.314 0.041 
-5.0 23.3 1.1 0.125 0.006 35.4 7.9 0.187 0.042 
-4.5 15.0 3.0 0.080 0.016 21.5 4.1 0.113 0.022 
-4.0 7.9 0.9 0.042 0.005 12.8 2.5 0.068 0.013 
-3.5 7.6 0.7 0.041 0.004 8.7 0.2 0.046 0.001 
-3.0 -- -- -- -- 7.6 0.2 0.040 0.001 
Coincubation, 50 µM copper sulfate 
Untreated 80.5 3.2 0.430 0.017 90.1 2.4 0.476 0.013 
-7.5 93.5 13.6 0.499 0.073 -- -- -- -- 
-7.0 84.8 2.6 0.453 0.014 90.7 4.6 0.479 0.024 
-6.5 74.9 8.1 0.400 0.043 92.3 2.4 0.487 0.013 
-6.0 40.1 1.4 0.214 0.008 88.6 1.7 0.468 0.009 
-5.5 33.1 5.4 0.177 0.029 89.5 7.7 0.472 0.041 
-5.0 27.2 0.9 0.145 0.005 56.2 6.7 0.297 0.035 
-4.5 21.8 1.7 0.117 0.009 34.5 2.4 0.182 0.013 
-4.0 8.5 0.2 0.045 0.001 23.9 3.7 0.126 0.019 
-3.5 8.5 0.9 0.045 0.005 10.1 0.3 0.053 0.002 
-3.0 -- -- -- -- 9.0 0.3 0.048 0.002 
SD, standard deviation; --, concentration was not used 
Appendix  151 
Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
coincubation of oxaliplatin and 10 mM, 10 mM or 10 µM TEA. The mean absorption 
determined in a representative experiment is indicated in the table (n = 3). The 
absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 1.9 0.501 0.009 100.0 12.8 0.574 0.073 
-7.5 79.1 3.7 0.396 0.019 -- -- -- -- 
-7.0 82.9 1.8 0.415 0.009 88.7 10.5 0.509 0.060 
-6.5 73.4 3.1 0.368 0.016 87.2 3.8 0.500 0.022 
-6.0 44.0 0.8 0.221 0.004 92.1 6.4 0.529 0.037 
-5.5 27.7 3.0 0.139 0.015 87.9 4.7 0.505 0.027 
-5.0 22.3 0.4 0.112 0.002 65.9 5.8 0.378 0.033 
-4.5 18.0 0.7 0.090 0.004 36.5 1.1 0.210 0.007 
-4.0 6.5 0.3 0.033 0.002 25.5 1.0 0.146 0.006 
-3.5 5.5 0.1 0.028 0.001 6.3 0.3 0.036 0.002 
-3.0 -- -- -- -- 6.9 0.1 0.039 0.001 
Coincubation, 10 mM TEA 
Untreated 79.8 2.5 0.400 0.012 77.0 8.6 0.442 0.050 
-7.5 90.7 13.5 0.454 0.068 -- -- -- -- 
-7.0 87.8 3.5 0.440 0.018 85.6 10.3 0.491 0.059 
-6.5 67.6 5.5 0.339 0.027 78.9 4.2 0.453 0.024 
-6.0 41.4 3.0 0.207 0.015 76.1 6.8 0.437 0.039 
-5.5 24.7 0.6 0.124 0.003 70.4 12.6 0.404 0.073 
-5.0 21.8 1.1 0.109 0.005 58.1 6.2 0.333 0.036 
-4.5 20.6 0.8 0.103 0.004 31.5 1.8 0.181 0.010 
-4.0 8.2 0.5 0.041 0.003 23.0 0.8 0.132 0.005 
-3.5 6.9 0.9 0.035 0.005 6.9 0.2 0.039 0.001 
-3.0 -- -- -- -- 6.6 0.3 0.038 0.002 
Coincubation, 1 mM TEA 
Untreated 80.1 8.8 0.401 0.044 90.5 4.1 0.520 0.024 
-7.5 92.4 1.6 0.463 0.008 -- -- -- -- 
-7.0 81.3 5.5 0.407 0.028 86.3 0.3 0.495 0.002 
-6.5 75.8 2.5 0.380 0.013 85.9 13.7 0.493 0.078 
-6.0 45.3 3.2 0.227 0.016 82.5 5.3 0.473 0.030 
-5.5 23.8 2.9 0.119 0.014 83.6 9.1 0.480 0.052 
-5.0 23.3 2.1 0.117 0.011 63.7 4.2 0.366 0.024 
-4.5 19.6 1.1 0.098 0.006 33.3 1.8 0.191 0.010 
-4.0 8.0 0.2 0.040 0.001 22.3 0.8 0.128 0.004 
-3.5 7.6 0.2 0.038 0.001 6.9 0.1 0.040 0.001 
-3.0 -- -- -- -- 7.5 0.0 0.043 0.000 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone 
and after coincubation of oxaliplatin and 10 mM, 10 mM or 10 µM TEA. The mean 
absorption determined in a representative experiment is indicated in the table (n = 3). 
The absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Coincubation, 10 µM TEA 
Untreated 83.2 4.0 0.417 0.020 78.7 11.5 0.452 0.066 
-7.5 108.4 6.5 0.543 0.032 -- -- -- -- 
-7.0 103.1 5.1 0.517 0.026 105.6 2.7 0.606 0.015 
-6.5 91.4 2.3 0.458 0.012 99.7 4.5 0.572 0.026 
-6.0 47.9 5.0 0.240 0.025 98.1 2.4 0.563 0.014 
-5.5 26.4 0.8 0.132 0.004 93.1 3.3 0.534 0.019 
-5.0 22.7 1.6 0.114 0.008 72.6 2.2 0.417 0.013 
-4.5 20.3 1.1 0.102 0.006 32.5 2.8 0.186 0.016 
-4.0 7.9 0.1 0.039 0.001 22.8 1.4 0.131 0.008 
-3.5 6.1 0.7 0.030 0.004 6.8 0.3 0.039 0.002 
-3.0 -- -- -- -- 6.6 0.3 0.038 0.002 
SD, standard deviation, --, Concentration was not used. 
 
Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
preincubation with 1 mM atropine for 1 h and subsequent incubation with oxaliplatin 
alone, as well as after coincubation of oxaliplatin and 1 mM or 100 µM atropine. The 
mean absorption determined in a representative experiment is indicated in the table 
(n = 3). The absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 7.9 0.469 0.037 100.0 9.1 0.478 0.043 
-7.5 112.9 2.8 0.529 0.013 -- -- -- -- 
-7.0 112.9 4.6 0.529 0.022 109.6 4.1 0.524 0.019 
-6.5 100.1 16.4 0.469 0.077 116.7 9.8 0.558 0.047 
-6.0 51.7 6.4 0.243 0.030 113.0 4.8 0.540 0.023 
-5.5 30.9 1.2 0.145 0.006 112.6 4.6 0.538 0.022 
-5.0 30.8 1.7 0.145 0.008 87.3 5.5 0.417 0.026 
-4.5 27.1 0.4 0.127 0.002 44.1 1.1 0.211 0.005 
-4.0 9.4 0.2 0.044 0.001 31.4 1.3 0.150 0.006 
-3.5 5.8 0.2 0.027 0.001 8.4 0.2 0.040 0.001 
-3.0 -- -- -- -- 8.6 0.1 0.041 0.001 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone 
and after coincubation of oxaliplatin and 10 mM, 10 mM or 10 µM TEA. The mean 
absorption determined in a representative experiment is indicated in the table (n = 3). 
The absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Preincubation, 1 h, 1 mM atropine 
Untreated 85.8 5.0 0.402 0.023 97.4 4.2 0.466 0.020 
-7.5 94.6 12.7 0.444 0.060 -- -- -- -- 
-7.0 95.7 7.4 0.449 0.035 103.6 6.7 0.495 0.032 
-6.5 84.8 5.0 0.398 0.024 113.1 8.0 0.541 0.038 
-6.0 47.0 5.1 0.220 0.024 99.2 5.0 0.474 0.024 
-5.5 29.1 2.1 0.137 0.010 107.2 0.9 0.512 0.005 
-5.0 28.6 2.0 0.134 0.009 81.9 7.9 0.391 0.038 
-4.5 23.8 1.5 0.112 0.007 39.7 4.6 0.190 0.022 
-4.0 8.2 0.1 0.039 0.001 30.1 2.6 0.144 0.013 
-3.5 5.6 0.3 0.026 0.002 6.7 0.4 0.032 0.002 
-3.0 -- -- -- -- 6.6 0.1 0.032 0.001 
Coincubation, 1 mM atropine 
Untreated 46.1 7.5 0.216 0.035 53.9 6.6 0.258 0.031 
-7.5 63.3 0.5 0.297 0.002 -- -- -- -- 
-7.0 66.4 4.0 0.311 0.019 68.3 3.9 0.327 0.019 
-6.5 59.8 1.0 0.280 0.005 64.6 3.6 0.309 0.017 
-6.0 56.6 2.3 0.265 0.011 71.4 4.3 0.341 0.021 
-5.5 38.1 0.6 0.179 0.003 64.4 6.4 0.308 0.031 
-5.0 31.4 1.0 0.147 0.005 65.8 2.7 0.315 0.013 
-4.5 22.5 0.5 0.106 0.003 46.6 5.0 0.223 0.024 
-4.0 9.0 0.7 0.042 0.003 29.8 3.0 0.143 0.015 
-3.5 5.5 0.2 0.026 0.001 6.9 0.2 0.033 0.001 
-3.0 -- -- -- -- 7.7 0.1 0.037 0.001 
Coincubation, 100 µM atropine 
Untreated 103.9 7.3 0.487 0.034 109.6 5.9 0.524 0.028 
-7.5 111.2 8.6 0.521 0.041 -- -- -- -- 
-7.0 123.2 12.4 0.578 0.058 130.3 3.2 0.623 0.015 
-6.5 117.2 4.2 0.550 0.020 123.6 5.1 0.591 0.024 
-6.0 59.3 4.4 0.278 0.021 117.6 7.8 0.562 0.038 
-5.5 36.5 2.4 0.171 0.011 129.8 3.1 0.621 0.015 
-5.0 31.33 5.1 0.147 0.024 103.0 4.9 0.492 0.023 
-4.5 31.1 3.7 0.146 0.017 52.8 5.4 0.252 0.026 
-4.0 10.2 0.2 0.048 0.001 34.2 2.0 0.163 0.010 
-3.5 5.1 0.6 0.024 0.003 6.9 0.4 0.033 0.002 
-3.0 -- -- -- -- 7.3 0.0 0.035 0.000 
SD, standard deviation, --, Concentration was not used. 
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Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
preincubation with 1.5 mM cimetidine for 6 h and subsequent incubation with 
oxaliplatin alone, as well as after coincubation of oxaliplatin and 1.5 mM or 0.15 mM 
cimetidine. The mean absorption determined in a representative experiment is 
indicated in the table (n = 3). The absorption of oxaliplatin-untreated cells was set to 
100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 2.5 0.505 0.012 100.0 12.2 0.540 0.066 
-7.5 96.1 1.6 0.476 0.008 -- -- -- -- 
-7.0 94.5 3.5 0.483 0.018 94.9 6.5 0.513 0.035 
-6.5 81.7 1.8 0.403 0.009 98.6 7.2 0.532 0.039 
-6.0 37.8 2.0 0.200 0.010 98.6 2.5 0.533 0.014 
-5.5 27.5 0.7 0.143 0.004 95.8 5.6 0.517 0.030 
-5.0 24.5 1.8 0.134 0.009 58.5 4.0 0.316 0.027 
-4.5 19.9 0.8 0.104 0.004 29.9 2.4 0.162 0.013 
-4.0 5.7 0.2 0.029 0.001 21.0 2.1 0.114 0.012 
-3.5 4.8 0.2 0.024 0.001 5.6 0.4 0.030 0.002 
-3.0 -- -- -- -- 5.4 0.2 0.029 0.001 
Preincubation, 6 h, 1.5 mM cimetidine 
Untreated 100.0 8.5 0.505 0.043 94.7 1.4 0.511 0.007 
-7.5 91.2 5.7 0.460 0.029 -- -- -- -- 
-7.0 95.8 8.8 0.484 0.045 94.6 7.2 0.511 0.039 
-6.5 87.0 9.2 0.439 0.046 88.7 2.5 0.479 0.014 
-6.0 67.9 15.6 0.343 0.079 94.3 10.7 0.509 0.058 
-5.5 30.4 9.9 0.154 0.050 110.2 11.4 0.595 0.062 
-5.0 25.3 1.8 0.128 0.009 95.1 8.0 0.514 0.043 
-4.5 22.0 1.4 0.111 0.007 53.1 10.5 0.287 0.057 
-4.0 16.2 2.5 0.082 0.013 29.6 0.8 0.160 0.005 
-3.5 4.7 0.1 0.024 0.001 11.9 3.3 0.064 0.018 
-3.0 -- -- -- -- 5.9 0.2 0.032 0.001 
Coincubation, 1.5 mM cimetidine 
Untreated 91.0 10.0 0.460 0.050 87.4 6.1 0.472 0.033 
-6.5 101.5 2.1 0.513 0.011 92.2 5.9 0.498 0.032 
-6.0 103.6 1.5 0.523 0.007 106.0 3.6 0.573 0.019 
-5.5 97.5 8.9 0.492 0.045 98.0 5.7 0.529 0.031 
-5.0 77.1 7.4 0.389 0.037 110.6 12.9 0.597 0.069 
-4.5 39.9 1.5 0.201 0.008 103.8 2.1 0.560 0.012 
-4.0 26.5 1.4 0.134 0.007 82.3 2.5 0.445 0.013 
-3.5 23.2 3.2 0.117 0.016 53.2 5.9 0.287 0.032 
-3.0 4.5 0.1 0.023 0.001 21.0 1.9 0.114 0.010 
-2.5 3.8 0.0 0.019 0.000 3.3 0.4 0.018 0.002 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone 
and after preincubation with 1.5 mM cimetidine for 6 h and subsequent incubation 
with oxaliplatin alone, as well as after coincubation of oxaliplatin and 1.5 mM or 
0.15 mM cimetidine. The mean absorption determined in a representative experiment 
is indicated in the table (n = 3). The absorption of oxaliplatin-untreated cells was set 
to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Coincubation, 0.15 mM cimetidine 
Untreated 73.7 2.5 0.372 0.013 92.0 5.7 0.497 0.031 
-7.5 82.3 6.7 0.416 0.034 -- -- -- -- 
-7.0 82.6 9.0 0.417 0.045 94.0 11.2 0.508 0.060 
-6.5 78.0 3.9 0.394 0.020 97.3 18.0 0.525 0.097 
-6.0 53.9 11.8 0.272 0.059 84.8 4.1 0.458 0.022 
-5.5 28.2 1.2 0.142 0.006 85.1 3.9 0.459 0.021 
-5.0 23.0 1.9 0.116 0.010 78.3 9.6 0.423 0.052 
-4.5 18.5 0.6 0.094 0.003 49.0 2.2 0.264 0.012 
-4.0 10.9 0.7 0.055 0.003 25.2 2.4 0.136 0.013 
-3.5 4.5 0.2 0.023 0.001 13.1 1.8 0.071 0.010 
-3.0 -- -- -- -- 5.6 0.5 0.030 0.003 
SD, standard deviation; --, concentration was not used 
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Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
coincubation of oxaliplatin and 1 µM or 0.1 µM decynium-22. The mean absorption 
determined in a representative experiment is indicated in the table (n = 3). The 
absorption of oxaliplatin-untreated cells was set to 100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 1.6 0.633 0.010 100.0 14.9 1.095 0.164 
-7.5 101.1 1.7 0.640 0.011 -- -- -- -- 
-7.0 88.3 8.7 0.559 0.055 100.7 15.7 1.103 0.172 
-6.5 68.1 3.0 0.431 0.019 93.4 10.2 1.022 0.112 
-6.0 37.1 1.4 0.235 0.009 85.6 16.0 0.938 0.176 
-5.5 29.0 1.1 0.183 0.007 98.7 5.4 1.081 0.059 
-5.0 27.1 1.4 0.172 0.009 52.5 4.4 0.575 0.048 
-4.5 15.6 0.7 0.099 0.005 29.1 2.5 0.318 0.027 
-4.0 8.3 0.2 0.053 0.002 18.9 0.6 0.207 0.007 
-3.5 7.8 0.2 0.050 0.002 6.6 0.1 0.073 0.002 
 -- -- -- -- 5.5 0.2 0.060 0.003 
Coincubation, 1 µM decynium-22 
Untreated 60.0 3.0 0.380 0.019 49.3 1.1 0.540 0.012 
-7.5 59.1 3.8 0.374 0.024 -- -- -- -- 
-7.0 58.6 3.0 0.371 0.019 50.3 9.8 0.550 0.108 
-6.5 48.3 4.5 0.306 0.028 51.7 6.3 0.566 0.069 
-6.0 23.4 1.5 0.148 0.010 43.9 2.5 0.481 0.027 
-5.5 18.0 0.2 0.114 0.002 55.5 3.3 0.607 0.036 
-5.0 18.3 1.1 0.116 0.007 35.2 3.4 0.385 0.037 
-4.5 14.4 0.7 0.091 0.005 21.8 1.2 0.239 0.013 
-4.0 8.3 0.6 0.052 0.004 16.2 1.6 0.178 0.018 
-3.5 7.6 0.2 0.048 0.002 5.6 0.3 0.061 0.004 
-3.0 -- -- -- -- 5.2 0.1 0.057 0.001 
Coincubation, 0.1 µM decynium-22 
Untreated 61.2 3.3 0.388 0.021 68.9 4.3 0.754 0.047 
-7.5 63.8 1.0 0.404 0.006 -- -- -- -- 
-7.0 67.9 9.7 0.430 0.062 73.6 5.8 0.806 0.063 
-6.5 52.6 4.6 0.333 0.029 71.9 6.8 0.787 0.074 
-6.0 20.5 0.9 0.130 0.006 71.9 8.1 0.787 0.089 
-5.5 17.9 0.6 0.113 0.004 64.6 5.5 0.707 0.061 
-5.0 15.3 0.1 0.097 0.001 39.1 1.2 0.429 0.014 
-4.5 11.8 0.4 0.075 0.002 19.1 1.5 0.209 0.016 
-4.0 7.8 0.2 0.050 0.001 15.3 0.8 0.167 0.009 
-3.5 8.2 0.3 0.052 0.002 5.1 0.1 0.057 0.002 
-3.0 -- -- -- -- 5.9 0.4 0.064 0.004 
SD, standard deviation; --, concentration was not used 
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C3 Gene expression profile 
Results of the qRT-PCR analysis. Ct values (cycle threshold; mean, SD, n), 
quantities (QGOI) calculated based on the Ct values, normalisation factors (NF) 
calculated based on the Ct values of the housekeeping genes, the normalized 
expression (GOInE) and the rescaled normalized expression (GOIrnE) obtained by 
setting GOInE in untreated HCT-8 cells to 1 are presented in the table.  
 Treatment Mean Ct SD Ct n QGOI NF GOInE GOIrnE 
HCT-8 
Untreated 22.955 0.047 2 0.833 0.620 1.343 1.000 
2 h + 24 h 22.690 0.062 2 1.000 1.000 1.000 0.745 
24 h + 24 h 24.091 0.032 2 0.379 0.673 0.563 0.419 
24 h + 0 h 26.128 0.227 2 0.092 0.335 0.275 0.205 
HCT-8ox 
Untreated 24.513 0.067 2 0.283 0.449 0.630 0.469 
2 h + 24 h 23.724 0.199 2 0.488 0.581 0.840 0.626 
24 h + 24 h 23.920 0.136 2 0.426 0.454 0.939 0.699 
hC
TR
1 
24 h + 0 h 23.422 0.071 2 0.602 0.748 0.805 0.600 
 HCT-8 
Untreated 34.058 0.443 2 0.081 0.185 0.437 1.000 
2 h + 24 h 34.566 0.154 2 0.057 0.382 0.149 0.340 
24 h + 24 h 33.416 0.093 2 0.126 0.257 0.491 1.123 
24 h + 0 h 33.155 0.697 2 0.151 0.128 1.179 
24 h + 0 h 30.857 0.082 2 0.744 0.602 1.236 
2.763 
HCT-8ox 
Untreated 34.211 0.267 2 0.073 0.148 0.490 
Untreated 31.096 0.590 2 0.630 0.629 1.001 
1.603 
2 h + 24 h 34.553 0.464 2 0.057 0.222 0.258 
2 h + 24 h 31.095 0.246 2 0.630 0.997 0.632 
0.925 
24 h + 24 h 33.925 1.015 2 0.089 0.185 0.478 
24 h + 24 h 31.528 1.320 2 0.467 0.822 0.568 
1.192 
hO
C
T1
 
24 h + 0 h 33.369 0.188 2 0.130 0.245 0.531 1.215 
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(Cont.) Results of the qRT-PCR analysis. Ct values (cycle threshold; mean, SD, n), 
quantities (QGOI) calculated based on the Ct values, normalisation factors (NF) 
calculated based on the Ct values of the housekeeping genes, the normalized 
expression (GOInE) and the rescaled normalized expression (GOIrnE) obtained by 
setting GOInE in untreated HCT-8 cells to 1 are presented in the table.  
 Treatment Mean Ct SD Ct n QGOI NF GOInE GOIrnE 
 HCT-8 
Untreated 35.331 0.260 2 0.068 0.150 0.454 
Untreated 32.838 1.041 2 0.383 0.654 0.585 
1.000 
2 h + 24 h 36.821 0.174 2 0.024 0.242 0.100 
2 h + 24 h 32.925 0.494 2 0.361 1.000 0.361 
0.369 
24 h + 24 h 36.853 0.361 2 0.024 0.163 0.146 0.282 
24 h + 0 h 37.963 0.651 2 0.011 0.081 0.135 
24 h + 0 h 34.385 2.012 2 0.131 0.381 0.344 
0.419 
HCT-8ox 
Untreated 36.437 1.396 2 0.032 0.094 0.337 
Untreated 34.413 0.296 2 0.129 0.398 0.323 
0.640 
2 h + 24 h 37.045 0.796 2 0.021 0.141 0.148 
2 h + 24 h 33.831 0.058 2 0.192 0.631 0.305 
0.412 
24 h + 24 h 35.112 0.280 2 0.079 0.117 0.674 
24 h + 24 h 31.453 0.231 2 1.000 0.521 1.921 
2.208 
24 h + 0 h 36.796 0.586 2 0.025 0.155 0.159 
hO
C
T2
 
24 h + 0 h 34.077 2.155 2 0.162 0.800 0.203 
0.348 
HCT-8 
Untreated 29.873 0.085 2 0.608 0.655 0.928 1.000 
2 h + 24 h 29.156 0.192 2 1.000 0.964 1.037 1.118 
24 h + 24 h 29.256 0.072 2 0.933 0.910 1.025 1.104 
24 h + 0 h 31.683 0.281 2 0.173 0.397 0.437 0.471 
HCT-8ox 
Untreated 31.697 0.217 2 0.172 0.410 0.419 0.451 
2 h + 24 h 31.074 0.263 2 0.265 0.599 0.442 0.476 
24 h + 24 h 30.165 0.210 2 0.497 0.511 0.973 1.048 
hO
C
T3
 
24 h + 0 h 30.738 0.053 2 0.334 0.815 0.410 0.442 
SD, standard deviation, n, number of experiments 
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Appendix D 
 
Results of the investigation on interaction between oxaliplatin and 
cimetidine 
 
D1 Cytotoxicity 
Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone and after 
preincubation with 1.5 mM cimetidine for 12 h and subsequent incubation with 
oxaliplatin alone, as well as after coincubation of oxaliplatin and 1.5 mM or 0.15 mM 
cimetidine. The mean absorption determined in a representative experiment is 
indicated in the table (n = 3). The absorption of oxaliplatin-untreated cells was set to 
100 %.  
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Oxaliplatin 
Untreated 100.0 2.5 0.505 0.012 100.0 12.2 0.540 0.066 
-7.5 96.1 1.6 0.485 0.008 -- -- -- -- 
-7.0 94.5 3.5 0.477 0.018 94.9 6.5 0.513 0.035 
-6.5 81.7 1.8 0.413 0.009 98.5 7.2 0.532 0.039 
-6.0 37.8 2.0 0.191 0.010 98.6 2.5 0.533 0.014 
-5.5 27.5 0.7 0.149 0.004 95.7 5.6 0.517 0.030 
-5.0 24.5 1.8 0.124 0.009 58.4 4.9 0.316 0.027 
-4.5 19.9 0.8 0.101 0.004 29.9 2.4 0.162 0.013 
-4.0 5.7 0.2 0.029 0.001 21.0 2.1 0.114 0.012 
-3.5 4.8 0.2 0.024 0.001 5.6 0.4 0.030 0.002 
-3.0 -- -- -- -- 5.4 0.2 0.029 0.001 
Preincubation, 6 h, 1.5 mM cimetidine 
Untreated 100.0 8.5 0.505 0.043 94.7 1.4 0.511 0.007 
-7.5 91.2 5.7 0.460 0.029 -- -- -- -- 
-7.0 95.8 8.8 0.484 0.045 94.6 7.2 0.511 0.039 
-6.5 87.0 9.2 0.439 0.046 88.7 2.5 0.479 0.014 
-6.0 67.9 15.6 0.343 0.079 94.3 10.7 0.509 0.058 
-5.5 30.4 9.9 0.154 0.050 110.2 11.4 0.595 0.062 
-5.0 25.3 1.8 0.128 0.009 95.1 8.0 0.514 0.043 
-4.5 22.0 1.4 0.111 0.007 53.1 10.5 0.287 0.057 
-4.0 16.2 2.5 0.082 0.013 29.6 0.8 0.160 0.005 
-3.5 4.7 0.1 0.024 0.001 11.9 3.3 0.064 0.018 
-3.0 -- -- -- -- 5.9 0.2 0.032 0.001 
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(Cont.) Survival of HCT-8 and HCT-8ox cells after incubation with oxaliplatin alone 
and after preincubation with 1.5 mM cimetidine for 12 h and subsequent incubation 
with oxaliplatin alone, as well as after coincubation of oxaliplatin and 1.5 mM or 
0.15 mM cimetidine. The mean absorption determined in a representative experiment 
is indicated in the table (n = 3). The absorption of oxaliplatin-untreated cells was set 
to 100 %. 
 HCT-8 HCT-8ox 
 Absorption [%]  Absorption [units]  Absorption [%]  Absorption [units]  
log [conc.]  Mean SD Mean SD Mean SD Mean SD 
Preincubation, 12 h, 1.5 mM cimetidine 
Untreated 100.0 5.4 0.369 0.020 100.0 1.2 0.543 0.006 
-7.5 93.8 1.2 0.346 0.004 -- -- -- -- 
-7.0 87.4 1.7 0.323 0.006 94.8 0.5 0.514 0.003 
-6.5 81.4 3.6 0.300 0.013 94.6 5.4 0.513 0.029 
-6.0 42.6 1.8 0.157 0.007 94.2 3.1 0.511 0.017 
-5.5 28.0 2.4 0.103 0.009 87.3 1.7 0.474 0.009 
-5.0 24.0 2.6 0.089 0.010 66.2 4.5 0.359 0.025 
-4.5 18.5 1.3 0.068 0.005 32.2 4.1 0.175 0.022 
-4.0 8.1 0.3 0.030 0.001 21.3 2.2 0.115 0.012 
-3.5 5.4 0.3 0.020 0.001 4.7 0.6 0.025 0.003 
-3.0 -- -- -- -- 4.7 0.5 0.025 0.003 
Coincubation, 1.5 mM cimetidine 
Untreated 91.0 10.0 0.460 0.050 87.4 6.1 0.472 0.033 
-6.5 101.5 2.1 0.513 0.011 92.2 5.9 0.498 0.032 
-6.0 103.6 1.5 0.523 0.007 106.0 3.6 0.573 0.019 
-5.5 97.5 8.9 0.492 0.045 98.0 5.7 0.529 0.031 
-5.0 77.1 7.4 0.389 0.037 110.6 12.9 0.597 0.069 
-4.5 39.9 1.5 0.201 0.008 103.8 2.1 0.560 0.012 
-4.0 26.5 1.4 0.134 0.007 82.3 2.5 0.445 0.013 
-3.5 23.2 3.2 0.117 0.016 53.2 5.9 0.287 0.032 
-3.0 4.5 0.1 0.023 0.001 21.0 1.9 0.114 0.010 
-2.5 3.8 0.0 0.019 0.000 3.3 0.4 0.018 0.002 
SD, standard deviation; --, concentration was not used 
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D2 Influx 
Protein concentration in HCT-8 and HCT-8ox cells [µg protein/mL cell suspension]. 
The mean protein concentration of each day (n = 6), the within-day precision 
(SD [%], within-day) and the between-day precision (SD [%], between-day) are 
presented in the table. 
HCT-8 HCT-8ox Number  
of cells Mean SD [%] , within-day 
SD [%] , 
between-day Mean 
SD [%] , 
within-day 
SD [%] , 
between-day 
233.7 12.2 488.6 7.2 
263.0 9.6 548.8 11.5 
237.3 9.6 482.7 6.1 
313.7 13.4 470.4 7.9 
231.1 7.2 511.9 4.5 
1,000,000 
222.5 14.3 13.6 473.5 5.9 6.0 
544.4 6.0 1106.6 7.9 
616.1 11.2 1004.3 10.1 
517.0 4.7 894.3 8.8 
662.2 9.8 990.6 8.1 
522.3 6.4 1016.9 4.6 
2,000,000 
548.0 9.7 10.2 995.1 9.1 8.1 
791.8 10.6 1438.3 7.3 
927.6 10.9 1657.8 10.4 
837.6 4.9 1503.3 5.2 
891.0 13.7 1454.0 10.4 
827.8 11.0 1531.4 10.2 
3,000,000 
778.2 8.9 6.8 1554.8 11.5 5.2 
1167.8 4.5 2005.6 11.2 
1071.5 9.1 1760.1 13.3 
1093.5 3.5 1988.0 6.6 
1267.8 13.2 2057.4 3.4 
1145.5 6.9 2074.7 7.1 
4,000,000 
1165.7 7.1 6.0 1936.3 5.1 5.8 
SD, standard deviation 
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Intracellular platinum concentration [ng/mg protein] in HCT-8 and HCT-8ox cells after 
incubation with 20 µM oxaliplatin up to 24 h, after coincubation with 20 µM oxaliplatin 
and 1.5 µM cimetidine and after preincubation with 20 µM oxaliplatin for 12 h and 
subsequent incubation with 20 µM oxaliplatin alone. 
 HCT-8 HCT-8ox 
Time [h]  Median IQR n Median IQR n 
Oxaliplatin 
2 6.26 2.69 9 2.16 0.84 9 
4 11.26 1.61 9 5.30 1.10 9 
6 15.22 2.86 9 5.71 3.36 9 
8 25.54 8.74 9 11.01 8.72 9 
10 30.26 5.52 9 13.81 3.21 9 
12 27.71 8.33 9 11.66 5.81 9 
24 33.50 2.22 9 18.34 1.15 9 
Preincubation, 12 h, 1.5 mM cimetidine 
2 5.70 2.84 9 2.68 1.63 9 
4 10.44 2.58 9 4.91 1.84 9 
6 14.03 3.52 9 6.87 1.03 9 
8 20.50 6.09 9 10.23 4.65 9 
10 31.29 1.18 9 14.34 0.91 9 
12 23.88 0.48 9 12.50 0.34 9 
24 29.02 7.50 9 15.15 4.01 9 
Coincubation, 1.5 mM cimetidine 
2 2.98 1.23 6 2.09 0.28 6 
4 5.10 1.06 6 2.72 0.38 6 
6 5.69 0.97 6 4.29 1.47 6 
8 6.42 2.38 6 3.80 2.23 6 
10 6.87 2.34 3 5.48 2.51 3 
12 6.71 1.31 3 5.78 0.86 4 
24 5.44 0.71 6 4.06 0.58 6 
n, number of experiments; IQR, interquartile range 
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